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The first section of this thesis describes the development of an enantioselective synthesis 
of terminally unsubstituted methylenecyclopropanes. The key feature of this approach is a Rh2(S-
TBPTTL)4-mediated catalytic asymmetric cyclopropanation of unsubstituted allene to produce 
enantioenriched methylenecyclopropanes bearing alkyl or activated ester functionalities. This 
method was successfully applied to the enantioselective total synthesis of cycloclavine.   
The second section of this thesis describes the development of an improved 12 
steps/5.2% overall yield racemic total synthesis of the clavine alkaloid cycloclavine. The first 
enantioselective total syntheses of the unnatural enantiomer (–)-cycloclavine and the natural 
enantiomer (+)-cycloclavine were also accomplished in 8 steps/7.1%(brsm) overall yield and 8 
steps/4% overall yield, respectively.  Noteworthy features of this approach include a strain-
promoted intramolecular Diels-Alder reaction followed by a highly regioselective aerobic α,β-
dehydrogenation to form a key enone intermediate in >99.5:0.5 er after crystallization. 
Additional noteworthy features include the enone 1,2-addition of a novel TEMPO-carbamate 
aminomethyl carbanion and an IMDAF reaction to install the indole core. The mechanism of 
thermolysis of the new TEMPOC amine protecting-group was investigated. Finally, the natural 
and unnatural enantiomers were evaluated for their ability to bind to several neurotransmitter 
receptors in radioligand binding assays.  
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1.0  ENANTIOSELECTIVE CYCLOPROPANATIONS OF ALLENES 
1.1 INTRODUCTION 
1.1.1 Methylenecyclopropane: Structure and Properties 
The study and preparation of strained carbocycles has captivated synthetic and theoretical 
chemists for decades. Adolf Von Baeyer first introduced the concept of ring strain in 1885.1,2 At 
the time numerous compounds containing five- and six-membered rings had been synthesized or 
isolated from natural sources. In contrast, smaller three- and four-membered rings had not been 
prepared despite considerable effort. This observation led von Baeyer to hypothesize that three 
and four membered rings were less stable due to ring strain.1  
Methylenecyclopropanes are a unique subset of strained carbocycles with high ring strain 
energy (40.9 kcal/mol). This high ring strain can be largely attributed to the inherent angle strain 
caused by the deviation of the internal angles from the ideal sp2 bond angle of 120° and the ideal 
sp3 bond angle of 109.5° to ~64° and partly because of the torsional strain imparted by eclipsing 
C–H bonds on adjacent carbons (Figure 1-1). The introduction of the exocyclic double bond in 
methylenecyclopropane (1.1) increases the ring strain by ca. 11 kcal/mol relative to 
methylcyclopropane (1.2). Studies by Wiberg revealed that the additional ring strain arises in 
part from the incorporation of a trigonal sp2 center in the ring.3 The replacement of two relatively 
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strong C-H bonds (110.5 kcal/mol) in methylcyclopropane (1.2) with relatively weaker allylic C-
H bonds in methylenecyclopropane (1.1) (99.3 kcal/mol) has also been reported to contribute to 
the added ring strain.4 
    
          Figure 1-1 Properties of methylcyclopropane and methylenecyclopropane 
 
The unique bonding characteristics of methylenecyclopropane (1.1) have been studied by 
several spectroscopic methods. Allen et al. showed that the exocyclic methylene distorts the C–C 
bond lengths in the cyclopropyl ring (Figure 1-2). Analysis of equilibrium geometries obtained 
from microwave and Raman studies show that the C1–C2 and C1–C3 bonds are 1.457 Å in 
methylenecyclopropane (1.1), which is slightly shorter than the bonds in the parent cyclopropane 
(1.3) (1.512 Å).5 In contrast, the opposite C2–C3 bond in methylenecyclopropane (1.1) was 
determined to be 1.542 Å, which is marginally longer than the parent cyclopropane (1.3) C–C 
bonds (1.512 Å).   
                       
    Figure 1-2 Geometric properties of cyclopropane and methylenecyclopropane  
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1.1.2 Biological Profile of Natural and Synthetic Methylenecyclopropanes 
Methylenecyclopropanes are found in several biologically active natural products and 
synthetic drug candidates. Amphimic acids A, B and C are a group of naturally occurring C27 or 
C28 methylenecyclopropane containing unsaturated fatty acids originally isolated from an 
Australian sea sponge of the genus Amphimedon at the Great Barrier Reef (Figure 1-3).6 These 
natural products exhibited inihibitory activity against human DNA topoisomerase I in 
preliminary biological evaluations. Amphimic acid A proved to be a potent inhibitor of human 
topoisomerase I with an IC50 of 0.47 µM. Amphimic acid B and C were less potent exhibiting an 
IC50 of 0.72 and 6.7 µM respectively. The natural product G1499-2 was isolated from a culture 
broth of Cytophaga johnsonii and was characterized by the presence of a methylenecyclopropane 
substituent on a 4-quinolinone core.7 G1499-2 showed moderate antibiotic activity against 
flavobacterium 1980 and Staphylococcus aureus. Hypoglycin A is a naturally occurring non-
proteinogenic amino acid isolated from unripened fruit of the Ackee tree.8 Its metabolite 
methylenecyclopropane acetyl CoA was identified as the causative agent of Jamaican vomiting 
sickness and is known to reduce blood glucose levels leading to hypoglycemia.9,10 Clinical 
features of the illness include hypoglycemia, cerebral edema, convulsions and vomiting, which 
can progress to coma and in severe cases death.  
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Figure 1-3 Select methylenecyclopropane-containing natural products   
 
Several methylenecyclopropane nucleosides possess potent antiviral activities. 
Cyclopropavir is a potent inhibitor of human cytomegalovirus with an EC50 of 0.46 µM and is 
currently undergoing early stage clinical trials for the treatment of this viral disease.11 
Cyclopropavir also demonstrated antiviral activity against Epstein-Barr virus and human 
herpesvirus HHV-6 and HHV-8. The analogue (S)-synaguanol exhibited a broader spectrum of 
antiviral properties including anti-hepatitis B and anti-HIV activity.12  
 
       Figure 1-4 Selected methylenecyclopropane nucleosides  
1.1.3 Synthesis of Methylenecyclopropanes 
Despite their high strain energy, many methylenecyclopropanes are surprisingly stable. 
The parent hydrocarbon 1.1 was first synthesized in 1952 by Gragson who showed that the 
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reaction of 3-chloro-(2-chloromethyl)-1-propene (1.4) with magnesium in refluxing THF formed 
methylenecyclopropane (1.1) in 17% yield after fractional distillation (Scheme 1-1).13 The 
boiling point was determined to be 8.8 °C.  
                               
Scheme 1-1 Synthesis of methylenecyclopropane by Gragson 
 
Numerous synthetic methods have since emerged to construct methylenecyclopropanes. 
These syntheses have been the subject of several comprehensive reviews and can be broadly 
classified into two major groups,14,15,16,17 specifically, reactions that form the cyclopropane ring 
or reactions that form the exocyclic olefin from a pre-formed cyclopropane. The following 
section provides a brief overview of these approaches.  
1.1.3.1 Cyclopropyl Ring Formation 
The addition of a carbene to an unsaturated alkene or allene is one of the most 
extensively utilized and general methods to form methylenecyclopropanes. Two variants of this 
reaction have been developed.  
The first approach involves the addition of an alkylidenecarbene to an olefin to forge the 
cyclopropyl ring through C1–C2 and C1–C3 bond formation (Scheme 1-2a). The 
alkylidenecarbene substrate is typically generated by a base-mediated, thermal or 
photochemically induced 1,1-elimination of a substituted alkene.17 One example of this 
alkylidenecarbene cyclopropanation is the reaction of 1,1-dibromo-2-methyl-1-propene (1.5) and 
vinyl ether 1.6 with methyllithium to form methylenecyclopropane 1.7 in 59% yield (Scheme 1-
2b).18   
Cl
Mg
THF, reflux; 17%
Cl
Bp. 8.8 °C
1.4 1.1
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Scheme 1-2 Synthesis of methylenecyclopropanes by alkylidenecarbene addition to an olefin 
 
The second variant of this approach involves the cyclopropanation of an allene with a 
diazo carbenoid to forge the cyclopropyl ring through C1–C2 and C2–C3 bond formation 
(Scheme 1-3a). Highly stereoselective variants of this reaction have been developed, particularly 
in the presence of transition metal catalysts like rhodium, ruthenium and copper complexes. For 
example, during their synthetic studies toward members of the Melodinus alkaloid family, the 
Stoltz group showed that the reaction of homoallenyl acetate 1.8 with dimethyl 2-diazomalonate 
1.9 in the presence of 0.1 mol% of the dirhodium complex Rh2(esp)2 formed the E-isomer 1.10 in 
80% yield (Scheme 1-3b).19  
 
      
Scheme 1-3 Methylenecyclopropane formation by carbenoid addition to an allene 
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Huang et al. have reported a stepwise variant of this strategy in which 
methylenecyclopropanes were synthesized through sequential formation of the C1–C2 and C2–
C3 bonds (Scheme 1-4).20 In this approach, a base-mediated intermolecular cyclization of 
bromoallene 1.11 and dimethyl malonate proceeded smoothly to deliver methylenecyclopropane 
1.14 in 74% yield. Various mono- and disubstituted aryl bromoallenes were tolerated. The 
mechanism is proposed to involve initial attack of the dimethyl malonate carbanion on the 
central carbon of the bromoallene 1.11 to generate intermediate 1.12. An intramolecular proton 
transfer then forms the allylic anion 1.13. Finally, an intramolecular substitution reaction of 
carbanion 1.13 produces methylenecyclopropane 1.14.  
 
Scheme 1-4 Methylenecyclopropane formation by an addition/elimination sequence   
1.1.3.2 Exocyclic Olefin Formation 
The conversions of 1-alkylcyclopropanes to the corresponding olefins by elimination 
reactions are among the most widely utilized and practical methods to form 
methylenecyclopropanes. For example, tertiary halides 1.15 and 1.17 readily undergo 
dehydrohalogenation upon treatment with base to from methylenecyclopropanes 1.16 and 1.18 in 
75% and 69% yield respectively (Scheme 1-5b and 1-5c).21,22 
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Scheme 1-5 Methylenecyclopropane formation by elimination of HX  
The dehydro-elimination of a non-halogen group like a selenoxide is another practical 
way to synthesize methylenecyclopropanes (Scheme 1-6a). Liu and colleagues showed that the 
oxidation of cyclopropyl selenide 1.19 with mCPBA formed the corresponding selenoxide, 
which then underwent syn-elimination to form olefin 1.20 (Scheme 1-6b).23 The de Meijere 
group demonstrated that the oxidation of the phenylselenyl group in 1.21 with mCPBA followed 
by β-elimination produced the corresponding α,β-unsaturated ester 1.22 in 89% yield (Scheme 
1-6c).24
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Finally, the elimination of an XY group is also frequently exploited to form 
methylenecyclopropanes from cyclopropane precursors (Scheme 1-7a). For example, lithiated 
cyclopropane 1.23 reacted with benzophenone to give intermediate β-hydroxy silane 1.24. This 
intermediate then underwent a Peterson elimination upon treatment with KH to afford 
methylenecyclopropane 1.25 in 81% yield (Scheme 1-7b).25 Taguchi demonstrated that the 
reaction of β-hydroxy silane 1.26 with TBAF at low temperatures in THF formed the 
corresponding difluorosubstituted methylenecyclopropane 1.27 in 80% yield (Scheme 1-7c).26  
 
 
Scheme 1-7 Methylenecyclopropane formation by elimination of XY 
 
Alkylcyclopropenes can be transformed into methylenecyclopropanes by isomerizations 
or nucleophilic displacement reactions (Scheme 1-8a). Shi et al. showed that arylcyclopropene 
1.28 could be converted into the E-methylenecyclopropane 1.29 in 65% yield by a DBU-
mediated isomerization (Scheme 1-8b).27 Marek developed a copper-catalyzed addition 
of LiAlH4 to cyclopropenylcarbinol 1.30 to form methylenecyclopropane 1.31 in 87% yield 
(Scheme 1-8c). The reaction proceeds through a formal SN2’ reaction to produce the 
methylenecyclopropane exclusively.28 Hydroalumination of the cyclopropenyl alkene was not 
observed.  
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    Scheme 1-8 Methylenecyclopropane formation by double bond isomerization and allylic alcohol reduction 
 
Other, albeit less widely utilized methods to form methylenecyclopropanes include the 
rearrangement of metal-allyl complexes, Wittig reactions, Horner-Wadsworth-Emmons 
reactions, Horner-Wittig olefinations and rearrangement reactions of cyclobutyl carbenes.15 
 
1.1.4 Synthesis of Chiral Methylenecyclopropanes 
 Methods to access enantioenriched methylenecyclopropanes are limited. Most 
approaches rely on enzymatic resolution or the use of chiral substrates and have narrow substrate 
scope. For example, the desymmetrization of prochiral alcohols by a lipase-catalyzed acylation is 
commonly used to produce enantiopure alcohols. The reaction of prochiral diol 1.32 with 
Pseudomonas fluorescens lipase AK or porcine pancreas lipase produced monoacetate 1.33 in 
>98% ee (Scheme 1-9).29 
     
 Scheme 1-9 Enzymatic resolution of prochiral methylenecyclopropyl diol 
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The majority of protocols to form chiral methylenecyclopropanes rely on the use of 
enantiomerically pure starting materials. For example, the Satoh group showed that the reaction 
of the enantiopure sulfoxide 1.34 with cyclopentylmagnesium chloride generated the 
corresponding magnesium carbenoid, which underwent spontaneous rearrangement to provide 
methylenecyclopropane 1.35 in 87% yield and 97% ee (Scheme 1-10).30  
 
Scheme 1-10 Conversion of enantiopure cyclobutane into a chiral methylenecyclopropane 
 
When enantiopure alcohol 1.36 was reacted with chlorodiphenylphosphane at room 
temperature, intermediate 1.37 formed and a spontaneous [3,3]-sigmatropic rearrangement 
occurred to form diphenylphosphine oxide derivative 1.38 in 85% yield and with complete 
transfer of chirality (Scheme 1-11).31  
 
        Scheme 1-11 Methylenecyclopropane synthesis by a [3,3]-sigmatropic rearrangement  
 
In the last decade, significant advances have been made in the synthesis of chiral 
methylenecyclopropanes from enantioenriched cyclopropene precursors. The Marek group 
showed that the reaction of cyclopropenylcarbinols like 1.39 with excess Grignard reagent in the 
presence of substoichiometric amounts of CuI produced enantiopure methylenecyclopropanes 
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such as 1.40 in good yield and diastereoselectivity (Scheme 1-12a).32 Excellent retention of 
chirality from chiral cyclopropene 1.39 (99% ee) to methylenecyclopropane 1.40 (97% ee) was 
observed. Corey demonstrated that the reaction of enantiopure cyclopropenyl ester 1.41 with 
TASF at -78 °C under an atmosphere of CO2 generated a methylenecyclopropane carboxylic acid 
intermediate 1.42, which upon esterification with phenyldiazomethane gave the chiral 
methylenecyclopropane 1.43 in 65% yield over two steps and 98% ee (Scheme 1-12b).33 Notable 
contributions to this area have been made by the Fox group who showed that enantiomerically 
pure alkylcyclopropenes could be converted to methylenecyclopropanes in high yield and with 
broad substrate scope by a nucleophilic displacement reaction (Scheme 1-12c).34,35 Under 
optimized conditions they found that the reaction of cyclopropenyl alcohol 1.44 with excess 
MeMgBr proceeded with excellent regio- and diastereoselectivity to form 
methylenecyclopropane 1.46 in 86% yield and 82% ee. The free alcohol is proposed to chelate 
one equivalent of Grignard reagent to direct the delivery of the reagent from the same face in a 
pseudo-intramolecular manner. A second equivalent of the Grignard reagent is proposed to act as 
a Lewis acid to coordinate the MEM ether and olefin and block delivery of the Grignard to the 
more substituted position of the double bond.  
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Scheme 1-12 Synthesis of chiral methylenecyclopropanes from enantiopure cyclopropenes 
 
A catalytic asymmetric Michael addition of aldehyde 1.47 to a series of nitrostyrenes in 
the presence of organocatalyst 1.49 has been reported (Scheme 1-13). The reaction between 
aldehyde 1.47 and nitrostyrene 1.48 in the presence of catalytic amounts of the chiral prolinol 
catalyst 1.49 and 4-nitrophenol as an acid co-catalyst furnished methylenecyclopropane 1.50 in 
63% yield and 93% ee. A variety of electron deficient and electron rich aryl substituents and a 2-
thienyl substituent were tolerated on the olefin component, giving the corresponding 
methylenecyclopropanes in moderate yields (27-60%) and high enantiomeric excesses (85-99% 
ee).36  
  
Scheme 1-13 Catalytic asymmetric Michael addition to nitroalkenes 
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1.1.5 Enantioselective Cyclopropanations of Allenes 
Only three transition metal catalyzed enantioselective cyclopropanations of substituted 
allenes with diazoesters have been reported.37 This is surprising given the wide array of chiral 
catalysts available for the analogous reaction with alkyl olefins and styrenes. Gregg et al. 
developed a Rh2(S-DOSP)4 catalyzed cyclopropanation of diazoester 1.52 with several mono- 
and 1,1-disubstituted allenes to form methylenecyclopropanes in 80-90% ee. One example 
includes the cyclopropanation of phenylallene 1.51 with ester 1.52 to produce 
methylenecyclopropane 1.54 in 76% yield and 90% ee (Scheme 1-14).38    
      
Scheme 1-14 Rh2(S-DOSP)4 catalyzed enantioselective cyclopropanation of phenylallene 
 
Iwasa reported that Ru(II)–Ph-Pheox (1.57) was an excellent catalyst for the asymmetric 
cyclopropanation of allenes with succinimidyl diazoacetate (Scheme 1-15).39 
Methylenecyclopropane products were obtained in high enantiomeric excesses ranging from 84-
99% ee. The Ru(II)-Ph-Pheox catalyzed cyclopropanation of cyclohexylallene with succinimidyl 
diazo acetate proceeded smoothly at room temperature to form methylenecyclopropane 1.58 in 
82% yield and 92% ee with excellent selectivity for the E-isomer.  
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Scheme 1-15 Ru(II)-Ph-Pheox catalyzed asymmetric cyclopropanation of cyclohexylallene  
 
Finally, Charette showed that chiral dirhodium complex Rh2(S-IBAZ)4 (1.60) can catalyze 
the enantioselective cyclopropanation of diacceptor diazoesters with several mono- and 1,1-
disubstituted allenes (Scheme 1-16).40 The reaction between phenylallene 1.51 and diazo ester 
1.59 in the presence of catalytic Rh2(S-IBAZ)4 delivered methylenecyclopropane 1.61 in 92% 
yield and 95% ee.  
      
Scheme 1-16 Rh2(S-IBAZ)4 catalyzed cyclopropanation of phenylallene with an α-cyano diazo ester  
  
A major limitation of these methods is the restriction of the allene component to 
substituted allenes, especially arylallenes. Expanding the scope of the allene substitution is 
necessary to further improve the utility of this methodology. We were thus interested in 
developing a method to access terminally unsubstituted methylenecyclopropanes in an 
enantioselective manner.  
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1.2 RESULTS AND DISCUSSION 
The Wipf group has an ongoing interest in the synthesis and application of terminally 
unsubstituted methylenecyclopropanes. During the groups first total synthesis of cycloclavine the 
methylenecyclopropane 1.62 was converted into methylenecyclopropyl diene 1.63 and subjected 
to an intramolecular Diels-Alder reaction to forge the indoline-fused cyclopropane core 1.64 of 
the natural product (±)-cycloclavine (Figure 1-5).41  
 
Figure 1-5 Methylenecyclopropane Diels-Alder reaction en route to cycloclavine 
 
In order to accomplish an enantioselective synthesis of cycloclavine, we sought to 
develop an enantioselective synthesis of a terminally unsubstituted methylenecyclopropane like 
1.65 (Figure 1-6). To achieve this goal, we envisioned that methylenecyclopropane 1.65 could be 
formed through an enantioselective cyclopropanation of diazopropanoate 1.66 with an allene 
1.67 using a transition metal catalyst and chiral ligand. Alternatively, an approach could use the 
reaction of diazopropanoate 1.66 with olefin 1.68, followed by exocyclic alkene formation.  
 
        
Figure 1-6 Proposed cyclopropanation of an allene or alkene with a diazopropanoate 
N
1.62 1.64
N
H
HN
OTBS
N
OTBS
H
[4+2]
1.63
OH
(±)-cycloclavine
O
1.65
OR*
ML*n 
asymmetric 
cyclopropanation
•R
OR
O
N2
+
1.67
1.66
X1
X2
or
1.68
 17 
1.2.1  Cyclopropanations with α-Alkyl Diazoesters   
Diazopropanoates like 1.66 are difficult substrates for metal-mediated cyclopropanations 
because of the propensity of the corresponding metal carbenoid 1.70 to undergo competing β-
hydride elimination to form an acrylic ester 1.71 rather than the desired intermolecular 
cyclopropanation to form cyclopropane ester 1.69 (Figure 1-7).   
 
Figure 1-7 Competing β-hydride migration and cyclopropanation pathways  
 
In the past decade, several methods have emerged that address these limitations. In a 
landmark study, Fox et al. found that dirhodium complexes with sterically hindered carboxylate 
ligands in conjunction with low reaction temperatures effectively promoted intermolecular 
cyclopropanations over the competing β-H migration pathway.42 The achiral catalyst 
tetrakis(triphenylacetato) dirhodium(II) Rh2(TPA)4 was particularly effective at converting a 
range of α-alkyl-α-diazoesters to the corresponding cyclopropanes in high yield and with 
excellent diastereoselectivity.42 The Fox group subsequently reported an enantioselective variant 
of this reaction using bulky carboxylate ligands derived from L-tert-leucine. The N-imido-tert-
leucinate complexes Rh2(S-PTTL)4 (1.72) and Rh2(S-PTTL)3TPA (1.73) were identified as the 
most effective catalysts providing cyclopropanes in high enantiomeric excesses (Scheme 1-17). 
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The level of enantioinduction was sensitive to the length of the α-alkyl side chain. High levels of 
enantioinduction were obtained for diazoesters incorporating a long side chain. The 
corresponding methylenecyclopropane esters 1.74a-1.74d were obtained in high ee’s ranging 
from 79-96% ee.  
 
Scheme 1-17 Fox’s approach for the enantioselective cyclopropanation of α-alkyl-α-diazoesters 
 
Recently, Hashimoto et al. showed that the substrate scope of these reactions could be 
further expanded to include diazopropanoates when the dirhodium complex Rh2(S-TBPTTL)4 
(1.75) was used as the catalyst (Scheme 1-18).43 The use of sterically bulky esters with styrene 
derivatives as the olefin component led to high levels of enantioinduction (86-92% ee for esters 
1.76a-1.76d). 
R
N2
OEt
O
+ Ph
Rh2(L*)4
(0.5 mol%)
hexanes, -78 °C
CO2EtR
Ph
CO2Et
Ph
Me
Me
1.74b
catalyst 1.72: 92% (99% ee)
Rh2(S-PTTL)4 (1.72)
Rh Rh
OO
NH
t-Bu
O
O
4
Rh2(S-PTTL)3TPA (1.73)
Rh Rh
OO
N
H
t-Bu
O
O
3
O O
Ph PhPh
CO2EtEt
Ph
1.74a
catalyst 1.72: 95% (79% ee)
catalyst 1.73: 91% (88% ee)
CO2Etn-Pr
Ph
              1.74c
catalyst 1.72: 100% (94% ee)
catalyst 1.73: 92% (95% ee)
CO2Etn-Bu
Ph
              1.74d
catalyst 1.72: 96% (96% ee)
catalyst 1.72: 93% (96% ee)
 19 
 
Scheme 1-18 Hashimoto’s approach for the enantioselective cyclopropanation of diazopropanoates 
1.2.2 First Strategy: Enantioselective Cyclopropanation/Elimination 
Our first approach to form the enantioenriched methylenecyclopropane 1.65 is outlined in 
Figure 1-8. We proposed that the chiral methylenecyclopropane 1.65 could be obtained via 
sequential Rh(II)-catalyzed asymmetric cyclopropanation and elimination reactions.   
    
         Figure 1-8 First strategy to access enantioenriched methylenecyclopropane 1.65 
 
Dirhodium catalysts Rh2TPA4 (1.83) and Rh2(S-PTTL)4 (1.72) were prepared according 
to literature protocols and screened in the cyclopropanation of ethyl 2-diazopropanoate (1.80) 
and 2-bromopropene (1.78) (Table 1-1, Entries 1-3) or 2,3-dichloroprop-1-ene (1.79) (Table 1-1, 
Entry 4).43,44 Unfortunately, the desired cyclopropane was obtained at best in a moderate yield of 
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39% and a poor er of 62:38 when Rh2(S-PTTL)4 (1.72) was employed as the catalyst and 2-
bromopropene (1.78) as the vinyl halide (Table 1-1, Entry 3).   
 
Table 1-1 Catalytic Asymmetric Cyclopropanation of Vinyl Halides 
 
Entry Substrate Catalyst Solvent Yield er 
1 1.78 Rh2(OAc)4 CH2Cl2 0% - 
2 1.78 1.83 CH2Cl2 8%a - 
3 1.78 1.72 hexanes 39%a 62.4: 37.6 b,c 
4 1.79 1.72 hexanes 26%a NDd 
aisolated yield; bee determined by chiral GC; cabsolute configuration was not determined; dnot determined. 
 
All attempts to convert cyclopropane 1.81 to the corresponding methylenecyclopropane 
using a variety of bases including NaH, KOt-Bu, DBU and KOH and in the presence of super-
stoichiometric silver nitrate (Scheme 1-19) failed. Additionally, no reaction was observed when 
vicinal dichloride 1.82 was subjected to a zinc-mediated dehalogenation reaction.  
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           Scheme 1-19 Attempted elimination reactions to form methylenecyclopropane 1.84 
 
The poor enantioinduction in the cyclopropanation step combined with the failure of 
tertiary halides to undergo an elimination reaction to the corresponding methylenecyclopropane 
forced us to revise our strategy.  
1.2.3 Second Strategy: Enantioselective Cyclopropanation of a Silyl Allene 
We reasoned that using an allene in the asymmetric cyclopropanation would provide 
direct access to a functionalized methylenecyclopropane, thus circumventing the problematic 
elimination step. Retrosynthetically, we expected that terminal methylenecyclopropanes such as 
1.65 could be formed from the corresponding vinyl silanes 1.85 by a protodesilylation reaction 
(Figure 1-9). The substituted methylenecyclopropane 1.85 could in turn be synthesized by a 
rhodium(II) carboxylate catalyzed enantioselective cyclopropanation of a silyl allene 1.86 and a 
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diazopropanoate 1.66. Furthermore, we hoped that the silyl group would facilitate the 
cyclopropanation through the well-documented β-silicon effect.38   
 
Figure 1-9 Cyclopropanation/protodesilylation strategy  
 
The syntheses of the known diazo ester substrates 1.80 and 1.89-1.91 are outlined in 
Scheme 1-20. The two-step protocol began with the deprotonation of β-ketoesters 1.87 with NaH 
followed by alkylation of the carbanion intermediate with methyl iodide. The methylated 
products 1.88 were then converted into the diazo esters 1.66 by a Regitz diazo transfer 
reaction.45,46 
 
        Scheme 1-20 Preparation of alkyl diazopropanoates by alkylation and Regitz diazo transfer reactions 
  
In order to establish the ee of the methylenecyclopropane products, the ester products 
were reduced to the corresponding alcohols and reacted with (R)-(−)-MTPACl to give the 
diastereomeric Mosher ester adducts 1.93 and 1.94 (Scheme 1-21). The dr was determined by 
NMR analysis of the crude reaction mixture and reflects the enantiomeric enrichment obtained in 
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the prior cyclopropanation step. Complete conversion of the alcohol to the ester is important for 
accurate dr measurements due to differing rates of formation of the (S,S)- and (R,S)-
diastereomers.47  
 
       Scheme 1-21 Resolution of enantioenriched esters with (R)-(–)-MTPACl to assess ee  
  
Our investigation commenced with a catalyst screen using the reaction of ethyl 
diazopropanoate with DMPS allene as a model system (Table 1-2, Entries 1-3). We were pleased 
to see that the reaction proceeded smoothly in the presence of the achiral catalyst Rh2(TPA)4 to 
form the desired methylenecyclopropane in 60% yield (Table 1-2, Entry 1). Next, chiral catalysts 
1.72 and 1.73 were evaluated. The dirhodium complex Rh2(S-PTTL)3•TPA (1.73) formed the 
desired methylenecyclopropane, albeit in a low yield of 31% and a poor er of 69:31 (Table 1-2, 
Entry 2). Switching to Rh2(S-PTTL)4 (1.72) resulted in a better yield of 61% and an improved er 
of 76:24 (Table 1-2, Entry 3). Using Rh2(S-PTTL)4 (1.72) as the optimal catalyst we then 
examined the cyclopropanation of different ester substrates. Unfortunately, the benzyl, t-butyl 
and menthyl diazo esters 1.89-1.91 resulted in moderate yields and poor er’s in all cases (Table 
1-2, Entries 4-6). The best result was obtained using a menthyl diazo ester 1.91 in the presence of 
the achiral catalyst Rh2(TPA)4 (1.83) (Table 1-2, Entry 7), which gave the 
methylenecyclopropane adduct in a good yield of 83% and an er of 19:81. 
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Table 1-2 Catalytic Asymmetric Cyclopropanation of DMPS Allene  
 
Entry R Catalyst Solvent T (°C) Yield (%) era,b 
1 OEt (1.80) 1.83 CH2Cl2 -78 60 50:50 
2 OEt (1.80) 1.73 hexanes -78 31 69:31 
3 OEt (1.80) 1.72 hexanes -78 64 76:24 
4 OBn (1.89) 1.72 hexanes -78 41 72:28 
5 Ot-Bu (1.90) 1.72 hexanes -78 34 68:32 
6 
 (1.91) 
 
1.72 
 
hexanes 
 
-78 
 
62 
 
73:27 
7 
 (1.91) 
 
1.83 
 
CH2Cl2 
 
-78 
 
83 
 
19:81c 
abased on analysis of MTPA-ester derivative; bthe absolute configuration was not determined; cfavors the opposite 
enantiomer.  
 
In addition to the modest enantioinduction observed in the reaction, all attempts to 
convert the vinylsilane to the terminal methylenecyclopropane failed. Attempts to remove the 
silyl group using nucleophilic fluoride conditions gave no reaction or decomposition under 
harsher conditions (TBAF 5 eq., 80 °C, overnight). Additional attempts to cleave the analogous 
TMS or TBS methylenecyclopropane with reagents such as TBAF, HF•pyridine and AgF also 
failed to deliver the desired product. Overall, the poor enantioinduction combined with the 
failure to promote protodesilylation of the vinylsilane products forced us to further revise our 
strategy. 
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1.2.4 Third Strategy: Enantioselective Cyclopropanation of Allene 
For our third-generation strategy we planned to exploit the asymmetric cyclopropanation 
of a diazopropanoate with unsubstituted allene (1.96) to form the chiral methylenecyclopropane 
1.65 (Figure 1-10).  
     
  Figure 1-10 Retrosynthetic analysis of methylenecyclopropane 1.65 
 
Allene is an ideal, atom-economical precursor to methylenecyclopropanes. However, the 
successful use of allene in an enantioselective metal carbenoid cyclopropanation remained 
uncertain because only two metal-mediated cyclopropanations of allene were reported in the 
literature, and both reactions gave poor yields of racemic product (Scheme 1-22).48,49 
 
Scheme 1-22 Precedent for metal carbenoid cyclopropanations of allene 
 
Our efforts began with the synthesis of a series of activated esters to screen in the 
asymmetric cyclopropanation reaction (Scheme 1-23). The condensation of pyruvic acid with 
tosyl hydrazine under acidic conditions provided hydrazone 1.97 in 93% yield.  The resulting 
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hydrazone was treated with N-hydroxy succinimide under Steglich esterification conditions, 
followed by triethylamine to deliver the diazo ester 1.98 in 63% yield. Alternatively, hydrazone 
1.97 could be converted into the acid chloride followed by esterification with pentafluorophenol 
or pentachlorophenol to deliver the corresponding ester intermediates. Base-mediated diazo 
formation produced diazo esters 1.99 and 1.100 in 21% and 17% yield, respectively.   
 
 
Scheme 1-23 Synthesis of diazo substrates bearing an activated ester  
 
With the requisite diazo esters in hand, we first explored the feasibility of the key 
cyclopropanation of unsubstituted allene. We were delighted to see that the reaction of ethyl 
diazopropanoate 1.80 and allene 1.96 proceeded smoothly at low temperature in the presence of 
a catalytic amount of the achiral dirhodium catalyst Rh2(TPA)4 1.83 to afford the desired 
methylenecyclopropane (±)-1.101 in 88% yield (Scheme 1-24).  
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     Scheme 1-24 Trial cyclopropanation of allene with ethyl diazopropanoate 
 
Next, a substrate screen was conducted to identify the optimal diazo ester. The dirhodium 
catalyst Rh2(S-TBPTTL)4 (1.75) was chosen for initial enantioselective conversions because of 
its successful use in a related cyclopropanation of diazopropanoates and styrene derivatives.43 
The enantiomeric excess of the ester product was evaluated by reduction of the ester to the 
alcohol and derivatization as the Mosher ester using the same protocol employed earlier for the 
methylenecyclopropyl silanes (Scheme 1-25). The absolute configuration of the major 
enantiomer was tentatively assigned at this stage by comparing the optical rotation sign of the 
ester products 1.65 to the reported optical rotation sign of related compounds of known absolute 
configuration.43 The absolute configuration of the methylenecyclopropanes 1.65 was 
unambiguously determined the completion of the synthesis of enantiomerically pure 
cycloclavine.  
 
      
       Scheme 1-25 Resolution of enantioenriched esters with (R)-(–)-MTPACl to assess er 
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We found that both the reaction outcome and degree of enantioinduction was influenced 
by the nature of the ester. Unfortunately, the menthyl diazo ester 1.91 failed to deliver the 
desired methylenecyclopropane (Table 1-3, Entry 4). However, a moderate er of 81:19 was 
obtained with the ethyl diazopropanoate 1.80 (Table 1-3, Entry 1). Pleasingly, the sterically 
demanding t-butyl diazopropanoate 1.90 delivered the best er at low temperatures (Table 1-3, 
Entries 2 and 3). However, for additional transformations, methylenecyclopropanes bearing a 
Weinreb amide or activated ester to facilitate direct aminolysis were more attractive (Table 1-3, 
Entries 5-8). Disappointingly, the Weinreb amide 1.104 failed to deliver the expected 
methylenecyclopropane (Table 1-3, Entry 5). In contrast, we were pleased to see that the 
activated ester diazo compounds 1.98, 1.99 and 1.100 were compatible with the reaction 
conditions. A moderate degree of enantioinduction was obtained with the succinimide 1.98 and 
pentachlorophenyl 1.100 diazopropanoates (Table 1-3, Entries 6 and 7). Gratifyingly, the 
pentafluorophenyl diazopropanoate 1.99 provided better enantioinduction, delivering the desired 
methylenecyclopropane in a good er of 87:13 and a high yield of 86% (Table 1-3, Entry 8).  
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Table 1-3 Catalytic Asymmetric Cyclopropanation of Allene: Diazo Ester Screen 
 
Entry R T (°C) Yield           era 
1 OEt (1.80) -78 20-62b 81:19c 
2 Ot-Bu (1.90) -78 51 91:9d 
3 Ot-Bu (1.90) -98 to -80 47 93:7d 
4 
 (1.91) 
-78  0 - 
5 NMeOMe (1.104) -78 0 - 
6 OSue (1.98) -78f to rt 27 77:23d 
7 OPcpg (1.100) -78 74h(84)i 77:23d 
8 OPfpj (1.99) -78  86 87:13 c 
athe absolute configuration was assigned based on literature43 and the specific rotation of (−)-cycloclavine; bvariable 
isolated yields due to volatility of product; cer determined by SFC analysis of derivative 2.87; der was determined by 
1H NMR analysis of the diastereomeric Mosher esters; esuccinimidyl; fnegligible conversion at -78 °C; 
gpentachlorophenyl; hreaction on 0.2 mmol scale; ireaction on 9 mmol scale; jpentafluorophenyl. 
 
 
Since the pentachlorophenyl methylenecyclopropane 1.105 was obtained as a crystalline 
solid we attempted to upgrade the er by preferential crystallization of the excess enantiomer 
(Figure 1-11).50 Interestingly, after two crystallizations from boiling heptanes we found that the 
mother liquor had been enriched from an er of 77:23 to 88:12. Switching solvent and 
crystallizing the mother liquor a third time from boiling 1,2-dichloroethane only slightly 
enriched the mother liquor to an er of 90:10. An x-ray crystal structure of 
methylenecyclopropane 1.105 was obtained confirming the structure of the product.   
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Figure 1-11 X-ray of 1.105 and attempts to upgrade the ee by crystallization 
     
Next, a catalyst screen was carried out. The commercially available or known dirhodium 
catalysts 1.53, 1.106, 1.72, 1.107 and 1.75 were evaluated (Figure 1-12).51,52,53 The ruthenium(II) 
complex 1.57 was also selected because it was highly effective in related asymmetric 
cyclopropanations of various mono- and disubstituted allenes with succinimidyl diazoacetate.39 
The (salen)cobalt(II) catalyst 1.108 was also screened since Katsuki showed that it was an 
excellent catalyst for the enantioselective cyclopropanation of α-alkyl diazoacetates and styrene 
derivatives.54  
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Figure 1-12 Selected chiral catalysts  
 
The chiral catalysts in Figure 1-12 were evaluated in the reaction of allene (1.96) and 
pentafluorophenyl diazopropanoate (1.99) to form methylenecyclopropane 1.109 (Table 1-4). 
We found that the reaction of Ru(II)-Ph-Pheox (1.57) did not deliver the desired 
methylenecyclopropane. Instead, upon warming the reaction from -78 °C to room temperature, 
full conversion to the undesired β-H elimination product 1.110 was observed (Table 1-4, Entry 
1). Davies’ proline based catalyst Rh2(R-DOSP)4 (1.53) provided the desired 
methylenecyclopropane in a moderate yield of 61%. Unfortunately, negligible enantioinduction 
was observed (Table 1-4, Entry 2). Similarly, the chiral cyclopropane catalyst 1.106 delivered 
the desired product in moderate yields and with poor enantioinduction (Table 1-4, Entry 3). 
Next, we evaluated different Rh(II) catalysts with sterically hindered carboxylate ligands. The 
dirhodium catalysts Rh2(S-PTTL)4 (1.72) and Rh2(S-PTAD)4 (1.107) led to slight improvements 
in er to ~70:30 (Table 1-4, Entries 4-5). The (salen)cobalt(II) catalyst 1.108 showed no catalytic 
activity (Table 1-4, Entry 6). Overall, Hashimoto’s tetrabromophthaloyl tert-leucine dirhodium 
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catalyst 1.75 remained the optimal catalyst, giving desired cyclopropane 1.109 in a high yield 
with a good er of 87:13 (Table 1-4, Entry 7).  
 
Table 1-4 Catalytic Asymmetric Cyclopropanation of Allene: Catalyst Screen 
 
Entry Catalyst Solvent T (° C) Product Yield (%) 
era 
(SFC) R/S 
1 
[Ru(II) (S)-Ph-Pheox]PF6 
(1.57) 
CH2Cl2 -78 to rt 1.110 ND - - 
2 Rh2(R-DOSP)4 (1.53) hexanes -78 1.109 61 53:47 R 
3 Rh2(R-BTPCP)4 (1.106) CH2Cl2 -78 1.109 59 59:41 S 
4 Rh2(S-PTTL)4 (1.72) hexanes -78 1.109 83 72:28 R 
5 Rh2(S-PTAD)4 (1.107) hexanes -78 1.109 84 73:27 R 
6 Co(II)-salen (1.108)b THF -78 to rt NR - - - 
7 Rh2(S-TBPTTL)4 (1.75) CH2Cl2 -78 1.109 86 87:13 R 
athe ester was derivatized as the vinylogous imide 2.87 for SFC analysis; b10 mol% NMI was employed in the 
reaction  
 
 
Given the success of the sterically demanding dirhodium tetrabromophthaloyl-tert-
leucine catalyst, we synthesized a novel sterically demanding dirhodium catalyst 1.117, 
reasoning that the 4,7-diphenyl substitution pattern on the phthalimide ring would impose greater 
steric demand than the corresponding bromide substituents, hopefully leading to greater 
differentiation between the enantiotopic faces of the allene (Scheme 1-26). The synthesis of the 
catalyst began with a Diels-Alder reaction of diphenylbutadiene 1.111 and maleic anhydride 
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1.112 to afford bicycle 1.113 in 78% yield. DDQ oxidation delivered phthalic anhydride 1.114 
which was reacted with S-tert-leucine (1.115) in the presence of triethylamine to form 
phthalimide 1.116. A ligand exchange reaction generated the dirhodium catalyst 1.117 in 48% 
yield.  
 
Scheme 1-26 Synthesis of dirhodium catalyst 1.117   
 
Unfortunately, when allene was reacted with pentafluorophenyl diazopropanoate (1.99) 
in the presence of the novel dirhodium catalyst Rh2(S-4,7-DPPTTL)4 (1.117) no reaction 
occurred at -78 °C and the reaction had to be warmed to -40 °C before conversion was observed. 
Disappointingly, virtually no enantioinduction was observed in this reaction (55:45 er, Scheme 
1-27).  
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Scheme 1-27 Cyclopropanation of allene using Rh2(S-4,7-DPPTTL)4 
 
An X-ray structure of the catalyst Rh2(S-TBPTTL)4 (1.75) was obtained by Hashimoto 
and coworkers. The X-ray structure revealed that the dirhodium complex adopts a C4 symmetric 
chiral crown conformation in the solid state form.55 This same conformation was reported for the 
related catalyst Rh2(S-PTTL)4 and other phthalimide based catalysts.53,56 In this conformation the 
four phthalimide moieties are oriented on the same face and form four halogen bonds between a 
carbonyl of the phthalimide and a bromide substituent on an adjacent ligand (Figure 1-13a). The 
four tert-butyl groups are oriented on the opposite face and block approach from that face. 
Assuming the chiral crown conformation is formed in solution, Hashimoto proposed a plausible 
stereochemical pathway to explain the high levels of enantioselectivity observed using Rh2(S-
TBPTTL)4 in the enantioselective cyclopropenation of alkynes and α-alkyl-α-diazoesters.55 
Their hypothesis was supported by DFT calculations of the proposed transition states. According 
to their analysis transition state A should be strongly favored over transition state B in our 
system due to the unfavorable steric repulsion that arises between the pentafluorophenyl ester 
and the tetrabromophthalimido ligand in transition state B (Figure 1-13a).  
In the case of the dirhodium 4,7-diphenylphthaloyl tert-leucine [Rh2(S-4,7-DPPTTL)4] 
complex, the poor er of 55:45 obtained suggests that there is negligible differentiation between 
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the enantiotopic faces of the allene substrate with this catalyst. Davies et al. have shown that 
chiral dirhodium carboxylate catalysts commonly exist in C1, C2, C4, or D2 symmetric 
conformations (Figure 1-13b). 56,57 Charette has postulated the chiral crown conformation of the 
tetrahalogenated phthalimido dirhodium catalysts is stabilized in solution by the halogen-
bonding interactions.56 In contrast, non-halogenated complexes, which lack this stabilizing 
interaction, may be less rigid in solution leading to scrambling of the ‘all up’ conformation. 
Furthermore, poor levels of enantioinduction were also observed with the Rh2(DOSP)4 catalyst 
(er 53:47; Table 1-4, Entry 2). Davies proposed that this catalyst adopts a D2 symmetric 
conformation in solution.58 This result indicates the D2 symmetric conformation is not effective 
at inducing high levels of enantioinduction in the cyclopropanation of allene with 
pentafluorophenyl diazopropanoate.  
   
Figure 1-13 a) Proposed transition states for the asymmetric cyclopropanation of allene with diazoester 1.99 b) 
possible conformations of dirhodium carboxylate catalysts. (Figure 1-13 b was reprinted with permission from 
Lindsay, V. N. G.; Lin, W.; Charette, A. B. J. Am. Chem. Soc. 2009, 131, 16383. Copyright 2009 American 
Chemical Society). 
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Thus the poor levels of enantioinduction observed for the novel [Rh2(S-4,7-DPPTTL)4] 
complex could be due to the scrambling of the optimal C4 chiral crown complex in solution 
which could give rise to a large number of possible transition states and lead to low overall 
enantioselectivity. Alternatively, the poor enantioinduction could be rationalized by a preference 
for an ineffective conformation of the catalyst such as the D2 conformation which is known to 
lead to poor enantioinduction in this system.   
1.3 CONCLUSIONS 
α-Methyl diazopropanoates were shown to be effective metal carbenoid precursors for 
asymmetric cyclopropanation reactions with dimethylphenylsilyl allene and unsubstituted allene. 
Key features of this chapter include the first use of unsubstituted allene in a catalytic asymmetric 
cyclopropanation reaction to deliver a range of methylenecyclopropanes bearing alkyl or 
activated ester moieties. This reaction is the most direct and atom-economical method to form 
methylenecyclopropanes with a terminal olefin. Although the mechanism of enantioinduction 
remains unclear, we determined that the degree of enantioinduction depends on the identity of 
the transition metal ion, the steric and electronic properties of the chiral ligand and the 
temperature.  
Overall, the dirhodium complex Rh2(S-TBPTTL)4 (1.75) was identified as the optimal 
catalyst for enantioselective conversions. The tert-butyl diazopropanoate (1.90) and the 
pentafluorophenyl diazopropanoate (1.99) were identified as the best substrates for 
enantioselective conversions, providing the corresponding methylenecyclopropanes in 47% 
yield/93:7 er and 86% yield/87:13 er respectively. The optimal solvent for the reaction was 
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dichloromethane. Looking forward to an enantioselective synthesis of cycloclavine, we selected 
the pentafluorophenyl diazopropanoate for further synthetic operations, hoping that the er could 
be further upgraded from 87:13 through recrystallization of a crystalline intermediate later in the 
synthesis.   
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2.0  TOTAL SYNTHESIS OF CLAVINE ALKALOIDS 
2.1 INTRODUCTION 
2.1.1 Ergot Alkaloids 
The ergot alkaloids are a large group of structurally diverse indole-containing natural 
products produced by Clavicipitaceae and Trichocomaceae fungi.59 These fungi are known to 
invade grass species causing ergot, a disease that is recognized by the replacement of healthy 
kernels with dark sclerotia that contain high concentrations of ergot alkaloids.59,60 Susceptible 
host plants include cultivated cereals like rye, sorghum, pearl millet, triticale, barley and oats as 
well as several species of wild grasses.61 Historically, ergot alkaloids have had a major impact on 
human health and agriculture.  During the Middle Ages, ingestion of ergot contaminated grains 
led to fatal epidemics of ergotism across central Europe.59 Two forms of the disease are 
described clinically. Convulsive ergotism is characterized by hallucinations, fever and 
convulsions, whereas, gangrenous ergotism is characterized by burning sensations in the limbs 
followed by gangrene caused by potent and long-lasting vasoconstriction.62 Ergotism in humans 
and livestock is rare in modern times because of the strict regulations governing the permissible 
amount of ergot in grain. However, ergotism can still cause economic loss when commercial 
grains are downgraded or discarded due to ergot contamination.63  
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Structurally ergot alkaloids can be classified into the lysergic acid or clavine subclasses 
based on the oxidation state of the C8 substituent (Figure 2-1). The lysergic acid subclass, which 
comprises both lysergic acid amides and ergopeptines have a C8 substituent at the carboxylic 
acid oxidation level. In contrast, the clavine subclass typically possess a C8 substituent at the 
alkane or alcohol oxidation state.64 Ergot alkaloids have an astonishingly diverse spectrum of 
pharmacological activity that covers numerous therapeutic areas including CNS diseases, 
obstetrics and oncology. These alkaloids bear a strong structural resemblance to natural 
neurotransmitters like serotonin, dopamine and adrenalin and as such the biological activities of 
these alkaloids have been attributed to agonistic or antagonistic activity toward neurotransmitter 
receptors. For example, the naturally occurring alkaloid ergotamine has been used to treat 
migraines, bromocriptine has been used to treat Parkinson’s disease and ergonovine is a front-
line pharmaceutical for the treatment of post-partum haemorrhage.65,66 
      
Figure 2-1 Lysergic acid and clavine subclasses and representative Ergot alkaloid pharmaceuticals 
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2.1.2 Clavine Alkaloids: Structure and Biological Profile 
The clavine alkaloids can be divided into three distinct groups based on their biosynthetic 
origin and structure (Figure 2-2).59 The tricyclic clavines are formed during the early stages of 
ergot alkaloid biosynthesis and serve as precursors to more complex tetracyclic clavines. The 
tetracyclic clavines are either advanced intermediates or the end products of the biosynthetic 
pathway and possess a common tetracyclic core. They differ in the presence and location of an 
olefin in the D-ring and the identity of the C8 substituent. The rearranged clavine alkaloid sub-
group possesses a rearranged ergoline skeleton and are the products of diverted biosynthetic 
pathways off the primary route leading to tetracyclic clavines. These rare alkaloids include (+)-
cycloclavine (+)-(2.1), rugulovasine A (2.2) and aurantioclavine (2.3)  
 
 
Figure 2-2 Tricyclic, tetracyclic and rearranged clavine alkaloids 
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Lysergic acid amides and ergopeptines have been extensively used in drug 
development.59 In contrast, the therapeutic potential of clavine alkaloids remains relatively 
unexplored. Several natural clavines possess promising anti-cancer properties. Pibocin B 
exhibited moderate cytotoxicity against mouse Ehrlich carcinoma cells with an ED50 of 25 
µg/mL (Figure 2-3).67 Fumigaclavine C showed cytotoxic activity against the human breast 
cancer cell line MCF-7 and the mouse leukemia cell line P388.68 Several marketed drugs are 
structurally related to clavine alkaloids. The PARP inhibitor rucaparib is used to treat advanced 
ovarian cancer and strongly resembles the rearranged clavine alkaloids aurantioclavine (2.3) and 
clavicipitic acid.69 The semi-synthetic alkaloid pergolide has been used to treat early-onset 
Parkinson’s disease.70 Clavine alkaloids have also demonstrated promising insecticidal activities. 
For example, cycloclavine and the methyl carbamate derivative 2.4 induced a mortality of 75% 
at 300 ppm in several species of aphids compared to untreated controls. Furthermore, the methyl 
carbamate 2.4 also induced 75% mortality in diamond black moth, orchid thrips, red spider mite 
and striped flea beetle at a concentration of 300 ppm.71 
 
Figure 2-3 Therapeutically relevant clavine alkaloids 
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2.1.3 Cycloclavine: Isolation and Structure 
(+)-Cycloclavine (+)-(2.1) was first isolated from seeds of the African morning glory 
shrub (Ipomea hildebrandtii) in 1969.72 The natural product was characterized using a 
combination of NMR spectroscopy, IR, elemental analysis, specific rotation and X-ray analysis 
(Figure 2-4). The relative and absolute configuration was unambiguously assigned through X-ray 
analysis of the methyl bromide salt (+)-(2.1)•CH3Br. Following the initial isolation, cycloclavine 
has subsequently been isolated in Japan from a culture of the fungus Aspergillus japonicus.73 
 
Figure 2-4 Cycloclavine numbering and the methyl bromide salt derivative 
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2.1.4 Cycloclavine: Biosynthesis 
In recent years, remarkable advances have been made in elucidating the biogenetic origin 
of ergot alkaloids. While the early biosynthetic transformations leading to the ergoline scaffold 
are well understood, the roles of the mid to late pathway genes involved in the structural 
derivatization of the ergoline core are less clear and have been the subject of intensive 
investigations. In 2012 a biosynthetic gene cluster containing eight genes was identified in the 
genome of the cycloclavine producer Aspergillus japonicus.74  
In 2015, the O’Connor group proved that this gene cluster is responsible for the 
biosynthesis of cycloclavine by reconstituting the entire eight enzyme pathway in a host yeast 
strain with excellent production levels (>500 mg L−1).75 Cycloclavine biosynthesis begins with 
prenylation of L-tryptophan (2.5) to produce 4-dimethylallyltryptophan (4-DMAT) (2.6) 
(Scheme 2-1). Next, N-methylation of the primary amine is catalyzed by easF in the presence of 
a S-adenosyl methionine (SAM) cofactor. The resulting N-methylated amine 2.7 can be 
converted into chanoclavine-I (2.11) through sequential oxidation, decarboxylation and 
cyclization reactions. Oxidation of chanoclavine-I gives chanoclavine-I aldehyde (2.12) the last 
common biosynthetic precursor of all ergot alkaloids. At this point the biosynthetic pathway 
branches off to produce agroclavine (2.13) in the biosynthesis of lysergic acid alkaloids or 
festuclavine (2.14) in the biosynthesis of clavine alkaloids.  
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Scheme 2-1 Early stage transformations in the biosynthesis of cycloclavine 
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enamine 2.17, which undergoes an intramolecular cyclopropanation to generate the 
pyrrolidinium-fused cyclopropane 2.18. Reduction of iminium ion 2.18 affords cycloclavine. 
 
Scheme 2-2. Late stage transformations in the biosynthesis of cycloclavine 
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Scheme 2-3 Potential mechanisms of the EasH mediated biosynthetic cyclopropanation 
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was isolated as the hydrochloride salt in a modest yield of 32% (brsm). In summary, the 
synthesis was accomplished in 7 steps and 1% overall yield (brsm) from 4-bromo Uhle’s ketone 
2.22. 
 
Scheme 2-4 Total synthesis of (±)-cycloclavine by Szántay 
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2.29 with 2,3-dihydropyran and catalytic HCl to form the corresponding THP ether (Scheme 2-
5). The protected allylic alcohol was then subjected to a cyclopropanation reaction with 
bromoform and NaOH under phase transfer conditions to deliver gem-dibromocyclopropane 
2.30. Exposure of cyclopropane 2.30 to one equivalent of n-BuLi at -95 °C gave the mono-
lithiated cyclopropane which was quenched with methyl iodide to afford the tertiary bromide. A 
KOt-Bu mediated dehydrobromination followed by acid-catalyzed THP cleavage furnished 
methylenecyclopropane 1.62. The primary alcohol 1.62 was then activated as the mesylate and 
alkylated with the anion of 4-(methylamino)but-3-en-2-one to form the diene precursor 2.31. 
Next, the key intramolecular Diels-Alder reaction with the pendant methylenecyclopropane 
dienophile was attempted. The methyl ketone 2.31 underwent enolization when added to a 
solution of NaHMDS in THF at -78 °C. The resulting enolate was trapped in situ with TBSCl to 
deliver the reactive silyloxy diene intermediate. Gratifyingly, when this key diene was irradiated 
at 195 °C for 1 h in the microwave, a highly diastereoselective Diels-Alder cycloaddition 
occurred to give the cyclic enol ether adduct 1.64 as a single diastereomer. The silyl enol ether 
was converted to ketone 2.32 upon treatment with TBAF. With the tricyclic ketone in hand, 
attention shifted to the installation of the 3,4-disubstituted-indole core. Unfortunately, 
dehydrogenation of ketone 2.32 failed under standard Saegusa-Ito conditions possibly due to the 
coordination of the basic tertiary amine to the palladium catalyst. This problem was 
circumvented by a dealkylative protection of the amine with methyl chloroformate followed by a 
Saegusa-Ito dehydrogenation to successfully introduce the olefin 2.33 at C11/C16. 
Transmetallation of stannane 2.34 with n-BuLi formed the organolithium reagent, which was 
treated with enone 2.32 to deliver the expected tertiary alcohol 2.35. The alcohol 2.35 was then 
subjected to a microwave promoted IMDAF reaction to form intermediate 2.36, which then 
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underwent a double dehydrative aromatization sequence under the reaction conditions to furnish 
indole 2.37 in 44% yield. Finally, LiAlH4 reduction of carbamate 2.37 afforded cycloclavine in 
quantitative yield.  Overall, the total synthesis proceeded in 14 steps and 1.2 % yield. 
 
Scheme 2-5 Total synthesis of (±)-cycloclavine by Petronijevic and Wipf 
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to a Rubottom oxidation to form an intermediate α-hydroxy ketone that was immediately 
converted to corresponding TBS ether 2.39 (Scheme 2-6). An aldol-like addition of ethyl 
lithiodiazoacetate produced diazo ester 2.40 as an inseparable mixture of diastereomers. The key 
fragmentation reaction proceeded smoothly when diazo ester 2.40 was treated with SnCl4 at 0 °C 
to form the tethered aldehyde ynoate 2.42. Aldehyde 2.42 was then condensed with sarcosine 
silyl ester 2.43 and heated at 120 °C in toluene to generate the azomethine ylide intermediate 
2.44. This ylide underwent an intramolecular 1,3-dipolar cycloaddition to give the expected 2,5-
dihydropyrrole 2.45 in 65% yield. Pivalate deprotection provided the protecting-group-free 
indole and intercepted Szántay’s synthesis. The Brewer group also explored alternative 
cyclopropanation conditions. They found that the tetrasubstituted olefin was unreactive toward 
diazomethane and Corey-Chaykovsky conditions. They reasoned that reduction of the ester to 
the corresponding allylic alcohol might enable an alcohol directed cyclopropanation to occur. 
Reduction of the ester with DIBAL-H proceeded smoothly to give alcohol 46. Unfortunately, 
attempts to promote a Simmons-Smith cyclopropanation with various metals including Zn, Sm, 
Pd, Mg and Cr failed. Only Charette’s gem-dizinc carbenoid cyclopropanation protocol provided 
the desired cyclopropane 2.47, albeit in a low yield of 24%. Mesylation of the primary alcohol 
2.47 followed by hydride displacement provided the deoxygenated product. The synthesis was 
completed by hydrolysis of the sulfonamide to give cycloclavine (±)-2.1.  In summary, Brewers 
approach provided the racemic natural product in 13 steps and 1.1% overall yield from tricycle 
2.38. 
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Scheme 2-6 Total synthesis of (±)-cycloclavine by Brewer 
2.1.5.4 Cao’s Formal Synthesis of (±)-Cycloclavine (2014) 
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in 83% yield. The aldehyde was reduced with NaBH4 to the corresponding alcohol, which was 
immediately converted to sulfide 2.54. The final challenge of the synthesis was to close the C-
ring from precursor 2.54 by a C10/11 bond formation. Initial attempts to perform an 
intramolecular Heck reaction were low yielding. However, an alternative radical initiated ring 
closure gave the desired tetracycle 2.55 in an excellent yield of 91%. Next, the exocyclic olefin 
2.55 was isomerized to the tetrasubstituted olefin 2.56 using p-TsOH•H2O in refluxing benzene. 
Finally, Szántay’s intermediate 2.28 was accessed by sodium naphthalenide-mediated global 
cleavage of the tosyl groups and selective N-methylation of the aliphatic amine, thereby 
completing the formal synthesis of cycloclavine in 27% yield and 7 steps from known aldehyde 
2.49. 
 
Scheme 2-7 Formal total synthesis of (±)-cycloclavine by Cao 
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2.1.5.5 Opatz’ Formal Synthesis of (±)-Cycloclavine (2016) 
In 2016, the Opatz group reported a convergent formal synthesis of (±)-cycloclavine.90 
Their approach centred on a late-stage formation of the C-ring through the combination of a D-
ring fragment and the indole AB-ring. The synthesis of the D-ring started with methylation of 
allylamine using a two-step protocol involving sequential formylation, then LiAlH4 reduction 
(Scheme 2-8). N-Allylmethylamine (2.57) was acylated with methacryloyl chloride 2.58 to 
afford amide 2.59. Ring closing metathesis with catalytic amounts of catMETium 2.60 afforded 
the D-ring fragment 2.61 in 73% yield. 
 
Scheme 2-8 Synthesis of pyrrolinone 2.61 
 
The A-B fragment 2.62 was synthesized in four steps and 78% overall yield from 4-
bromoindole (2.48) (Scheme 2-9). Pyrrolinone 2.61 was deprotonated with NaH to form the 
corresponding anion, which underwent a highly regioselective alkylation with bis-bromoindole 
2.62 in 52% yield. The regioselective alkylation at the γ-position of the anion rather than the α-
position was attributed to the steric demand imposed on the α-position by the bulky bromine 
substituent in the SN2 transition state. Gratifyingly, the key Ag2CO3 promoted intramolecular 
Heck reaction of aryl bromide 2.63 afforded tetracycle 2.64 in 74% yield. Reduction of the 
lactam to the tertiary amine with LiAlH4 was accompanied by Boc-cleavage to deliver amine 
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2.28, which intercepted Szántay’s route and thus completed the formal synthesis of cycloclavine 
in 17% yield and 7 steps to cycloclavine precursor 2.48. 
 
Scheme 2-9 Formal total synthesis of (±)-cycloclavine by Netz and Opatz 
2.1.5.6 Cao’s Formal Synthesis of (+)-Cycloclavine (2017) 
In 2017, the Cao group reported the first enantioselective formal synthesis of the natural 
enantiomer (+)-cycloclavine.91 A key feature of the synthesis was a Barbier-type addition to a 
chiral N-tert-butanesulfinyl imine to set the absolute configuration of the secondary amine.  
The synthesis commenced with a 4-step gram-scale preparation of known aldehyde 2.67 
(Scheme 2-10). 2-Bromoindole (2.48) was subjected to a regioselective C3-allylation to form 3-
allyl indole 2.65. The free indole was then Boc-protected and the olefin 2.66 subjected to 
oxidative cleavage conditions with OsO4/NaIO4 to afford aldehyde 2.67 in 75% over two steps. 
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Scheme 2-10 Synthesis of aldehyde 2.67 
 
The known aldehyde 2.67 was then reacted with (S)-2-methylpropane-2-sulfinamide in 
the presence of Ti(Oi-Pr)4 to form the chiral imine 2.68 in 87% yield and >99% ee by chiral 
HPLC analysis (Scheme 2-11). The crucial Barbier addition of 2-(bromomethyl)acrylate 2.69 to 
imine 2.68 proceeded smoothly to produce sulfinamide 2.70. This product was immediately 
subjected to an acid mediated cleavage of the sulfinyl auxiliary followed by a base promoted 
intramolecular ester aminolysis to form lactam 2.71. Methylation of the lactam delivered 2.72 in 
97% yield. The exocyclic methylene lactam 2.72 was then isomerized to pyrrolinone 2.63 by 
heating the lactam in dioxane at 100 °C in the presence of Ru3(CO)12. Finally, the C-ring was 
forged by an intramolecular Heck reaction using Opatz’ conditions and the resulting lactam 2.64 
was reduced with LiAlH4 in refluxing THF to deliver Szántay’s amine 2.28 in 68% yield and 
>99% ee. Overall, the first formal synthesis of (+)-cycloclavine was accomplished in 11 steps 
and 19.7% yield from commercially available 4-bromoindole (2.48). 
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Scheme 2-11 Formal total synthesis of (+)-cycloclavine by Cao 
2.1.5.7 Bisai’s Formal Synthesis of (+)- and (–)-Cycloclavine (2018) 
Bisai’s enantioselective formal synthesis of both the natural and unnatural enantiomer of 
cycloclavine further highlights the utility of the intramolecular Heck reaction in the total 
synthesis of clavine alkaloids.92 The absolute configuration of the secondary amine was set using 
a key enantioselective α-aminoxylation reaction followed by a SN2 inversion with NaN3.  
The synthesis began with a palladium-catalyzed allylation of 4-bromoindole (2.48) with 
allyl alcohol in the presence of triethylborane to form 3-allyl-4-bromoindole (Scheme 2-12). The 
indole nitrogen was then protected as the tosylate 2.73 and subjected to a 
hydroboration/oxidation/Swern oxidation sequence to give aldehyde 2.74 in 83% yield over two 
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steps. The vital α-aminoxylation reaction was initiated by treating aldehyde 2.74 with a catalytic 
amount of D-proline, followed by the addition of nitrosobenzene to afford the expected α-
aminoxy intermediate. This compound was immediately reacted with the stabilized Wittig 
reagent ethyl 2-(triphenylphosphoranylidene)propionate to provide the E-ester 2.75 exclusively 
in 85% yield over two steps and 96% ee.  
With the chiral ester 2.75 in hand, their attention moved to the elaboration of the allylic 
amine precursor 2.78 for the Heck cyclization. N-O cleavage of the hydroxylamine ether 2.75 
was accomplished with anhydrous Cu(OAc)2. The resulting secondary alcohol was converted to 
the mesylate and subjected to a SN2 reaction with NaN3 to deliver azide 2.76 in 82% yield over 
three steps. The azide moiety was reduced to the corresponding amine under Staudinger 
conditions and the free amine protected in situ as the Boc carbamate 2.77. Finally N-methylation 
of the amino group provided the cyclization precursor 2.78. The crucial intramolecular Heck 
reaction proceeded smoothly when 4-bromoindole 2.78 was reacted with Pd(OAc)2, PPh3 and 
K2CO3 in DMF at 100 °C for 12 h to afford tricycle 2.79 in 87% yield.  
The final sequence to form the D-ring was initiated by Boc deprotection to form 
secondary amine 2.80. When amine 2.80 was heated in toluene at reflux an intramolecular ester 
aminolysis occurred to give the tetracyclic lactam 2.81. The exocyclic double bond in 2.81 was 
then isomerized upon treatment with Cs2CO3 in THF to give pyrrolinone 2.82. Finally, lactam 
reduction and indole deprotection completed the formal synthesis of (+)-cycloclavine in 17 steps 
and 25.5% overall yield. 
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Scheme 2-12 Formal total synthesis of (+)-cycloclavine by Bisai 
 
To complete a formal synthesis of the unnatural enantiomer, the catalytic enantioselective 
α-aminoxylation reaction was carried out with L-proline instead of D-proline to provide the 
enantiomer of the hydroxylamine ether ent-2.77 in 97% ee (Scheme 2-13). This material was 
carried through the same sequence to form the enantiomeric amine ent-2.78 that was then 
converted into the enantiomer of Szántay’s amine ent-2.28.  
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Scheme 2-13 Key α-aminoxylation in the formal synthesis of (–)-cycloclavine 
2.2 RESULTS AND DISCUSSION 
2.2.1 Retrosynthetic Analysis of (±)-Cycloclavine 
Before embarking on an enantioselective total synthesis of cycloclavine, we planned to 
carry out an improved racemic synthesis of the natural product. The original 14-step/1.2% 
overall yield racemic synthesis was revised and an improved version that retains the innovative 
double Diels-Alder approach to the ABCD-ring system was envisaged (Figure 2-5). We aimed to 
install the indole last through an IMDAF reaction from enone 2.85. Given the challenge in 
installing the C11/C16 double bond in the original synthesis, a key modification of the revised 
route was to protect the tertiary amine as the amide, which we anticipated would allow a direct 
regioselective oxidation to access enone 2.85 from ketone 2.86. A strain-promoted 
intramolecular methylenecyclopropane Diels-Alder reaction leads retrosynthetically to diene 
precursor 2.87. The amide 2.87 could be synthesized by an amidation reaction of vinylogous 
amide 2.88 and methylenecyclopropane carboxylic acid 2.89. The methylenecyclopropane could 
in turn be generated through a literature reported Rh2(OAc)4 catalyzed cyclopropanation reaction 
between ethyl diazoacetate and 2-bromopropene.   
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Figure 2-5 Retrosynthetic analysis of (±)-cycloclavine 
2.2.2 Synthesis of the Key Tricyclic Ketone   
The first portion of the synthesis was focused on the formation of the tricyclic 
cyclopropa[c]indoline core of the natural product. Our approach to tricycle 2.86 began with the 
known reaction of 2-bromopropene and ethyl diazoacetate in the presence of 0.1 mol% 
Rh2(OAc)4 to form an intermediate tertiary cyclopropyl bromide (Scheme 2-14).93 This 
intermediate underwent an elimination reaction upon treatment with NaH to form the known 
methylenecyclopropane 2.89 in 83% yield over two steps.93 The methylenecyclopropane 2.89 
underwent enolization when reacted with the sterically hindered base LiN(i-Pr)2 at -78 °C to 
form the corresponding enolate which was subsequently quenched with CH3I to form the α-
methyl ester in 73% yield. Saponification of the ester with excess LiOH•H2O in MeOH/H2O 
afforded the methylenecyclopropane carboxylic acid (±)-2.90 in 90% yield. The ester was 
O
OEt
N2
N
H
N H
IMDAF
N H
O
OH
N O
O
t-Bu
O
1,2-addition
N H
O
O N
O
+
(±)-cycloclavine
O
H
N
O
regioselective
oxidation
N H
O
O
intramolecular
Diels-Alder
11
16
6
O OH
amide
formation
N Ot-Bu
O
O
Li
Br
Rh
Rh2(OAc)4
cyclopropanation
(±)-2.83 (±)-2.85
olefin 
formation
(±)-2.86 (±)-2.87 (±)-2.89
2.84
(±)-2.88
 61 
converted to the corresponding acid chloride using the Vilsmeier reagent, which was generated 
in situ by the reaction of oxalyl chloride and DMF. The acyl chloride was then coupled to the 
anion of the vinylogous amide 2.88 to produce the vinylogous imide (±)-2.87 in 79% yield. The 
vinylogous imide was added to a solution of NaHMDS at -78 °C to form the corresponding 
enolate. We found that it was crucial to allow the reaction to warm to -50 °C over 1 h after the 
vinylogous imide had been added to ensure complete enolization. The enolate was quenched at -
78 °C by the addition of TBSCl to form the highly reactive amino silyloxy diene (±)-2.91.    
 
Scheme 2-14 Synthesis of the key amino silyloxy diene (±)-2.91  
 
With the diene in hand, we were positioned to explore the key strain-promoted 
methylenecyclopropane Diels-Alder [4+2] cycloaddition (Table 2-1). When a solution of crude 
silyl enol ether (±)-2.91 was heated in trifluorotoluene at 150 °C under microwave irradiation for 
25 min, it underwent an anti-selective intramolecular Diels-Alder reaction with the pendant 
methylenecyclopropane. The expected Diels-Alder adducts were formed in a 2.2:1 ratio (±)-2.92: 
(±)-epi-2.92 based on NMR analysis (Table 2-1, Entry 1). While this result was promising, we 
sought to improve the diastereomeric ratio to further favor the desired trans-ring fusion product 
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(±)-2.92. Lowering the temperature to 110 °C led to an improved diastereomeric ratio of 3.7:1 
(±)-2.92: (±)-epi-2.92 (Table 2-1, Entry 3). Switching the solvent to THF and carrying the 
reaction out at 100 °C further increased the dr to 4.1:1 (Table 2-1, Entry 4). Attempts to conduct 
the Diels-Alder reaction using the Lewis acid Et2AlCl led to silyl deprotection to form amide 
2.87 (Table 2-1, Entry 5). Overall, heating the diene in THF at 100 °C for 25 min under 
microwave irradiation was identified as the optimum conditions for the Diels-Alder reaction.  
 
Table 2-1 Optimization of the Intramolecular Methylenecyclopropane Diels-Alder Reaction 
 
Entry Conditions Product Ratio (
1H NMR)a 
(±)-2.92  (±)-epi-2.92 
1 PhCF3, 150 °C, µw, 25 min 2.2 1 
2 PhCF3, 130 °C, µw, 25 min 2.9 1 
3 PhCF3, 110 °C, µw, 25 min 3.7 1 
4 THF, 100 °C, µw, 25 min 4.1 1 
5 Et2AlCl, CH2Cl2, -78 to -40 °C Amide 2.87 
athe C4 vinyl proton in (±)-2.92 (δ 5.05 ppm) and (±)-epi-2.92 (δ 5.01 ppm) were integrated in the crude 1H NMR spectrum to assign the dr of 
crude enol ether adducts 
 
The crude enol ether products were directly subjected to TBAF cleavage at room 
temperature to afford diastereomers of ketone (±)-2.86 in a 4:1 dr at C(5) (Scheme 2-15). The 
diastereomers could be separated by chromatography on SiO2. The ring-junction configuration of 
the major diastereomer was assigned as the trans-diastereomer (±)-2.86 through analysis of the 
vicinal coupling constants. The ring junction methine showed a vicinal coupling constant of J = 
13.1 Hz to the adjacent axial proton and a coupling constant of J = 4.1 Hz to the adjacent 
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equatorial proton. A single crystal X-ray structure of (±)-2.86 confirmed this assignment. In 
contrast, the ring junction methine H5 in the minor cis-diastereomer appeared as an apparent 
triplet at δ 3.73 ppm with a coupling constant of J = 6.6 Hz to the adjacent equatorial proton and 
a coupling constant of J = 6.6 Hz to the adjacent axial proton. 
        
Scheme 2-15 Formation of ketones (±)-2.86 and (±)-epi-2.86 and the relative configuration of ketone (±)-2.86 
  
We found that it was important to perform the enolization, Diels-Alder cycloaddition and 
TBS-enol ether cleavage sequence directly without storage of the intermediate enol ethers 
(Scheme 2-16). The Diels-Alder adducts (±)-2.91 and (±)-epi-2.91 exhibited limited stability 
when stored overnight in the freezer before TBAF cleavage, with a partial conversion to the 
undesired regioisomer (±)-2.93 occurring. This undesired side reaction could be completely 
avoided by subjecting the crude enol-ether adducts directly to TBAF.  
 
       Scheme 2-16 Partial conversion of enol ethers (±)-2.91 and (±)-epi-2.91 to the undesired enone (±)-2.93 
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2.2.3 Ketone Dehydrogenation  
The next challenge in the synthesis was to perform a regioselective dehydrogenation of 
the tricyclic ketone (±)-2.86 to enone (±)-2.85. Traditional two-step methods for this conversion 
include α-bromination/dehydrobromination, α-selenation/oxidative elimination or a Saegusa-Ito 
reaction, which proceeds via a Pd(II)-mediated dehydrosilylation of a silyl enol ether (Figure 2-
6).94,95,96,97 Alternatively, stoichiometric oxidants like 2-iodoxybenzoic acid (IBX) and 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) can be employed to access the enone directly; 
however, the use of stoichiometric oxidant is not atom economical (Figure 2-6).  
 
            Figure 2-6 Classical methods for the dehydrogenation of ketones to enones  
 
We were particularly inspired by work carried out by Diao and Stahl who showed that 
catalytic amounts of Pd2(TFA)2 in the presence of DMSO (0.1 eq) and an atmosphere of oxygen 
promoted the direct dehydrogenation of cyclic ketones to the corresponding enones in high 
yields for a wide range of substrates.98 This one-step protocol is especially appealing because it 
uses catalytic Pd(II) and molecular O2, an atom-economical reagent as the stoichiometric 
oxidant.  
Br
O
SePh
O
O
Base
[O]
IBX
O
DDQ
OR3Si
Pd
 65 
 Initial optimizations were conducted on the dehydrogenation of 3-phenylcyclohexanone 
(2.94) (Table 2-2). When ketone 2.94 was subjected to Stahl’s conditions of 5 mol% Pd(TFA)2, 
10 mol% DMSO in AcOH (0.2 M) at 80 °C for 12 h under an atmosphere of oxygen, enones 
2.95 and 2.96 were obtained in a 1.7:1 mixture of regioisomers in a combined yield of 63%. Pre-
activating the catalytic system overnight prior to the addition of the ketone and performing the 
reaction at a lower temperature of 55 °C led to a more regioselective reaction and an improved 
ratio of 2.17:1 of 2.95: 2.96.   
 
Table 2-2 Optimization of the Dehydrogenation of 3-Phenylcyclohexanone under Stahl Conditions  
                     
Conditions 
Product Ratio  
(1H NMR) 
2.95 2.96 
ketone 2.94, Pd(TFA)2 (0.05 eq), O2 (1 atm), AcOH (0.2 M), 
DMSO (0.1 eq), 80 °C, 12 h 1.7 1 
1. Pd(TFA)2 (0.05 eq), O2 (1 atm), AcOH (0.2 M), DMSO (0.1 
eq) 55 °C, 20 h 
2. ketone 2.94, 55 °C, 2 d 
2.17 1 
 
Using the conditions optimized on the model system, the dehydrogenation of tricyclic 
ketone (±)-2.86 was attempted. We were pleased to see that under the optimal conditions, the 
reaction of ketone (±)-2.86 with 5 mol% of Pd(TFA)2 and 10 mol% DMSO in AcOH under an 
atmosphere of oxygen at 55 °C for 7 days proceeded with excellent regioselectivity, forming the 
O O
+
2.95 2.96
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2.94
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less-substituted enone (±)-2.85 exclusively (Scheme 2-17). During the reaction it was necessary 
to add additional catalyst (2 x 10 mol%) to drive the reaction to completion.    
 
  
      Scheme 2-17 Pd(II)-mediated aerobic oxidation of ketone (±)-2.86 to enone (±)-2.85 
 
The proposed catalytic cycle is outlined in Figure 2-7.98,99 The reaction is initiated by the 
formation of a palladium(II) enolate that exists in a tautomeric equilibrium of O- and C-bound 
palladium enolates (±)-2.98 and (±)-2.99. When the C-bound palladium tautomer (±)-2.98 forms, 
the proximity of the palladium center to the β-hydrogen can facilitate β-hydrogen elimination to 
form enone (±)-2.85. The resulting Pd(II)-hydride intermediate undergoes reductive elimination 
to form an equivalent of carboxylic acid and Pd(0) species 2.101. The Pd(0) species can be 
oxidized by molecular oxygen to form the η2-peroxo complex 2.102. Protonolysis generates 
complex 2.103 which can react with a second equivalent of carboxylic acid to regenerate the 
active Pd(II) catalyst.100 Kinetic and computational experiments support the mechanism for the 
conversion of palladium(II)-hydride intermediate 2.100 to the palladium(II) peroxide complex 
2.103.100,101   
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Figure 2-7 Proposed mechanism for the Pd(II)-catalyzed aerobic dehydrogenation of ketones 
 
We also investigated whether the Pd(II) catalyst would impart similar regioselectivity in 
the oxidation of the minor cis-diastereomer (±)-epi-2.86 to form enone (±)-epi-2.85, an 
intermediate in Wipf and Petronijevic’s route to epi-cycloclavine.41 However, when (±)-epi-2.86 
reacted with Pd(TFA)2 and DMSO in AcOH under an atmosphere of oxygen at 55 °C for 3 days, 
the more substituted regioisomer (±)-2.93 was formed exculsively in 56% yield (Scheme 2-18). 
 
   Scheme 2-18 PdII-mediated aerobic oxidation of ketone (±)-epi-2.86 to enone (±)-2.93 
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The complete switch in regioselectivity for the trans and cis diastereomers parallels 
results obtained for the enolization of trans and cis 2-decalones (Figure 2-8). The trans or cis 
stereochemistry at the decalin ring junction governs the regioselectivity of enolate formation due 
to torsional strain in the enolate transition state.102,103 House and Trost showed that a 1:1 mixture 
of trans-enol acetates 2.104 and 2.105 could be equilibrated in the presence of catalytic p-
toluenesulfonic acid at 100 °C to give equilibrium mixtures having the compositions indicated in 
Figure 2-8.102 The trans-2-decalone was shown to favor the 2,3-enol acetate 2.105 (Figure 2-8a). 
In contrast, when the same experiment was performed on cis-2-decalone, the 1,2-enol acetate 
2.106 was favored (Figure 2-8b).   
 
 
      Figure 2-8 Correlation between enolate stability and ring junction stereochemistry in cis and trans decalins 
 
The torsional effects that have been proposed to govern the regiochemistry of enolization 
in cis and trans-decalones has been investigated in greater detail in relevant cis-and trans-
octalins (Figure 2-9a).103,104 The introduction of a double bond at the 1,2 position of the parent 
decalin leads to an opening of the saturated ring B by approximately 10° (from +55° to +65°) 
and causes a corresponding ring closure by 10 ° in the unsaturated ring A (from -55° to -45°).  In 
contrast the introduction of a double bond at the 2,3-position of the parent decalin leads to a ring 
opening of 6° in the unsaturated A-ring (from -55° -61°) and a corresponding ring-closure by 6° 
in the saturated B ring (from 55° to 49°). Overall, this means that the double bond at the 2,3-
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position is more favorable as it imparts less torsional strain in the transition state leading to the 
trans-fused octalin product.  
 
Figure 2-9 Regioselectivity in the enolization of trans-enolate 2.99 
 
These effects are presumably amplified in the smaller 5,6-fused ring system, rationalizing 
the regioselectivity observed for the conversion of trans-ketone (±)-2.86 to the less substituted 
enone (±)-2.85 and the conversion of cis-ketone (±)-epi-2.86 to the more substituted enone (±)-
2.93 and accordingly, indicates that regioselectivity is due to substrate control rather than 
governed by catalyst effects.  
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2.2.4 Completion of the Synthesis of (±)-Cycloclavine 
With enone (±)-2.85 in hand, our attention turned to the installation of the amino furan 
side chain. We were pleased to see that the reaction of Boc-carbamate stabilized methyllithium 
reagent 2.84 with racemic enone (±)-2.85 delivered the desired tertiary alcohol (±)-2.83 (Scheme 
2-19). However, the addition was hampered by incomplete consumption of enone (±)-2.85 and 
the formation of a byproduct tentatively assigned as the bis-addition product (±)-2.108 by 
LCMS. This byproduct was likely formed via a second addition of the furanyl lithium reagent to 
the amide. The crude allylic alcohol was subjected directly to an IMDAF reaction in the presence 
of Kishi’s radical inhibitor 2.109. At best, indole (±)-2.110 was isolated in 37% yield over two 
steps. LiAlH4 reduction delivered racemic cycloclavine (±)-2.1 in 94% yield. Overall the revised 
racemic synthesis was completed in 12 steps and 5.2% overall yield. 
 
Scheme 2-19 Completion of the synthesis of (±)-cycloclavine  
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2.2.5 Retrosynthetic Analysis of (–)-Cycloclavine 
In order to accomplish an enantioselective total synthesis of cycloclavine and develop an 
efficient route to either enantiomer, we revised our 12 steps/5.2% racemic synthesis. We 
intended to employ the same endgame strategy where the indole AB-ring would be installed by 
an enone 1,2-addition/IMDAF sequence from enone 2.85 (Figure 2-10). The key enone 2.85 
would be synthesized from ketone 2.86 using the improved one-step regioselective aerobic 
dehydrogenation optimized during the racemic synthesis. The intramolecular Diels-Alder 
reaction to form ketone 2.86 would be retained. The main feature of the revised enantioselective 
route is a significantly improved strategy to access the vinylogous imide 2.87. We anticipated 
that the amide linkage in 2.87 could be generated by direct aminolysis of an activated ester with 
vinylogous amide 2.88. The key methylenecyclopropane moiety could be accessed via a chiral 
metal-mediated asymmetric cyclopropanation of a diazo ester 1.99 with allene 1.96, thereby 
providing a way to set the absolute configuration of either enantiomer of cycloclavine 2.1 from 
the outset of the synthesis. The successful implementation of this two-step approach to 2.87 
would represent a major improvement compared to our previous synthesis, which required six 
steps to access intermediate (±)-2.87.  
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Figure 2-10 Retrosynthetic analysis of (–)-cycloclavine 
                   
2.2.6 Synthesis of the Indoline-Fused Cyclopropane Core   
Our initial efforts were directed toward the assembly of the indoline-fused cyclopropane 
core. The synthesis began with an enantioselective cyclopropanation of allene 1.96 with diazo 
ester 1.99 in the presence of 1 mol% dirhodium complex Rh2(S-TBPTTL)4 to form 
methylenecyclopropane 1.109 in 86% yield (Scheme 2-20). The vinylogous amide 2.88 was 
deprotonated with n-BuLi at -78 °C in THF, then acylated with activated ester 1.109 to afford the 
vinylogous imide 2.87. Interestingly, the E/Z ratio of 2.88 proved to be inconsequential as both 
isomers produced the E-alkene product 2.87, probably due to rapid isomerization of the enamine 
upon deprotonation and preferential acylation of the E-enamide. Chiral SFC analysis of imide 
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2.87 revealed an 87:13 er, reflecting the enantiomeric enrichment obtained in the prior 
cyclopropanation step.   
            
                      
                   
Scheme 2-20 Synthesis of vinylogous imide 2.87 and SFC chromatograms of the a) racemic standard and b) 
enantioenriched imide 2.87 
 
Treatment of amide 2.87 with NaHMDS formed the corresponding enolate, which was 
trapped in situ with TBSCl to deliver the highly reactive amino silyloxy diene 2.91 that was used 
directly without purification (Scheme 2-21). Subjection of diene 2.91 to microwave irradiation at 
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95 °C triggered an anti-selective intramolecular Diels-Alder [4+2] cycloaddition with the 
pendant methylenecyclopropane to form a mixture of cyclic enol ethers 2.92. An improvement in 
dr from 4:1 to 4.8:1 was observed by lowering the temperature of the Diels-Alder reaction from 
100 °C to 95 °C.  The resulting diastereomeric enol ether products were directly subjected to 
TBAF cleavage at room temperature to afford separable diastereomers of ketone 2.86 and epi-
2.86 in 4.8:1 dr. 
 
   Scheme 2-21 Conversion of vinylogous imide 2.87 into tricyclic ketones 2.86 and epi-2.86  
2.2.7 Ketone Dehydrogenation and Enantiomeric Enrichment   
We next attempted the key aerobic dehydrogenation. We were pleased to see that the 
reaction of ketone 2.86 with 5 mol% of Pd(TFA)2, and 10 mol% DMSO in AcOH under an 
atmosphere of oxygen at 55 °C for 5 days proceeded with excellent regioselectivity, forming the 
less-substituted enone 2.85 exclusively in 76% yield (Scheme 2-22). Over the course of the 
reaction it was necessary to add additional catalyst to drive the conversion to completion. In 
contrast to earlier work in the racemic synthesis, which employed an additional 2 x 10 mol% of 
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the Pd(TFA)2 catalyst, we found that the loading of the additional palladium complex could be 
decreased to 2 x 2.5 mol%.  
 
Scheme 2-22 Pd(II)-mediated aerobic oxidation of ketone 2.86 to enone 2.85 
 
After generating an enantiomeric excess by a partially selective synthesis, the preferential 
crystallization of the major enantiomer from a supersaturated solution can be exploited to obtain 
enantiomerically enriched material.50 Enone 2.85 was obtained as a crystalline solid and we were 
delighted to discover that it proved highly suitable for further enantiomeric enrichment via 
preferential crystallization of the major enantiomer to provide tricycle 2.85 in high enantiomeric 
purity (up to >99.5:0.5 er by chiral SFC analysis). A typical enrichment protocol is outlined in 
Figure 2-11. A crystalline sample of enone 2.85 was dissolved in a 15:1 solution of boiling 
MTBE/1,2-DCE. The solution was cooled to room temperature, treated with a seed crystal and 
allowed to stand at -20 °C overnight during which time white needle shaped crystals of the 
excess enantiomer formed. The mother liquor was removed and the crystals washed with MTBE, 
dried and analyzed by chiral SFC to determine the enantiomeric purity of the crystallized 
material. The chromatogram of the racemic compound (±)-2.85 was used as a standard for 
comparison. After three rounds of crystallization the excess enantiomer of enone 2.85 was 
obtained in a combined yield of 56% of the theoretical maximum yield. Representative 
chromatograms are depicted in Figure 2-11 showing the racemic standard, and enone 2.85 after 
enantiomeric enrichment by crystallization.  
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Figure 2-11 Enantiomeric enrichment by recrystallization to upgrade the er of tricycle 2.85 and SFC 
chromatograms of the a) racemic standard and b) enantioenriched enone 2.85 
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2.2.8 Studies of Furanyl Lithium Additions to Enones  
The next challenge of the synthesis was to perform a chemoselective addition of a furanyl 
amino methyllithium reagent to an enone (Figure 2-12). During the racemic synthesis, this 
reaction suffered from low yields and poor chemoselectivity due to the formation of an undesired 
byproduct, which was tentatively identified as the bis-adduct by LCMS resulting from the 
addition of a second equivalent of organolithium reagent to the amide.  
 
              Figure 2-12 Requisite enone 1,2-addition   
 
To address this chemoselectivity problem, we first attempted to optimize the addition 
reaction by varying the additive, base and metal (Table 2-3). The addition of TMEDA afforded 
the desired allylic alcohol (±)-2.83, albeit in a low yield of 20% (Table 2-3, Entry 1). 
Disappointingly, recovered starting material was obtained when CeCl3 was used an additive 
(Table 2-3, Entry 2). We next investigated the use of the Lewis acid ATD 2.115 as an additive in 
the reaction (Table 2-3, Entry 3).105 We reasoned that the bulky Lewis acid would preferentially 
coordinate the more Lewis basic amide carbonyl, blocking the addition of the organolithium to 
the amide and thus directing the attack to the enone. Unfortunately, this reaction was not 
chemoselective and low yielding. An attempt to transmetallate the furanyllithium reagent to the 
corresponding titanium reagent prior to ketone addition also failed, delivering recovered starting 
material (Table 2-3, Entry 4). Shifting focus, we next screened different bases while reasoning 
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that the steric and electronic properties of the base may influence the chemoselectivity of the 
addition if a tin-ate complex formed during the transmetallation reaction. No reaction occurred 
when PhLi was used as the base (Table 2-3, Entry 5). Transmetallation with s-BuLi followed by 
enone addition led to the bis-adduct exclusively by LCMS (Table, 2-3, Entry 6).  Lastly, the use 
of 1-hexynyl lithium at -40 °C resulted in acetylide addition to the enone (Table 2-3, Entry 7). 
 
Table 2-3 Enone 1,2-Addition: Metal, Organolithium Reagent and Additive Screen  
 
Entry R1Li Eq. Additive T (°C) Time Yield 
1 n-BuLi 1.3 TMEDA (1.3 eq) -90 10 min 20% (±)-2.83 
2 n-BuLi 1.3 CeCl3 (1.1 eq)a -90 1.5 h RSM (±)-2.85 
3 n-BuLi 1.5 
 
2.115 (1.5 eq)b 
-90 5 min 25% (±)-2.83 + bis adduct 2.108 
4 n-BuLi 1.5 Ti(i-PrO)3Cl (3 eq)c 
 
-78 to 
-40 
10 min RSM (±)-2.85 
5 PhLi 1.5 - -90 5 min RSM (±)-2.85 
6 s-BuLi 1.5 - -90 5 min bis-adduct 2.108  (LCMS) 
7 1-hexynyl lithium 1.5 - -40 5 min 
1-hexynyl lithium 
addition to enone 
athe enone was added to a solution of CeCl3 in THF and stirred for 30 min before the resulting mixture was cooled to 
-90 °C and treated with the furanyl lithium reagent by cannula transfer; bthe ATD prepared as a 0.25 M solution in 
9:1 PhMe/THF; cafter Ti addition the resulting solution was stirred for 40 min for transmetallation prior to the 
addition of the enone. 
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We next attempted to reduce the tertiary amide prior to the addition step. To this end, 
direct reduction of the tertiary amide was attempted using Beller’s conditions (Scheme 2-23a).106 
Unfortunately, when amide (±)-2.85 was treated with Zn(OAc)2 and (EtO)2MeSiH in THF at 
room temperature, no reaction occurred. An attempt to force the reaction at reflux in THF 
resulted in decomposition. Reduction with Ru3(CO)12 and 1,1,3,3,-tetramethyldisiloxane 
(TMDS) gave a complex mixture of products in which reduction of the olefin was evident 
(Scheme 2-23b).107 Using a stepwise strategy, enone (±)-2.85 was converted into the thioamide 
(±)-2.116 using Belleau’s reagent 2.117 in 76% yield (Scheme 2-23c). Unfortunately, a 
chemoselective reduction of the thioamide with Ra-Ni only delivered trace amine by LCMS (±)-
2.32. 
 
Scheme 2-23 Attempts to chemoselectively reduce an amide in the presence of an enone 
 
Given the poor results obtained thus far with the enone 1,2-addition of a furanyl 
aminomethyl lithium reagent and the low yields in the subsequent Diels-Alder reaction, we next 
investigated pyrone 2.121 as a heterocyclic replacement for the furan moiety. We hoped that the 
pyrone aminomethyl lithium reagent would lead to a more chemoselective enone 1,2-addition 
and a higher yielding IMDAF cycloaddition, facilitated by the extrusion of CO2. The synthesis of 
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the pyrone reagent began with the reaction of hippuric acid with the 3-amino acrolein 2.119 to 
deliver pyrone 2.120 in 46% yield (Scheme 2-24). The pyrone 2.120 was deprotonated with NaH 
then treated with tributyl(iodomethyl)stannane to form stannane 2.121 in modest yield. 
Unfortunately, when stannane 2.121 was subjected to the Sn-Li exchange/enone 1,2-addition 
sequence, no product 2.122 was obtained and decomposition of the pyrone reagent was observed 
under the reaction conditions. 
 
Scheme 2-24 Synthesis of pyrone 2.121 and attempted enone 1,2-addition 
 
An intramolecular variant of this reaction was also attempted. When pyrone 2.120 was 
reacted with cyclohexenone under microwave irradiation at 170 °C, enone 2.124 was formed in 
12% yield along with the protected aniline 2.125 in 17% yield (Scheme 2-25). Product 2.124 was 
likely formed by a ring opening reaction of the initial Diels-Alder Adduct 2.123 followed by 
elimination and double bond isomerization into conjugation with the enone. The amide 2.125 
was probably formed from 2.124 by elimination to form the aromatized product. While these 
results were promising, the low yield and the need for further synthetic conversions to access the 
desired indole led us to explore alternative routes. 
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Scheme 2-25 Intermolecular Diels-Alder reaction of pyrone 2.120 and cyclohexenone 
 
We next attempted to mask the enone by the conjugate addition of a thiol (Figure 2-13). 
We reasoned that the resulting ketone 2.126 would be more electrophilic than the enone 
precursor, leading to greater electronic differentiation and better chemoselectivity for the ketone 
over the amide in the 1,2-addition reaction.  
     
          Figure 2-13 Thiol addition/elimination strategy to mask the enone and facilitate a 1,2-addition reaction 
 
The Wipf group has successfully employed a similar strategy in the total synthesis of the 
natural product (–)-tuberostemonine (Scheme 2-26).108,109 They found that the conjugate addition 
of thiophenol to enone 2.128 proceeded smoothly when the reaction was performed in the 
presence of a catalytic amount of Et3N (0.15 eq). After olefin reduction, the enone was 
regenerated by a DBU-mediated thiol elimination to afford tricycle 2.128.110 
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Scheme 2-26 Enone protection by a thiol addition/elimination strategy in Wipf’s synthesis of (–)-tuberostemonine 
 
Using this protocol, we synthesized several thiol derivatives in high yield. The relative 
stereochemistry of the intermediate thiols was assigned by analysis of vicinal coupling constants 
(Scheme 2-27). For example, the major diastereomer 2.135 from the conjugate addition of 
thiophenol to enone 2.85 exhibited coupling constants of J = 5.6 and 2.0 Hz between the C11 
methine and adjacent C16 axial and equatorial protons, indicating the C11 methine had an 
equatorial orientation. The minor diastereomer showed a coupling constant of J = 13.2 Hz 
between the minor C11 axial methine and adjacent C16 axial proton and a coupling constant of J 
= 4.0 Hz between the C11 axial methine and adjacent C16 equatorial proton. Unfortunately, the 
subsequent addition reaction with the organolithium reagents afforded the addition adducts 
2.132, 2.134 and 2.136 in low yields ranging from trace conversion to 11% yield at best. 
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Scheme 2-27 Thiol conjugate addition, ketone 1,2-addition 
 
We next surveyed different organolithium reagents, exchanging the Boc-group for other 
sterically demanding carbamate protecting groups and a urea derivative.  The stannane reagents 
2.139-2.141 were prepared from 2-furoyl chloride via a Curtius rearrangement followed by N-
alkylation (Scheme 2-28). The adamantyl and triethyl carbamates proved low yielding and were 
characterized by 1H NMR and screened directly in the addition step without further 
characterization. The pyrrolidine urea was isolated in high yields of 66% over two steps.  
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Scheme 2-28 Synthesis of stannanes 2.139-2.141 via a Curtius rearrangement/ alkylation sequence  
 
The stannanes were then evaluated in the transmetallation/1,2-addition to enone 2.85 
(Table 2-4). When enone 2.85 was reacted with excess N-adamantanyl organolithium reagent, 
the desired allylic alcohol was formed in low yield along with recovered starting material and 
trace bis-addition product by LCMS (Table 2-4, Entry 1). Unfortunately, when the crude alcohol 
was subjected to a thermal IMDAF cyclization, the reaction proceeded with only trace 
conversion. Disappointingly, the triethylcarbamate derivative was not chemoselective (Table 2-4, 
Entry 2). We also evaluated a pyrrolidine urea-based protecting group. The 1,2-addition of this 
furanyl lithium reagent afforded the allylic alcohol, albeit in a low yield of 6% (Table 2-4, Entry 
3). Further investigation of this reaction using cyclohexenone as a model system showed that the 
reagent was unstable and was prone to protodestannylation and demethylation side reactions. We 
reasoned that the instability of the pyrrolidine urea furanyl lithium was due to α-lithiation on the 
pyrrolidine ring, which could facilitate reagent decomposition. 
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Table 2-4 Enone 1,2-Addition: Amine Protecting Group Screen  
    
Entry R1 R
1-M 
(eq) T (° C) 
Time 
(min) Product ratio Yield 
1 
 
1.9 -78 30 
2.143 and epi-2.143  + 
trace 2.144 and epi-2.144 
+ SM 
50%a,b 
2  1.2 -90 20 
~ 1:1 (2.143+epi-2.143: 
2.144+epi-2.144)a ND
a,b 
3 
 
2 -90 20 2.143 + SM 6% 
aproduct distribution based on LCMS trace; bno reaction or trace conversion in the IMDAF reaction 
 
Hoping to avoid reagent degradation, a novel TEMPO-carbamate (TEMPOC) 2.149 was 
developed (Scheme 2-29). We anticipated that the tetramethyl substitution pattern at the α-
position of the piperidine ring would result in a more stable furanyllithium reagent. Additionally, 
we hoped that employing a TEMPO moiety instead of a tetramethylpiperidine ring would avoid 
severe steric hindrance that could lead to sluggish reactivity in the latter organolithium reagent. 
The TEMPO carbamate was synthesized according to the sequence outlined in Scheme 2-29. 2-
Furoyl chloride was reacted with NaN3 in H2O/Et2O to form the known acyl azide 2.145.111 
Heating acyl azide 2.145 in toluene at reflux for 1 h promoted a Curtius rearrangement to afford 
the intermediate isocyanate 2.146. IR analysis showed full conversion to the isocyanate as 
N H
O
OH
N R1
O
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N R1
O
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O
2.143
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O
2.85
N H
OH
N
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N
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O OH
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+
O
O
O
CEt3
N
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evidenced by the characteristic isocyanate stretching frequency at 2265 cm-1.  The isocyanate 
was cooled to room temperature and quenched with the reduced TEMPO hydroxylamine 2.147 
to give the desired carbamate 2.148 in 87% yield. The protected furan 2.148 was deprotonated by 
NaH at 0 °C and treated with tributyl(iodomethyl)stannane to afford the N-alkylation product 
2.149 in 81% yield. 
 
Scheme 2-29 Synthesis of stannane 2.149 
 
With the key stannane 2.149 in hand, we tested the transmetallation/enone 1,2-addition 
sequence on cyclohexenone as a model system (Table 2-5). We were pleased to see that stannane 
2.149 underwent facile transmetallation when treated with n-BuLi at -78 °C. The addition of neat 
cyclohexenone delivered the expected allylic alcohol 2.150 in 88% yield (Table 2-5, Entry 1). 
When cyclohexenone was added to the furanyllithium species at even lower temperatures of -90 
°C for 30 min, the reaction proceeded smoothly to deliver the allylic alcohol 2.150 in a 
comparable yield of 89% (Table 2-5, Entry 2).  
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•
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vNCO 2265 cm-1
2.147
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Table 2-5 Transmetallation/Addition of TEMPO-carbamate 2.149 on a Model System 
   
 
 
 
Using these optimized conditions, we next attempted the Sn/Li transmetallation and 
subsequent 1,2-addition sequence on the enantioenriched enone 2.85 (Scheme 2-30). A 
thermocouple thermometer was employed to continuously monitor the internal temperature of 
the reaction. A solution of stannane 2.149 in Et2O was cooled to -71 °C, treated with n-BuLi and 
stirred for 10 min to facilitate transmetallation. The resulting furanyllithium intermediate was 
then cooled to -94 °C and treated with enone 2.85 to afford allylic alcohols 2.111 and epi-2.111 
as separable diastereomers in 1.5:1 dr and 59% yield (80% brsm). We found that performing the 
reaction at these low temperatures led to a cleaner reaction profile and favoured the allylic 
alcohol 2.111.  
 
Scheme 2-30 Transmetallation/addition sequence using the optimized TEMPO furanyllithium reagent  
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The relative configuration of the addition adducts 2.111 and epi-2.111 were established 
through a combination of X-ray and NMR spectroscopy. The 1D-NOE spectra of the allylic 
alcohol diastereomers 2.111 and epi-2.111 are shown in Figure 2-14. Selective irradiation of the 
ring junction methine H5 in the axial diastereomer 2.111 showed a key correlation to the H2/2’ 
methylene, indicating these protons are located on the same face. In contrast, no correlation was 
observed between the ring junction methine H5 and the H2/2’ methylene in the minor equatorial 
diastereomer epi-2.111, supporting the assignment. 
                        
 
Figure 2-14 Key 1D-NOE correlations for the allylic alcohol diastereomers 
 70 
The relative configuration of the addition adducts X and epi-X was assigned through a 
combination of 2D-ROESY and 1D-NOE correlations. The 1D-NOE spectra of both 
diastereomers are shown in Figure X-X. Selective irradiation of the ring junction methine H5 in 
axial diastereomer X showed a key correlation to the H2/2’ methylene indicating these protons 
are located on the same face. In contrast, no correlation is observed between the ring junction 
methine H5 and the H2/2’ methylene in minor equatorial diastereomer X supporting the 
assignment. 
                                     
Figure 2-10 Key 1D-NOE correlations for the allylic alcohol diastereomers 
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2D ROESY correlations also supported the assignment of the two diastereomers. Key 
features of the 2D ROESY spectra of both diastereomers are shown in Figure 2-15. In the 
spectrum of the major diastereomer 2.111, there is a cross peak correlation between the ring 
junction methine H5 and the H2/2’ methylene was observed. This correlation is absent in the 
minor diastereomer epi-2.111.  
 
 
    Figure 2-15 Key ROESY correlations for allylic alcohol diastereomers 2.111 and epi-2.111 
 
In addition to the 1D-NOE and 2D-ROESY data, the relative configuration and structure of the 
major diastereomer 2.111 was unambiguously confirmed by X-ray analysis of a single crystal 
(Figure 2-16).  
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Figure 2-16 X-ray structure of the major diastereomer 2.111 
2.2.9 IMDAF Reaction and Completion of the Synthesis  
The last challenge of the synthesis was to carry out an IMDAF cycloaddition to form the 
indole. This reaction was first investigated using allylic alcohol 2.150 as a model system to test 
whether the new TEMPOC protecting group was compatible with the IMDAF reaction 
conditions. The reaction failed under Lewis acidic conditions (Table 2-6, Entry 4) and no 
reaction occurred when the allylic alcohol 2.150 was subjected to microwave irradiation in 
trifluorotoluene in the presence of Kishi’s radical inhibitor 2.109 at temperatures below 140 °C 
(Table 2-6, Entry 1). However, at 140 °C, in the presence of radical inhibitor 2.109, trace 
consumption of 2.150 was observed (Table 2-6, Entry 2) and we were encouraged that increasing 
the temperature to 160 °C led to full consumption of the starting material and the appearance of 
possible intermediates by LCMS (Table 2-6, Entry 3). Moving to conventional thermal heating 
we next investigated different solvent effects. While reaction at 130 °C in chlorobenzene (Table 
2-6, Entry 9) led to decomposition, several other aromatic solvents were found to promote the 
N H
O
3
OH
N O
O
N
O
2.111
 91 
IMDAF cyclization. The reaction proceeded with full conversion by 1H NMR when carried out 
in mesitylene, xylenes and toluene (Table 2-6, Entries 10, 8 & 7). Conventional heating in 
toluene at 130 °C in a sealed tube were the most effective conditions, affording the protected 
indole 2.151 in 51% isolated yield (Table 2-6, Entry 7). We also found that the presence of sub-
stoichiometric Pd(PPh3)4 and P(Oi-Pr)3 promoted the cycloaddition (Table 2-6, Entries 5 & 6) in 
low yields, possibly through the intermediacy of a putative π-allyl palladium complex. When the 
reaction mixture was heated for 37 h (Table 2-6, Entry 6), the protecting-group-free indole 2.152 
was obtained in 40%.  
 
Table 2-6 Optimization of the IMDAF Cyclization on a Model System 
     
Entry Solvent Additive Δ T (°C) Time Yield 
1 PhCF3 2.109 µW 120 0.5 h NR 
2 PhCF3 2.109 µW 140 0.5 h 
SM (major), trace 
intermediatesa 
3 PhCF3 2.109 µW 160 0.5 h Intermediatesa,b 
4 PhMe BF3•OEt2 - -30 5 min 0 
5 NMP Pd(PPh3)4 (10mol%) P(Oi-Pr)3 (20 mol%) 
µw 130 2 h 
~ 15% 1:1 2.151: 
2.152 
(25% brsm) 
6 NMP Pd(PPh3)4 (5 mol%), P(Oi-Pr)3 (20 mol%) 
cc 120-130 37 h 40% 2.152 
7 PhMe - cc 130 10 d 51%c 2.151 
8 Xylenes - cc 140 4 d NDd 
9 C6H5Cl - cc 130 4 d 0b 
10 Mesitylene - cc 130 4 d 28%d 
aobserved in LCMS trace; bdecomposition; cconventional heating in an oil bath; dfull conversion by 1H NMR. 
HO
N
OO
ON
2.150
NRconditions
O
O
2.151 R =
2.152 R = H
Kishi's radical inhibitor 
2.109
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S
OH
N
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The protected indole 2.151 was converted to the free indole 2.152 by a thermal cleavage 
of the TEMPO carbamate-protecting group (Scheme 2-31). We found that the thermolysis 
proceeded smoothly at an elevated temperature of 180 °C in trifluorotoluene under microwave 
irradiation for 20 min to provide the protecting group free indole 2.152 in 87% yield on small 
scale.  
 
Scheme 2-31 Thermal deprotection of TEMPOC-protected indole 2.151  
 
Given the success with the model system, we next attempted the IMDAF reaction on the 
allylic alcohol diastereomers 2.111 and epi-2.111. Disappointingly, when the equatorial 
diastereomer epi-2.111 was heated at 130 °C in toluene for 3 days, only starting material was 
observed (Scheme 2-32). Unfortunately, an attempt to force the conversion of epi-2.111 to indole 
2.110 at higher temperatures of 150 °C for 3 days failed and decomposition was noted. Several 
additional aromatic solvents were also evaluated without success. For example when alcohol epi-
2.111 was heated in mesitylene at 135 °C for 3 days only starting material was observed. Both 
the reaction of the allylic alcohol in xylenes at 145 °C for 4 days and in a solution of 
PhMe/PhCF3 under microwave irradiation at 180 °C for 1 h led to multiple unidentified products. 
We also pursued a different strategy where alcohol epi-2.111 was treated with NEt3, DMAP and 
Ac2O in CH2Cl2. The corresponding acetate 2.153 was detected by LCMS and 1H NMR and 
taken up directly in toluene and heated at reflux for 2 days. Unfortunately the major product was 
consistent with the deprotected alcohol epi-2.111 and attempts to convert this compound to 
N
O
O
N
2.151
HN
2.152
PhCF3, 180 °C
20 min, 87%
 93 
indole 2.110 in a 1:1 mixture of PhMe/PhCF3 at 180 °C in the microwave only formed trace 
product mass by LCMS.  
      
        Scheme 2-32 Attempts to convert the equatorial diastereomer epi-2.111 into indole 2.110  
 
In contrast, we were delighted to see that the axial diastereomer 2.111 was more reactive 
and could be cleanly converted into to indole 2.110 when heated in a sealed tube for 68 h at 135 
°C (external temperature) (Scheme 2-33). Fortuitously, the initial Diels-Alder adduct 2.154 
underwent aromatization accompanied by the thermolysis of the TEMPOC protecting group 
under the reaction conditions to afford the protecting group free indole 2.110. The tertiary amide 
2.110 was then reduced with excess LiAlH4 in refluxing THF to afford (−)-cycloclavine, (–)-
(2.1), in 48% over two steps. The specific rotation of the unnatural enantiomer was –58.9 (c 0.23, 
CHCl3), which was consistent in magnitude but opposite in sign to the literature value for the 
natural enantiomer, which was +63 (c 1, CHCl3). Overall, the synthesis of (–)-cycloclavine was 
accomplished in 8 steps and 5% (7.1% brsm) yield.   
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Scheme 2-33 Completion of the synthesis of (–)-cycloclavine 
2.2.10 Synthesis of (+)-Cycloclavine 
In order to synthesize the natural enantiomer, (+)-cycloclavine, we required the 
enantiomer of the catalyst Rh2(S-TBPTTL)4 (1.75). The dirhodium complex Rh2(R-TBPTTL)4 
(ent-1.75) was prepared from D-tert-leucine using the route outlined in Scheme 2-34. D-tert-
Leucine (2.155) reacted with tetrabromophthalic anhydride (2.156) and NEt3 (0.1 eq) in toluene 
at reflux to provide N-tetrabromophthaloyl-(R)-tert-leucine (TBPTTL) (2.157) in 98% crude 
yield. A ligand exchange reaction was then carried out by reacting Rh2(OAc)4 with excess 
TBPTTL ligand in a chlorobenzene/CH3CN mixture at 130 °C to form the dirhodium catalyst 
Rh2(R-TBPTTL)4 (ent-1.75) in 75% yield.  
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Scheme 2-34 Synthesis of the dirhodium catalyst Rh2(R-TBPTTL)4  
  
With the requisite catalyst in hand, the synthesis of (+)-(2.1) began with the 
cyclopropanation of allene 1.96 and diazopropanoate 1.99 in the presence of 1 mol% of the 
dirhodium catalyst Rh2(R-TBPTTL)4 (ent-1.75) to form the enantiomerically enriched 
methylenecyclopropane ent-1.109 in 86% yield (Scheme 2-35). This reaction was successfully 
performed on scales up to 9.0 g. Ester aminolysis gave the vinylogous imide ent-2.87 in 80% 
yield and 87:13 er. The SFC chromatograms for the racemic standard and enantiomerically 
enriched vinylogous amide are shown in Scheme 2-35. As expected, the opposite enantiomer 
was enriched when Rh2(R-TBPTTL)4 (ent-1.75) was employed as the catalyst in the 
cyclopropanation reaction.  
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Scheme 2-35 Synthesis of enantiomerically enriched vinylogous amide (ent-2.87) and SFC chromatograms of the a) 
racemic standard and b) enantioenriched amide 2.87 
 
The vinylogous imide ent-2.87 was reacted with NaHMDS in THF between -78 and -50 
°C to form the enolate which was trapped with TBSCl to form the corresponding TBS enol ether 
(Scheme 2-36). When heated at 95 °C in THF in the microwave, the enol ether underwent the 
intramolecular strain-promoted Diels-Alder reaction, followed by TBAF cleavage of the silyl 
enol ether to form the desired trans-adduct ent-2.86 in 66% yield on gram scale along with the 
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cis-adduct epi-ent-2.86 in 15% yield. Dehydrogenation of ketone ent-2.86 under modified Stahl 
conditions gave the corresponding enone 2.85 in 66% as a single regioisomer.  
 
 
Scheme 2-36 Synthesis of enantioenriched tricyclic enone ent-2.85    
 
Enone 2.85 was obtained as a crystalline solid and we were pleased to see that the excess 
enantiomer could be enriched by recrystallization from 87:13 er to >99% er using the same 
protocol employed in the earlier synthesis of (–)-cycloclavine.  
A typical enrichment procedure for ketone ent-2.85 is outlined in Figure 2-17. Chiral 
SFC analysis was used to evaluate each batch for enantiomeric purity. For example, the first 
round of crystallization provided crystals of 99.5:0.5 er, the second recrystallization provided 
crystals of 91% ee and the third recrystallization provided crystals of 96% ee. Overall the 
combined yield was 69% of the theoretical maximum. Representative chromatograms are 
depicted in Figure 2-17, showing the racemic standard and enone ent-2.85 after enantiomeric 
enrichment by crystallization.   
N
O
H
O
3. NaHMDS, TBSCl, THF  
    -78 to -50 °C
    then, THF, 95 °C, µw, 30 min
N
O
H
O
5
N
O
O
N H
O
OTBS
4. TBAF, THF, 30 min
       β-H (C5) ent-2.86: 66% (2 steps)
       α-H (C5) epi-ent-2.86: 15% (2 steps)
ent-2.87 ent-2.92
ent-2.85
single regioisomer
 5. Pd(TFA)2 (5 mol%), DMSO
      O2 (1 atm), AcOH, 55 °C, 12 h
      Then ketone ent-2.86, Pd(TFA)2 (2.5 mol% x 2)
      55 °C, 4 d;  66%
 98 
 
  
  
Figure 2-17 Enantiomeric enrichment of the excess enantiomer by crystallization SFC chromatograms of the a) 
racemic standard and b) enantioenriched ketone ent-2.85 
 
The final task of the synthesis was to install the indole core. The stannane 2.149 
underwent transmetallation to the corresponding furanyl lithium reagent when treated with n-
BuLi at low temperature (Scheme 2-37). Addition of the enantioenriched enone ent-2.85 
delivered the desired allylic alcohols, which could be separated by chromatography on SiO2 to 
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Chiralpak	IC	column		(250	x	10	mm),	gradient	elution:	1-30%	i-PrOH	(rate	1.0),	5.5	mL/min,	254	nm,	P=100	(BAR)	 
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give ent-2.111 and epi-ent-2.111 in 41% and 32% respectively. Allylic alcohol ent-2.111 
underwent the final IMDAF reaction to deliver intermediate ent-2.154. The initial Diels-Alder 
adduct underwent aromatization and cleavage of the TEMPOC protecting group under the 
reaction conditions to form indole ent-2.110. Amide reduction delivered the natural enantiomer 
(+)-2.1 in 34% over two steps. Overall, the synthesis of (+)-cycloclavine was accomplished in 8 
steps and 4% yield. The specific rotation of the synthetic material was determined to be +61.4 (c 
0.2, CHCl3), which was consistent with the literature value +63 (c 1, CHCl3).  
 
Scheme 2-37 Completion of the synthesis of (+)-cycloclavine   
 
The 1H and 13 C NMR data for (+)-cycloclavine were consistent with the previously 
reported data for the natural compound (Tables 2-7 and 2-8).  
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Table 2-7 A Comparison of the Literature and Synthetic 1H NMR Spectra of Cycloclavine  
 
Atom # 
Wipf and Petronijevic’s synthetic (±)-2.1 
1H NMR, CDCl3, 700 MHza 
δ (ppm), multiplicity J, # H 
Our synthetic (+)-2.1 
1H NMR, CDCl3, 500 MHzb 
δ (ppm), multiplicity J, # H 
1 7.92, bs, 1 H 7.89, bs, 1 H 
14 7.15, d, J = 8.4 Hz, 1H 7.13 dd, J = 8.0, 0.5 Hz, 1 H 
13 7.10, ap. t, J =7.7 Hz, 1 H 7.09, ap. t, J = 7.8 Hz, 1 H 
2 6.91, s, 1 H 6.90, ap. t, J = 1.8 Hz, 1 H 
12 6.84, d, J = 7.0 Hz, 1 H 6.82, dd, J = 7.0, 0.5 Hz, 1 H 
7A 3.17, d, J = 9.1 Hz, 1 H 3.15, d, J  = 9.0 Hz, 1 H 
4A 3.15, dd, J = 14.0, 4.2 Hz, 1 H 3.13, dd, J = 13.8, 3.8 Hz, 1 H 
5 2.79, dd, J = 11.2, 3.5 Hz, 1 H 2.78, dd, J = 11.5, 4.0 Hz, 1 H 
4B 2.61, t, J = 12.6 Hz, 1 H 2.63-2.57, m, 1 H 
7B 2.42, d, J = 8.4 Hz, 1 H 2.40, d, J = 8.5 Hz, 1 H 
17 2.37, s, 3 H 2.36, s, 3H 
18 1.70, s, 3 H 1.69, s, 3 H 
9A 1.61, d, J = 2.8 Hz, 1 H 1.60, d, J = 3.5 Hz, 1 H 
9B 0.46, d, J = 3.5 Hz, 1 H 0.45, d, J = 3.5 Hz, 1 H 
athe solvent reference for Wipf and Petronijevic’s sample was: 1H δ 7.27 (CDCl3); bthe solvent reference for our 
synthetic material (+)-2.1 was: 1H δ 7.26 (CDCl3). 
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Table 2-8 A Comparison of the Literature and Synthetic 13C NMR Spectra of Cycloclavine 
 
Atom # 
Wipf and Petronijevic’s synthetic (±)-2.1 
13C NMR, CDCl3, 175 MHz 
δ (ppm) 
Our synthetic (+)-2.1 
13C NMR, CDCl3, 150 MHz 
δ (ppm) 
11 135.4 135.6 
15 133.5 133.7 
16 128.7 128.8 
13 122.9 123.1 
2 118.1 118.2 
3 113.2 113.5 
12 110.3 110.5 
14 107.9 108.1 
5 69.6 69.8 
7 65.6 65.7 
17 39.9 40.1 
8 34.4 34.5 
10 27.8 27.9 
4 24.9 25.1 
9 24.2 24.4 
18 16.5 16.6 
athe solvent reference for Wipf and Petronijevic’s sample was: 13C δ 77.0 (CDCl3); bthe solvent reference for our 
synthetic material (+)-2.1 was: 13C δ 77.16 (CDCl3). 
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The overlaid circular dichroism (CD) spectra for (+)- and (–)-cycloclavine are shown in 
Figure 2-18. As expected, the CD spectra of the enantiomers were approximately equal in 
magnitude but opposite in sign. The natural enantiomer (+)-2.1 had a positive cotton effect while 
the unnatural enantiomer (–)-2.1 displayed a negative cotton effect.   
 
Figure 2-18 Comparison of the CD spectra of cycloclavine enantiomers  
2.2.11 Attempted Analogue Synthesis by Late Stage Derivatization  
We were also interested in synthesizing analogues of cycloclavine by carrying out late-
stage site-selective modifications to the cycloclavine core. The Murphy group has reported a 
highly selective C–H functionalization of N-CH3 groups using the radical cation DABCO+• and 
Grignard reagents.112 They demonstrated the utility of this method in the site-selective 
functionalization of several natural products and pharmaceutical agents. The proposed 
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mechanism involves conversion of the N-CH3 group to the corresponding iminium ion by two 
sequential single electron transfers in the presence of excess DABCO+•. The iminium ion then 
reacts with excess Grignard reagent to form a variety of N-alkylated products. Unfortunately, in 
our hands the reaction of (+)-cycloclavine with DABCO+• and PhMgBr gave a messy reaction 
profile with multiple unidentified products (Scheme 2-38a).  
We next attempted hydrogenation of the cyclopropane C–C bond to form the 
hydrogenated ring-opening product (Scheme 2-38b). The unactivated tetrasubstituted 
cyclopropane in (+)-cycloclavine is a highly challenging substrate for hydrogenation due to the 
severe steric hindrance imposed by the vicinal quaternary stereocenters upon interaction with the 
Pd/C catalytic system.113 However, we hoped that the release of ring-strain upon reductive ring 
opening of the cyclopropane would provide a driving force for the reaction. Unfortunately the 
substrate proved unreactive under classic hydrogenation conditions of 10% Pd/C under an 
atmosphere of hydrogen. Furthermore, no reaction occurred when (+)-2.1 was subjected to 
harsher hydrogenation conditions of 18 bar in a Parr hydrogenator. Switching catalysts to PtO2 in 
AcOH/AcONa under H2 at 11 atm gave recovered starting material.114    
 
Scheme 2-38 Attempted N-CH3 functionalization and hydrogenation of (+)-cycloclavine 
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We next examined the hydrogenation of the tertiary amide precursor ent-2.110 reasoning 
that the proximal Lewis-basic amide carbonyl could coordinate the metal center and thereby 
facilitate the desired hydrogenation reaction (Scheme 2-39). The amide did not react under the 
standard conditions of 10 mol% of Pd/C (10wt%)/H2 (1 atm). Higher catalyst loadings of 30 
mol% Pd/C (10wt%) and increased pressure of 18 bar in the Parr hydrogenator led to recovered 
starting material along with trace conversion by LCMS. The Crabtree catalyst is commonly used 
for the hydrogenation of unfunctionalized tri- and tetrasubstituted alkenes. Unfortunately, no 
reaction occurred when this catalyst was used on our system. 
 
      Scheme 2-39 Attempted hydrogenation of amide ent-2.110 
 
The SmI2/H2O/NEt3 reagent has recently emerged as one of the most powerful samarium-
based reducing agents (E° = -2.8 V) and is capable of reducing challenging substrates like 
carboxylic acids and amides, which were generally considered to lie outside the reducing range 
of SmI2.115 Proctor and coworkers reported that the reduction of cyclopropyl amides to alcohols 
can be achieved using the SmI2/NEt3/H2O system.116 This reaction represents the first general 
method to form ketyl-type radicals from unactivated amides. In a relevant experiment Proctor 
showed that the reaction of amide 2.162 with SmI2 (2 eq), Et3N (24 eq) and H2O (24 eq) in THF 
at room temperature for 1 min lead to a 92:8 ratio of amide 2.163 to alcohol 2.164 (Scheme 2-
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40). Using a larger excess of the SmI2-Et3N-H2O reagent over longer reaction times of 18 h led 
to increased formation of the alcohol 2.164.  
 
Scheme 2-40 Procter’s reductive ring-opening of a cyclopropyl amide using SmI2/NEt3/H2O 
  
We initially tested the reaction on cyclopropyl amide 2.167 as a model system. The 
cyclopropyl amide was synthesized from acrylic acid 2.165 according to the sequence outlined in 
Scheme 2-41. Acrylic acid 2.165 was reacted with oxalyl chloride and catalytic DMF to form the 
acyl chloride, then subjected to an amidation reaction with HNEt2 and NEt3 to form the acrylic 
amide 2.166 in 95% yield. Amide 2.166 was subjected to a chromium carbene mediated 
cyclopropanation to give cyclopropyl amide 2.167. We hoped that by employing relatively short 
reaction times the conversion could be halted at the ring-opened tertiary amide product without 
over-reduction to the alcohol. We were pleased to see when a degassed solution of cyclopropyl 
amide 2.167 and H2O in THF was treated with SmI2 (3 eq) then NEt3 for 1 h the desired ring-
opened adduct was obtained in 77% as an inseparable 4:1 mixture of ring-opened amide 2.168 to 
starting material 2.167.  
NEt2
OPh
1. SmI2 (2 eq), Et3N (24 eq), H2O (24 eq), THF, rt, 1 min
    51%; 92:8 2.163: 2.164
2. SmI2 (8 eq), Et3N (72 eq), H2O (72 eq), THF, rt, 18 h
    99%; 59:41 2.163: 2.164
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Scheme 2-41 Synthesis of cyclopropyl amide model system and SmI2-mediated ring opening  
 
 The amide ent-2.110 was subjected to reduction with the SmI2/amine/H2O system. 
However, only partial conversion to product was observed by LCMS under the same conditions 
identified on the model system and no further conversion was observed when additional SmI2 (3 
eq) was added (Scheme 2-42). Moving to harsher conditions we reacted amide ent-2.110 with a 
large excess of SmI2 (24 eq), NEt3 (72 eq) and H2O (72 eq). Consumption of the starting material 
was observed and a cyclopropyl cleavage product tentatively assigned as the amide 2.160 was 
formed in low yields. Insufficient material prevented full characterization.  Screening other 
additives including HMPA and H2O in combination with SmI2 gave recovered starting material. 
An attempt to reduce the cyclopropane with Bu3SnH/AIBN also failed. We also investigated a 
small scale Birch-type reduction. Amide ent-2.110 was reacted with excess lithium metal in dry 
EtNH2 for 5 min at 0 °C. We were pleased to see that the reduction product 2.160 was obtained 
in ~36% yield, however full characterization was again hampered by insufficient material. 
Unfortunately, an attempt to conduct the reaction on scale led to over reduction and a messy 
reaction profile.   
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    CH2Cl2, 0 °C, 3 h
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    rt, 12 h, 95% (2 steps)
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THF, reflux, 17.5 h
60%
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O1. Cyclopropyl amide, H2O (8 equiv.)
    THF (freeze pump thaw), then SmI2 (3 equiv.), 1 h
2. NEt3 (8 equiv. degassed freeze pump thaw), 1 h
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Scheme 2-42 Attempted radical reduction of amide ent-2.110   
 
 In summary, attempts to perform late stage derivatization reactions on the natural product 
(+)-cycloclavine and the precursor amide ent-2.110 proved challenging. Both the natural product 
and amide precursor ent-2.110 proved unreactive toward hydrogenation conditions. Radical-
mediated reduction with excess SmI2/H2O/NEt2 or Li metal/EtNH2 proved partially successful 
delivering small quantities of a reduction product 2.160 along with over reduction products. 
Overall, the successful implementation of a radical mediated reduction to obtain meaningful 
quantities of product in a reproducible manner was hindered by an inability to control a mono-
reduction reaction on small scale and in the presence of excess reducing reagent. 
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2.2.12 TEMPO-Carbamate Thermolysis Studies 
We also investigated the thermolytic cleavage of the novel TEMPO-carbamate protecting 
group that was employed in our synthesis of cycloclavine. We decided to study the thermolytic 
cleavage on a model system. To this end indole 2.169 was deprotonated with NaH followed by 
N-acylation with the mixed anhydride 2.170 to form the TEMPO-carbamate 2.171 in 90% yield 
(Scheme 2-43).  
 
Scheme 2-43 TEMPOC protection of indole 
 
  To gain insight into the mechanism of cleavage, the protected indole 2.171 was subjected 
to thermolysis in toluene-d8 (Table 2-9) and the resulting products were analyzed by NMR 
spectroscopy. We found that heating indole 2.171 at 150 °C for 20 h cleanly afforded the desired 
protecting-group free indole 2.169 along with a 3.6:1 ratio of pyrrolidine 2.173: 
tetramethylpiperidine (TMP) 2.172 (Table 2-9, Entry 1). When degassed solvent was employed 
(Table 2-9, Entry 2), a 2.3:1:0.98 ratio of pyrrolidine 2.173:TMP 2.169:enamine 2.175 
(tentatively assigned) was observed. Thermolysis at 150 °C with 4 equivalents of water (Table 2-
9, Entry 3) led to indole 2.169 in an isolated yield of 87% along with a 3.4:1 ratio of pyrrolidine 
2.173:TMP 2.172. Interestingly, when the thermal cleavage was conducted at lower temperatures 
of 135-140 °C (Table 2-9, Entry 4), a 1.8:1 ratio of 2.173:2.172 was observed. Only trace 
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conversion was observed when the thermolysis was conducted at 120 °C in benzene-d6 
overnight (Table 2-9, Entry 5).  
 
Table 2-9 Thermolysis of the TEMPOC-Protected Indole  
 
Entry Conditionsa 
Thermolysis Product Ratio 
2.172 2.173 2.174 2.175 
1 150 °C, PhMe-d8 (1 M), 20 h 1 3.6 NDb 0 
2 150 °C, PhMe-d8 (1 M, degassed), 9 h 1 2.3 NDb 0.98 
3 150 °C, PhMe-d8 (1 M), H2O (4 eq), 21.5 hc 1 3.4 NDb 0 
4 135-140 °C, PhMe-d8 (1 M), 32.5 h 1 1.8 NDb Trace 
5 120 °C, C6D6 (1 M), 12 h SM major, trace conversion 
aall reactions were carried out in a sealed tube, using conventional heating in an oil bath; bnot determined; cisolated 
yield 87%. 
 
These studies support a deprotection mechanism that occurs through a mixed mechanistic 
pathway. The major ionic cleavage is outlined in Scheme 2-44. When indole 2.171 is heated in a 
sealed tube in toluene-d8 at temperatures above 135 °C, a ring contraction and extrusion of CO2 
occurs to form indole anion 2.176 and iminium ion 2.177. Subsequent proton transfer affords the 
protecting-group-free indole 2.169 and enamine 2.175. The enamine 2.175 can be cleaved under 
the reaction conditions to form acetone 2.174 and pyrrolidine 2.173.  
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         Scheme 2-44 Proposed mechanism for the major ionic thermolysis pathway 
 
The minor thermolysis product tetramethylpiperidine (2.172) is most likely generated 
through a separate radical-mediated pathway (Scheme 2-45). A plausible mechanism involves 
homolysis of the N-O bond upon thermolysis in toluene-d8. The resulting tetramethylpiperidine 
radical 2.178 undergoes a radical abstraction from a proton source to generate 
tetramethylpiperidine 2.172. The carboxyl radical 2.179 is proposed to undergo rapid 
decarboxylation to generate CO2 and an indole radical 2.180, which can undergo a second proton 
abstraction to generate indole 2.169. While the proton source in the reaction remains unclear the 
toluene solvent or residual H2O are potential sources.   
 
    Scheme 2-45 Proposed mechanism for the minor radical pathway of thermolysis 
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2.2.13 Radioligand Binding Assays 
Ergot alkaloids display an extraordinarily broad spectrum of biological activity spanning 
multiple therapeutic fields including infectious diseases, CNS disorders, obstetrics and oncology. 
This diverse biological profile has been attributed to their ability to mimic or block the binding 
of natural neurotransmitters like serotonin, dopamine, noradrenalin and adrenalin to their 
receptors. 
Figure 2-19 Ergoline core and the structure of selected monoamine neurotransmitters 
While cycloclavine demonstrated promising insecticidal and antiparasitic activity, its 
broader biological profile remains unknown. We were thus interested in testing the binding 
affinity of our synthetic materials to several neurotransmitter receptors. Radioligand-binding 
assays were carried out to determine the affinity of each enantiomer for dopamine and serotonin 
receptor subtypes (Table 2-10). In these experiments both enantiomers of cycloclavine were 
evaluated for their ability to outcompete a radioligand control for binding to a neurotransmitter 
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receptor target.  The results are expressed as a percent inhibition of the controls specific binding 
to the receptor. 
The results are summarized in Table 2-10 along with the reported radioligand binding 
data for lysergic acid diethylamide (LSD) at 10 µM for comparison.117 Neither enantiomer 
showed significant binding to the GABAA, histamine H1, muscarinic M2 and M5, nicotinic 
acetylcholine α4β2, cytisine and the orexin OX1 receptors at 10 µM. The enantiomers exhibited 
moderate affinity for the adrenergic α1 receptor and the κ-opiate receptor. The natural enantiomer 
showed 57% radioligand displacement at the adrenergic α1 receptor and 73% displacement at the 
κ-opiate receptor. The unnatural enantiomer showed 59% radioligand displacement at the 
adrenergic α1 receptor and 75% radioligand displacement the κ-opiate receptor. Interestingly, the 
natural enantiomer (+)-2.1 exhibited a high affinity for both dopamine and serotonin receptor 
subtypes at 10 µM (Table 2-10, Entries 9-13). When re-evaluated at 1 µM, (+)-2.1 showed high 
affinity for the dopamine D3 receptor (75% inhibition) and quantitative binding to serotonin 
receptor subtypes (Table 2-10, entries 11-13). In contrast, while the unnatural enantiomer (–)-2.1 
showed significant binding to 5-HT1A and 5-HT2A at 10 µM, when re-evaluated at 1 µM it 
exhibited moderate affinity (Table 2-10, Entry 12-13).  The unnatural enantiomer (–)-2.1 
exhibited modest affinity for the dopamine receptor subtypes (Table 2-10, Entries 9-11). Overall, 
these studies identified serotonin and dopamine receptor subtypes as potential biological targets 
for the natural enantiomer.  
G-protein coupled dopamine receptors  (D1-D5) are widely expressed in the brain and 
periphery and mediate all physiological functions of the neurotransmitter dopamine including 
locomotion, emotion, endocrine regulation, reward and learning.118 Specific dopamine agonists 
or antagonists can enhance or reduce the physiological activities of dopamine. For example 
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dopamine D3 receptor agonists have neuroprotective effects and have been used as anti-
Parkinson’s agents, whereas dopamine D3 antagonists show antipsychotic activity.119,120,121  
The neurotransmitter serotonin modulates a wide range of neuropsychological activities 
For example, agonists of 5-HT1A, which is primarily located in the CNS, have been used to treat 
anxiety and depression.122 Non-selective agonists like ergotamine have been used to treat 
migraines.123 The 5-HT2A receptor is widely expressed throughout the CNS. In the periphery, it is 
highly expressed in platelets, where it facilitates platelet aggregation, and it is also expressed in 
several cell types of the cardiovascular system. For example, it is present on smooth arterial 
muscle where it mediates vasoconstriction.124,125 Agonists of 5-HT2A are well known for their 
psychoactive properties and hallucinogenic effects.126 The psychedelic drugs LSD, psilocin and 
mescaline are full or partial agonists of this receptor.127,128 Antagonists of 5-HT2A are widely 
used as antipsychotic drugs have been used to treat hypertension.129,130,131  
The unnatural enantiomer exhibited stronger binding to the 5-HT1A receptor (75% 
inhibition) compared to the 5-HT2A receptor (51% inhibition). This differential activity is 
particularly interesting, because the development of therapeutics without hallucinogenic effects 
is desired. In the future, functional assays could be performed to determine whether the natural 
and unnatural enantiomers of cycloclavine are inhibitors or activators of the serotonin 5-HT1A 
and 5-HT2A receptor subtypes. With this information in hand, the downstream consequences on 
the physiological processes mediated by these receptors can be probed.  
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Table 2-10 Radioligand Binding Studiesa 
 
Entry Receptor 
(+)-cycloclavine  (–)-cycloclavine  LSD117 
 10 µM 1 µM 10 µM 1 µM 10 µM 
1 GABAA, muscimol, central 9rat - -9rat - -2rat 
2 Histamine H1 17 - 27 - 85rat 
3 Muscarinic M2  -1 - -3 - 2 
4 Muscarinic M5 11 - 15 - 15 
5 Nicotinic acetylcholine α4β2, cytisine 9 - 11 - -2.5 
6 Orexin OX1 23 - 6 - - 
7 Adrenergic α1, non-selective 57rat - 59rat - - 
8 Opioid κ(OP2, KOP) 73 - 75 - 29 
9 Dopamine D1  91 - 30 - 30 
10 Dopamine D2L  81 - 14 - 14 
11 Dopamine D3 93 75 64 32 64 
12 Serotonin (5-HT1A) 97 97 91 73 100 
13 Serotonin (5-HT2A) 103 103 89 51 93 
abioassay measures binding affinity toward receptor by displacement of a radioligand at 10 and 1 µM of compound 
(>50% of max stimulation or inhibition is defined as significant). 
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2.3 CONCLUSIONS 
 
The clavine alkaloids are an important group of indole containing alkaloids that belong to 
the well-known ergot alkaloid family. Ergot alkaloids were among the first fungal-derived 
natural products identified and have since been a rich source of pharmaceutical agents with 
diverse applications in obstetrics and the treatment of a variety of diseases, including CNS 
disorders, migraine and cancer. Cycloclavine is a structurally intriguing member of the rare 
rearranged clavine alkaloids. It is unique among clavine alkaloids, possessing an unprecedented 
pyrrolidine-fused cyclopropane ring with vicinal all carbon quaternary stereocenters in place of 
the piperidine common for other clavine alkaloids. Synthetic studies have been particularly 
valuable in facilitating access to the racemic form as well as both enantiomers of cycloclavine.  
Herein, we describe the development of an improved racemic synthesis of cycloclavine 
that proceeded in 12 steps/5.2% overall yield compared to our 14 step/1.2% overall yield original 
synthesis. The key feature of the revised racemic route was the application of a regioselective 
aerobic dehydrogenation to form a bicyclic enone. We also describe the development and 
completion of the first enantioselective synthesis of the unnatural enantiomer (−)-cycloclavine 
(−)-(2.1) that was completed in 8 steps/7.1% overall yield from allene. Noteworthy features of 
the synthesis include the first application of the enantioselective cyclopropanation of allene 
described in Chapter 1. Additional significant features include the development and application 
of a TEMPO-carbamate as a new amine protecting-group that can be cleaved by thermolysis. 
Mechanistic studies were performed to elucidate the mechanism of thermolytic deprotection and 
showed that cleavage of the TEMPOC group proceed via a mixed mechanistic pathway 
involving a major ionic mechanism of thermolysis, and a minor homolytic mechanism of 
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cleavage. The first total synthesis of the natural enantiomer (+)-cycloclavine was also 
accomplished in 8 steps and 4% overall yield from allene using Rh2(R-TBPTTL)4 (ent-1.75) as 
the catalyst for the enantioselective cyclopropanation and the same route used to synthesize (–)-
2.1 thereafter. In an attempt to synthesize analogues of the natural product, several late-stage 
derivatization reactions on the cycloclavine core were carried out. A partially successful single 
electron reduction was identified. Further work is required to optimize this reaction and provide 
meaningful quantities of cycloclavine derivatives. Lastly, the synthetic materials were evaluated 
in radioligand binding assays with several potential target receptors. The natural enantiomer 
showed quantitative binding to the serotonin receptors 5-HT1A and 5-HT2A at 1 µM . Overall, 
these studies identified serotonin and dopamine receptor subtypes as potential biological targets 
for the natural enantiomer.       
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3.0  EXPERIMENTAL 
3.1 GENERAL EXPERIMENTAL 
All glassware was dried in an oven at 140 °C for at least 2 h prior to use. All air and 
moisture-sensitive reactions were performed under a dry N2 atmosphere. Reactions carried out at 
0 °C employed an ice bath and reactions carried out at -78 °C employed a dry ice/acetone bath. 
THF and Et2O were distilled over sodium/benzophenone ketyl, Et3N, CH2Cl2 and toluene were 
distilled from CaH2. All other materials were obtained from commercial sources and used as 
received. Microwave reactions were performed in a Monowave microwave synthesis reactor. 
Infrared spectra were obtained from neat solids or oils on ATR FT-IR spectrometers. Melting 
points were determined in open capillary tubes and are uncorrected. High- resolution mass 
spectra were obtained on a Q-TOF MS or a Thermo Scientific Exactive Orbitrap LC-MS.  1H 
and 13C NMR spectra were obtained at 300, 400, 500, 600 or 700 MHz NMR in CDCl3 unless 
otherwise specified. 13C NMR spectra were obtained at 100, 125, or 150 MHz using a proton-
decoupled pulse observed peak. Chemical shifts (δ) are reported in parts per million with the 
residual solvent peak used as an internal standard δ 1H/13C (Solvent); 7.26/77.16 (CDCl3); 
7.16/128.06 (C6D6), 5.32/54.00 (CD2Cl2) and 2.08/20.43 (PhMe-d8) and are tabulated as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), and 
coupling constant(s), number of protons. Reactions were monitored by thin layer 
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chromatography analysis (pre-coated silica gel 60 F254 plates, 250 µm layer thickness) and 
visualization was accomplished with a KMnO4 solution (1.50 g of KMnO4, 10 g of K2CO3, and 
1.25 mL of 10% NaOH in 200 mL of H2O) when needed. Flash chromatography was performed 
using SiO2 (40-63 µm). Optical rotations were measured on a polarimeter equipped with a 
sodium lamp. Specific rotation values were calculated using the equation: 
[α]λT = (100·a)/(l·c) 
Where [α] represents the specific rotation of the sample in (10-1·deg·cm2·g-1), T indicates 
ambient temperature in °C, λ indicates wavelength (D is used to indicate the sodium line, λ = 589 
nm), a indicates the measured optical rotation, l indicates the path length in decimeters and c 
indicates the concentration in g/100 mL. All enantiomeric excesses were determined by 
analytical SFC separations using a ChiralPak IC column. 
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3.2 EXPERIMENTAL PROCEDURES 
3.2.1 CHAPTER ONE EXPERIMENTAL PART 
 
Ethyl 2-bromo-1,2-dimethylcyclopropane-1-carboxylate (1.81). An oven dried flask 
was charged with Rh2(S-PTTL)4 (1.72) (0.018 g, 0.012 mmol) and 2-bromopropene (0.50 mL, 
5.6 mmol) in anhydrous hexanes (14.1 mL) under an atmosphere of nitrogen. The solution was 
cooled to -78 °C and treated with a solution of diazopropanoate 1.80 (0.60 g, 4.7 mmol) in 
anhydrous hexanes (2.3 mL) via syringe pump at a rate of 1 mL/h. After the addition was 
complete, the reaction was allowed to warm to room temperature, concentrated and purified by 
chromatography on SiO2 (0-10% Et2O/pentane) to deliver ester 1.81 (0.40 g, 39%, ~62:38 er) as 
a clear and colorless oil: [α]20D + 26 (c  1, CHCl3); IR (ATR) 2975, 2937, 1726, 1456, 1361, 
1286, 1178, 1122 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.17 (q, J = 7.1 Hz, 2 H), 1.83 (s, 3 H), 
1.71 (d, J = 6.6 Hz, 1 H), 1.57 (s, 3 H), 1.27 (t, J = 7.1 Hz, 3 H), 1.11 (d, J = 6.3 Hz, 1 H); 13C 
NMR (100 MHz, CDCl3) δ 171.7, 61.4, 42.4, 30.4, 28.9, 26.1, 21.6, 14.4; HRMS (ESI)+) m/z 
calcd for C8H1479BrO2 (M+H) 221.0177, found 221.0168.   
Chiral GC conditions: Astec CHIRALDEX G-TA capillary column (20m x 0.25mm x 
0.12 µm film thickness): 60 °C (hold for 3 min) then 0.25 °C/min to 63 °C (hold for 10 min), 
then 0.50 °C/min to 65 °C (hold for 3 min), then 0.50 °C/min to 75 °C (hold for 1 min), helium 
gas, 3.6 mL/ min, average velocity 53 cm/sec, P = 16.50 psi.   
Br
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Br
N2
OEt
O
Rh2(S-PTTL)4 (1.72)
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*
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Figure 3-1 Chiral GC resolution of racemic 1.81 
 
Figure 3-2 Chromatogram of enantiomerically enriched of ester 1.81 
Ethyl 2-chloro-2-(chloromethyl)-1-methylcyclopropane-1-carboxylate (1.82). An 
oven dried flask charged with Rh2(S-PTTL)4 (1.72) (0.052 g, 0.037 mmol) and vinyl chloride 
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1.79 (0.15 mL, 1.6 mmol) in anhydrous hexanes (2.8 mL) was cooled to -78 °C and treated with 
a solution of diazopropanoate 1.80 (0.10 g, 0.78 mmol) in anhydrous hexanes (0.5 mL) via 
syringe pump at a rate of 1 mL/h. After the addition was complete, the mixture was allowed to 
warm to room temperature and concentrated. The resulting residue was purified by 
chromatography on SiO2 (0-10% Et2O/pentane) to deliver vicinal dichloride 1.82 (0.043 g, 26%) 
as a clear and colorless oil and single diastereomer: IR (ATR) 2982, 2937, 1719, 1456, 1297, 
1223, 1154, 1059, 725 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.21 (qd, J = 7.1, 2.9 Hz, 2 H), 4.04 
(d, J = 12.3 Hz, 1 H), 3.95 (d, J = 12.3 Hz, 1 H), 1.96 (d, J = 6.6 Hz, 1 H), 1.57 (s, 3 H), 1.30 (t, 
J = 7.2 Hz, 3 H), 1.26 (d, J = 6.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 171.4, 62.0, 54.4, 
50.6, 31.7, 29.4, 18.4, 14.2; HRMS (ESI)+ m/z calcd for C8H13Cl2O2 (M+H) 211.0293, found 
211.0283.   
 
 
Ethyl (E)-2-((dimethyl(phenyl)silyl)methylene)-1-methylcyclopropane-1-carboxylate 
(S-1.1). An oven-dried flask charged with Rh2(S-PTTL)4•2EtOAc (1.72) (0.0028 g, 0.0020 
mmol) in anhydrous hexanes (2.3 mL) was treated with DMPS allene 1.95  (0.082 g, 0.47 mmol) 
and cooled to -78 °C under an atmosphere of nitrogen. The cooled solution was treated with a 
solution of ethyl 2-diazopropanoate 1.80 (0.050 g, 0.39 mmol) in anhydrous hexanes (1.1 mL) 
via syringe pump at a rate of 1 mL/h. After the addition was complete, the mixture was allowed 
to warm to room temperature and concentrated. The crude residue was purified by 
chromatography on SiO2 (0-5% Et2O/hexanes) to deliver ester S-1.1 (0.069 g, 64%) as a clear 
OEt
O
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and colorless oil: 1H NMR analysis of the diastereomeric Mosher ester derivatives showed an er 
~76: 24. [α]20D + 12.7 (c 1, CHCl3); IR (ATR) 3066, 2960, 2930, 2908, 1717, 1456, 1426, 1290, 
1137, 1111, 833, 729 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.54-7.53 (m, 2 H), 7.36-7.35 (m, 3 
H), 6.10 (ap. d, J = 2.4 Hz, 1 H), 4.10 (qd, J = 7.2, 0.9 Hz, 2 H), 2.06 (dd, J = 9.2, 2.0 Hz, 1 H), 
1.38 (s, 3 H), 1.31 (dd, J = 9.2, 2.4 Hz, 1 H), 1.23 (t, J = 7.2 Hz, 3 H), 0.41 (s, 3 H), 0.40 (s, 3 
H); 13C NMR (100 MHz, CDCl3) δ 173.6, 147.5, 139.1, 133.9, 129.1, 127.9, 113.3, 60.7, 22.8, 
19.7, 18.8, 14.3, -1.9, -2.2; HRMS (ESI+) m/z calcd for C16H23O2Si (M+H) 275.14618, found 
275.14787. 
 
 
Benzyl (E)-2-((dimethyl(phenyl)silyl)methylene)-1-methylcyclopropane-1-
carboxylate (S-1.2). An oven-dried round bottom flask containing Rh2(S-PTTL)4•2EtOAc (1.72) 
(0.0019 g, 0.0013 mmol) in anhydrous hexanes (1.6 mL) was treated with DMPS allene 1.95 
(0.055 g, 0.32 mmol) and cooled to -78 °C under an atmosphere of nitrogen. The resulting 
cooled solution was treated with a solution of benzyl 2-diazopropanoate 1.89 (0.050 g, 0.26 
mmol) in anhydrous hexanes (0.75 mL) via syringe pump at a rate of 1 mL/h. After the addition 
was complete, the mixture was allowed to warm to room temperature and concentrated. The 
crude residue was purified by chromatography on SiO2 (0-2% Et2O/hexanes) to deliver 
enantiomerically enriched ester S-1.2 (0.036 g, 41%) as a clear and colorless oil. 1H NMR 
analysis of the diastereomeric Mosher ester derivatives showed an er ~72: 28:  IR (ATR) 3066, 
2954, 2928, 1720, 1454, 1426, 1292, 1247, 1135, 1123, 911, 837, 731 cm-1; 1H NMR (400 MHz; 
OBn
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CDCl3) δ 7.53-7.51 (m, 2 H), 7.34-7.28 (m, 8 H), 6.13 (t, J = 2.6 Hz, 1 H), 5.15 (d, J = 12.8 Hz, 
1 H), 5.06 (d, J = 12.8 Hz, 1 H), 2.11 (dd, J = 9.4, 2.6 Hz, 1 H), 1.41 (s, 3 H), 1.34 (dd, J = 9.4, 
2.6 Hz, 1 H), 0.41 (s, 3 H), 0.40 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 173.5, 147.1, 138.9, 
136.4, 133.9, 129.1, 128.6, 128.1, 127.9, 127.7, 113.7, 66.3, 22.8, 19.8, 18.8, -2.0, -2.2; DEPT-
135 (100 MHz, CDCl3) δ 133.9 (CH), 129.1 (CH), 128.6 (CH), 128.1 (CH), 127.9 (CH), 127.7 
(CH), 113.7 (CH), 66.3 (CH2), 19.8 (CH2), 18.8 (CH3), -2.0 (CH3), -2.2 (CH3); HRMS (ESI+) 
m/z calcd for C21H25O2Si (M+H) 337.16183, found 337.16505. 
 
 
tert-Butyl (E)-2-((dimethyl(phenyl)silyl)methylene)-1-methylcyclopropane-1-
carboxylate (S-1.3). An oven-dried round bottom flask charged with Rh2(S-PTTL)4•2EtOAc 
(1.72) (0.0018 g, 0.0013 mmol) in anhydrous hexanes (1.5 mL) was treated with DMPS allene 
1.95 (0.054 g, 0.31 mmol) and cooled to -78 °C under an atmosphere of nitrogen. The resulting 
cooled solution was treated with a solution of tert-butyl 2-diazopropanoate 1.90 (0.040 g, 0.26 
mmol) in anhydrous hexanes (0.7 mL) via syringe pump at a rate of 1 mL/h. After the addition 
was complete, the reaction was allowed to stir for 1 h at -78 °C before the mixture was allowed 
to warm to room temperature and concentrated. The residue was purified by chromatography on 
SiO2 (0-2% Et2O/hexanes) to deliver ester S-1.3 (0.026 g, 34%) as a clear and colorless oil. 1H 
NMR analysis of the diastereomeric Mosher ester derivatives showed an er ~68: 32: IR (ATR) 
3068, 2969, 2930, 1713, 1456, 1426, 1377, 1305, 1247, 1141, 837 cm-1; 1H NMR (400 MHz; 
CDCl3) δ 7.55-7.52 (m, 2 H), 7.36-7.32 (m, 3 H), 6.07 (t, J = 2.4 Hz, 1 H), 1.97 (dd, J = 9.2, 2.4 
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Hz, 1 H), 1.40 (s, 9 H), 1.33 (s, 3 H), 1.25 (dd, J = 9.2, 2.4 Hz, 1 H), 0.40 (s, 3 H), 0.38 (s, 3 H); 
13C NMR (100 MHz; CDCl3) δ 172.9, 148.1, 139.2, 134.0, 129.1, 127.9, 112.7, 80.3, 28.1, 23.7, 
19.5, 18.8, -1.9, -2.2; HRMS (ESI+) m/z calcd for C18H27O2Si (M+H) 303.17748, found 
303.18031.  
 
                 
(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl (E)-2-
((dimethyl(phenyl)silyl)methylene)-1-methylcyclopropane-1-carboxylate (S-1.4). An oven-
dried round bottom flask charged with Rh2(S-PTTL)4•2EtOAc (1.72) (0.0015 g, 0.0011 mmol) in 
anhydrous hexanes (1.0 mL) was treated with DMPS allene 1.95 (0.044 g, 0.25 mmol) and 
cooled to -78 °C under an atmosphere of nitrogen. The resulting cooled solution was treated with 
a solution of menthyl diazoacetate 1.91 (0.050 g, 0.21 mmol) in anhydrous hexanes (0.50 mL) at 
a rate of 1 mL/h. After the addition was complete, the reaction was allowed to stir at -78 °C for 
7h before the mixture was allowed to warm to room temperature. The solvent was subsequently 
removed and the residue was purified by chromatography on SiO2 (0-2% Et2O/hexanes) to 
deliver ester S-1.4 (0.050 g, 62%) as a clear and colorless oil and as an inseparable mixture of 
diastereomers which were directly subjected to derivatization as the Mosher ester adducts. 
HRMS (ESI+) m/z calcd for C24H37O2Si (M+H) 385.25573, found 385.25922. 1H NMR analysis 
of the diastereomeric Mosher ester derivatives showed an er ~73: 27.  
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(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl (E)-2-
((dimethyl(phenyl)silyl)methylene)-1-methylcyclopropane-1-carboxylate (S-1.5). A solution 
of Rh2TPA4•2EtOAc (1.83) (0.0013 g, 0.00086 mmol) and DMPS allene 1.95 (0.030 g, 0.17 
mmol) in CH2Cl2 (1 mL) under an atmosphere of nitrogen was cooled to -78 °C and treated 
dropwise with a solution of menthyl diazo ester 1.91 (0.12 g, 0.52 mmol) in CH2Cl2 (0.5 mL). 
The resulting solution was stirred at -78 °C for approximately 6.5 h, warmed to room 
temperature and concentrated. The resulting residue was purified by chromatography on SiO2 (0-
2% Et2O/hexanes) to deliver cyclopropane S-1.5 (0.055 g, 83%) as a clear and colorless oil and 
mixture of diastereomers: 1H NMR analysis of the diastereomeric Mosher ester derivatives 
showed an er ~19: 81. 1H NMR (400 MHz, CDCl3) δ 7.54-7.52 (m, 2 H), 7.37-7.34 (m 3 H), 
6.07 (ap. t, J = 2.4 Hz, 1 H), 4.59 (td, J = 10.8, 4.4 Hz, 1 H), 2.03 (dd, J = 9.3, 2.6 Hz, 1 H), 
2.00-1.96 (m, 1 H), 1.77 (ddt, J = 14.1, 7.0, 3.5 Hz, 1 H), 1.69-1.61 (m, 2 H), 1.51-1.42 (m, 1 H), 
1.38 (s, 3 H), 1.30-1.26 (m, 1 H), 1.28 (dd, J = 9.4, 2.6 Hz, 1 H), 1.02 (td, J = 12.8, 9.4 Hz, 1 H), 
0.87 (m, 5 H), 0.80 (d, J = 7.0 Hz, 3 H), 0.69 (d, J = 7.0 Hz, 3 H), 0.39 (s, 3 H), 0.38 (s, 3 H) 
 
Mosher-acid chloride derivatization, representative procedure 
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(E)-(2-((Dimethyl(phenyl)silyl)methylene)-1-methylcyclopropyl)methanol (S-1.6). A 
solution of methylenecyclopropane (±)-S-1.1 (0.063 g, 0.23 mmol) in CH2Cl2 (1.5 mL) was 
cooled to 0 °C and treated with DIBAL-H (0.62 mL, 1M in hexanes, 0.62 mmol) and stirred at 0 
°C for 1 h. The reaction was treated successively with deionized H2O (0.025 mL), 15% NaOH 
(0.025 mL) and deionized H2O (0.062 mL), dried (MgSO4) and filtered through a pad of Celite 
washing with EtOAc to deliver alcohol S-1.6 (0.050 g, 93%) as a clear and colorless oil, 
which was used directly without further purification. Diastereomeric Mosher esters (1.93 & 
1.94): A solution of alcohol S-1.6 (0.015 g, 0.065 mmol) in CH2Cl2 (1.0 mL) under an inert 
atmosphere was treated sequentially with crude acid chloride (R)-(-)-MTPA-Cl47 (0.032 g, 0.13 
mmol), using CH2Cl2 (0.5 mL) to complete transfer, anhydrous NEt3 (0.027 mL, 0.19 
mmol) and DMAP (0.0010 g, 0.0081 mmol). The resulting clear and colorless solution 
was stirred at room temperature for 5 h during which time the solution became clear and 
pale yellow. The reaction was filtered through a small pad of florisil (washing with 20% EtOAc/
hexanes) and concentrated under reduced pressure to give crude Mosher ester adducts 193 and 
194. 1H NMR analysis of the crude reaction mixture showed ~ 1.1 ratio of vinyl protons: 
HRMS (ESI+) m/z calcd for C24H31O3NF3Si [M+NH4]+ 466.20198, found 466.2045 
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Figure 3-4 Enantioenriched ester derivatives 
a) Ethyl derivative (Table 1-2, entry 3, 500 MHz, CDCl3); (b) ethyl derivative (Table 1-2, entry 2, 500 MHz,
CDCl3); (c) benzyl derivative (Table 1-2, entry 4, 400 MHz, CDCl3); (d) t-butyl derivative (Table 1-2, entry 5, 500
MHz, CDCl3); (e) menthyl derivative (Table 1-2, entry 6, 400 MHz, CDCl3); (f) menthyl derivative (Table 1-2,
entry 7, 500 MHz, CDCl3)
2-(2-Tosylhydrazono)propanoic acid (1.97). A solution of p-toluenesulfonyl hydrazide 
(5.00 g, 26.3 mmol) in H2O (25 mL) was treated sequentially with 2.5M HCl (12.5 mL) and 
pyruvic acid S-1.6 (2.24 mL, 31.6 mmol) and the resulting heterogeneous mixture was heated at 
100 °C for 4 h. The reaction was cooled to room temperature and the white precipitate collected 
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by vacuum filtration, washing with cold H2O (3 x) and dried under high vacuum to deliver 2-(2-
tosylhydrazono)propanoic acid 1.97 (6.29 g, 93%) as a white solid: Mp 158.4-159.6 °C; IR 
(ATR) 3546, 3215, 2930, 1690, 1596, 1340, 1166, 1121, 1083, 907, 786 cm-1; 1H NMR (400 
MHz, DMSO-d6) δ 12.8 (bs, 1 H), 11.1 (s, 1 H), 7.76 (d, J = 8.4 Hz, 2 H), 7.41 (d, J = 8.0 Hz, 2 
H), 2.38 (s, 3 H), 1.93 (s, 3 H); 13C NMR  (100 MHz, DMSO-d6); δ 165.2, 145.3, 143.8, 136.0, 
129.7, 127.4, 21.0, 13.1; HRMS (LCMS ESI+) m/z calcd for C10H13N2O4S 257.0591, found 
257.0587. 
2,5-Dioxopyrrolidin-1-yl 2-diazopropanoate (1.98). Prepared using a modified protocol 
originally reported by Maruoka et al.132 A solution of p-toluenesulfonyl hydrazide (1.07 g, 5.56 
mmol) in MeOH (3 mL) was treated with pyruvic acid (S-1.6) (0.395 mL, 5.56 mmol) and the 
resulting clear and colorless solution stirred for 30 min at room temperature. The reaction was 
concentrated under reduced pressure to remove the MeOH and placed under high vacuum for 15 
min to deliver 2-(2-tosylhydrazono)propanoic acid (1.97) as a white foam that was immediately 
taken up in THF (55 mL) and cooled to 0 °C. The solution was treated with N-
hydroxysuccinimide (0.726 g, 6.12 mmol) and DCC (1.38 g, 6.12 mmol) and the resulting 
solution stirred at 0 °C for 3 h. The reaction was then treated with triethylamine (0.948 mL, 6.68 
mmol) and the resulting yellow mixture was stirred for 20 h warming slowly to room 
temperature. The mixture was filtered through a pad of Celite (washing with 50% 
EtOAc/hexanes) and the solvent removed under reduced pressure. The viscous brown residue 
was purified by chromatography on SiO2 (20-30% EtOAc/hexanes) to deliver 2,5-
O
O
N2
N
O
O
OH
1. TsHNNH2, MeOH, 30 min
2. DCC (1.1 equiv), DMAP (1.0 equiv)
N-hydroxysuccinimide (1.1 equiv.)
NEt3 (2 equiv.), 0 °C to rt; 63% (2 steps)
O
O
1.98S-1.6
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dioxopyrrolidin-1-yl 2-diazopropanoate (1.98) (0.695 g, 63%) as a yellow solid: IR (ATR) 2958, 
2947, 2095 (ν =N2), 1730, 1635, 1364, 1200, 1075 cm-1; 1H NMR (500 MHz, CDCl3) δ 2.78 (s, 4 
H), 2.58 (s, 3 H) 
Perchlorophenyl 2-diazopropanoate (1.100). A solution of p-toluenesulfonyl hydrazide 
(1.07 g, 5.56 mmol) in MeOH (3 mL) was treated with pyruvic acid (S-1.6) (0.395 mL, 5.56 
mmol) and the clear and colorless solution stirred for 30 min at room temperature. The reaction 
was concentrated under reduced pressure and then placed under high vacuum for 15 min to 
deliver 2-(2-tosylhydrazono)propanoic acid 1.97 as a white foam which was immediately 
dissolved in THF (55 mL), cooled to 0 °C and treated sequentially with pentachlorophenol (1.63 
g, 6.12 mmol) and DCC (1.38 g, 6.12 mmol). The resulting cream mixture was stirred at 0 °C for 
3 h during which time it turned yellow and then orange. The reaction was then treated with 
triethylamine (0.948 mL, 6.68 mmol) and the resulting orange, heterogeneous mixture was 
stirred for 24 h warming slowly to room temperature. The mixture was filtered through a pad of  
(washing with 50% Et2O/hexanes) and the solvent was removed under reduced pressure. The 
brown viscous residue was purified by chromatography on SiO2 (3% Et2O/hexanes) to deliver 
perchlorophenyl 2-diazopropanoate 1.100 (0.331 g, 17%) as a yellow solid: IR (ATR) 2984, 
2937, 2091 (ν =N2), 1722, 1465, 1454, 1392, 1361, 1325, 1064, 712 cm-1; 1H NMR (300 MHz, 
CD2Cl2) δ 2.08 (bs, 3 H). 
1.100
O
O
N2 Cl
Cl
Cl
Cl
ClO
O
OH
1. TsHNNH2, MeOH, 30 min
2. DCC (1.1 equiv), DMAP (1.0 equiv)
Pcp-OH (1.1 equiv.),  NEt3 (2 equiv.)
0 °C to rt; 17% (2 steps)
S-1.6
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Perfluorophenyl 2-diazopropanoate (1.99). Conditions A: A solution of p-
toluenesulfonyl hydrazide (10.7 g, 56.2 mmol) in MeOH (30 mL) was treated with pyruvic acid 
S-1.6 (3.95 mL, 56.2 mmol). The resulting clear and colorless solution was stirred at room
temperature for 0.5 h then concentrated to deliver 2-(2-tosylhydrazono)propanoic acid 1.97 as a 
white foam which was immediately dissolved in CH2Cl2 (576 mL), cooled to 0 °C and treated 
sequentially with DCC (13.9 g, 61.8 mmol) and DMAP (6.87 g, 56.2 mmol). The resulting 
mixture was stirred at 0 °C for 30 min then treated with pentafluorophenol (11.4 g, 61.8 mmol) 
in CH2Cl2 (5 mL). The reaction was allowed to stir at 0 °C for 5 h then treated with triethylamine 
(15.9 mL, 112 mmol) and the resulting yellow mixture was stirred for 12 h while warming 
slowly to room temperature. The mixture was filtered through a pad of Florisil (washing with 
CH2Cl2) and the filtrate was carefully concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (0-2% Et2O/hexanes) to deliver 1.99 (2.21 g, 15%) as a 
yellow oil: IR (ATR) 2940, 2094 (ν =N2), 1721, 1655, 1515, 1474, 1338, 1297, 1147, 1055, 992, 
713 cm-1; 1H NMR (300 MHz, C6D6) δ 1.20 (s, 3 H).   
Conditions B: A suspension of 2-(2-tosylhydrazono)propanoic acid 1.97 (8.00 g, 31.2 
mmol) in CH2Cl2 (336 mL) under an atmosphere of argon (balloon) was cooled to 0 °C and 
treated sequentially with oxalyl chloride (4.10 mL, 46.8 mmol) and DMF (0.0121 mL, 0.156 
mmol) upon the addition of which gas evolution was observed. The resulting suspension was 
stirred at 0 °C warming to room temperature 24.5 h during which time the white solid gradually 
O
O
OH
conditions A: 1. TsHNNH2, MeOH, 30 min
2. DCC (1.1 equiv), DMAP (1.0 equiv)
Pfp-OH (1.1 equiv.),  NEt3 (2 equiv.)
0 °C to rt; 15%
conditions B: N2
O
O F
F
F
F
F
1.99S-1.6 1. (COCl)2, DMF, CH2Cl2, 0 °C to rt, 24.5 h
2. Pentafluorophenol, rt, 24 h
3. NEt3, CH2Cl2, rt, 26 h; 21%
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went into solution becoming clear and pale yellow. The reaction was then treated dropwise with 
a solution of pentafluorophenol (8.62 g, 46.8 mmol) in CH2Cl2 (13 mL) and the resulting clear 
and pale yellow solution allowed to stir at room temperature for 24 h. The reaction was then 
treated with NEt3 (8.87 mL, 62.4 mmol) during the addition of which a white gas evolved and 
the solution became orange/ yellow color. The resulting orange solution was allowed to stir at 
room temperature for 26 h then filtered through a pad of florisil (washing with CH2Cl2) and 
concentrated. The resulting yellow was purified by chromatography on SiO2 (0-1% 
Et2O/hexanes) to deliver diazopropanoate 1.99 (1.76 g, 21%) as a yellow oil: 1H NMR (300 
MHz, C6D6) δ 1.21 (s, 3 H). 
Ethyl 1-methyl-2-methylenecyclopropane-1-carboxylate (±-1.101). An oven-dried 
three neck flask fitted with a nitrogen inlet, a dry-ice condenser and septum was charged with 
Rh2(TPA)4•2EtOAc (1.83) (0.0060 g, 0.0039 mmol) and CH2Cl2 (3.6 mL) and the resulting 
green solution cooled to -78 °C and treated dropwise with an excess of condensed allene (1.96) 
(10 drops). The resulting purple/brown solution was then treated with a solution of ethyl 
diazopropanoate 1.80 (0.10 g, 0.78 mmol) in anhydrous CH2Cl2 (1 mL) via syringe pump at a 
rate of 1 mL/h. After the addition was complete, the mixture was allowed to warm to room 
temperature. The reaction was concentrated and the resulting green residue purified by 
chromatography on SiO2 (10% Et2O/hexanes) to deliver methylenecyclopropane ethyl ester (±)-
1.101 (0.096 g, 88%) as a clear and very pale yellow oil. 1H NMR analysis of the diastereomeric 
•
O
OEt
N2
Rh2(TPA)4 (1.83) 
CH2Cl2, -78 °C to rt, 88% O
1.80
(±)-1.101
OEt
1.96
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Mosher ester derivatives showed an er ~50: 50: IR (ATR) 2902, 2978, 2934, 1719, 1459, 1445, 
1389, 1379, 1299, 1284, 1171, 1141, 1094, 1031 cm-1; 1H NMR (400 MHz; CDCl3) δ 5.45 (t, J = 
2.8 Hz, 1 H), 5.42 (t, J = 2.0 Hz, 1 H), 4.13 (dq, J = 10.8, 7.2 Hz, 1 H), 4.09 dq, J = 10.8, 7.2 Hz, 
1 H), 2.01 (dt, J = 8.9, 2.5 Hz, 1 H), 1.39 (s, 3 H), 1.31 (dt, J = 8.7, 2.2 Hz, 1 H), 1.23 (t, J = 7.2 
Hz, 3 H); 13C NMR (100 MHz; CDCl3) δ 173.7, 137.9, 102.7, 60.9, 23.2, 19.0, 18.9, 14.3; 
HRMS (ESI+) m/z calcd for C8H13O2 (M+H) 141.09101, found 141.09199. 
Ethyl (R)-1-methyl-2-methylenecyclopropane-1-carboxylate (1.101). An oven-dried 
three neck flask fitted with a nitrogen inlet, a dry-ice condenser and septum was charged with 
Rh2(S-TBPTTL)4 (1.75) (0.029 g, 0.012 mmol) and CH2Cl2 (6.5 mL) and the resulting green 
solution cooled to -78°C (dry ice, acetone bath) and treated dropwise with an excess of 
condensed allene gas (1.96) (ca. 0.50 g, 13 mmol). The resulting green solution was then treated 
with a solution of diazopropanoate 1.80 (0.15 g, 1.17 mmol) in anhydrous CH2Cl2 (1.2 mL) via 
syringe pump at a rate of approximately 1 mL/h. The resulting solution was allowed to stir at -78 
°C for 1 h before warming to room temperature. The resulting green residue was concentrated 
and purified by chromatography on SiO2 (0-1% Et2O/hexanes to deliver methylenecyclopropane 
1.101 (0.032 g, 20%) as a clear and pale yellow oil: 1H NMR (400 MHz; CDCl3) δ 5.45 (t, J = 
2.8 Hz, 1 H), 5.42 (t, J = 2.0 Hz, 1 H), 4.13 (dq, J = 10.8, 7.1 Hz, 1 H), 4.09 dq, J = 10.8, 7.2 Hz, 
1 H), 2.01 (dt, J = 8.8, 2.4 Hz, 1 H), 1.39 (s, 3 H), 1.31 (dt, J = 8.8, 2.4 Hz, 1 H), 1.23 (t, J = 7.2 
•
O
OEt
N2
Rh2(S-TBPTTL)4 (1.75) 
CH2Cl2, -78 °C to rt, 20% O
1.80
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Hz, 3 H). The er was determined to be 81:19 by derivatization as the amide 2.87 using the same 
protocol developed in the synthesis of (±)-cycloclavine and analyzed by chiral SFC.  
SFC resolution of racemic (±)-2.87 [Chiralpak IC column (250 x 10 mm), gradient 
elution 5-15% iPrOH (rate 1.0), 7 mL/ min, 245 nm, P = 100 (BAR)]:  
Figure 3-5 SFC chromatograms of racemic standard and imide derived from enantioenriched ester 1.101 
1.101 2.87
1. LiOH•H2O (5 eq), (4:1) H2O/MeOH (0.18 M), rt, 2 d
2. (COCl)2 (4 eq), DMF (0.1 eq), hexanes (0.08 M), 3 h
3. Acyl chloride (1.1 eq, 0.3 M solution in THF),
 Amide 2.87 (1 eq), BuLi (1 eq), THF (0.2 M), -78 °C to rt
er 81:19
N
O
O
O
OEt
(±)-2.87
N
O
O
2.87
87:13 er
N
O
O
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tert-Butyl (R)-1-methyl-2-methylenecyclopropane-1-carboxylate (S-1.7). An oven-
dried three neck flask fitted with a nitrogen inlet, a dry-ice condenser and septum was charged 
with Rh2(S-TBPTTL)4 (1.90) (0.00803 g, 0.00320 mmol) and CH2Cl2 (3.2 mL) under an 
atmosphere of nitrogen. The resulting clear, green solution was cooled to -78 °C and treated 
dropwise with condensed allene (6 liquid drops, 0.500 g, 12.5 mmol). The clear, purple reaction 
mixture was then treated with a solution of tert-butyl 2-diazopropanoate 1.90 (0.0500 g, 0.320 
mmol) in CH2Cl2 (0.9 mL) slowly at a rate of ~ 1 mL/ h during which time the solution became 
brown/ yellow in color. The reaction was stirred at -78 °C for 3 h after which time TLC indicated 
the complete consumption of the diazo starting material. The reaction was allowed to warm to 
room temperature and purified directly by chromatography on SiO2 (2-5% Et2O/hexanes) to 
deliver tert-butyl 1-methyl-2-methylenecyclopropane-1-carboxylate S-1.7 (0.0275 g, 51%) as a 
clear and colorless oil. 1H NMR analysis of the diastereomeric Mosher ester derivatives showed 
an er ~91: 9: IR (ATR) 2978, 2934, 1716, 1478, 1458, 1392, 1368, 1311, 1297, 1256, 1221, 
1189, 1141, 1097, 888, 733 cm-1; 1H NMR (400 MHz; CDCl3) δ 5.42 (t, J = 2.8 Hz, 1 H), 5.37 (t, 
J = 2.0 Hz, 1 H), 1.94 (dt, J = 8.8, 2.4 Hz, 1H), 1.41 (s, 9 H), 1.34 (s, 3 H), 1.24 (dt, J = 8.8, 2.4 
Hz, 1 H); 13C NMR (100 MHz; CDCl3) δ 172.9, 138.2, 102.1, 80.4, 28.1, 24.1, 19.0, 18.7; unable 
to obtain a HRMS on the sample due to volatility issues.  
•
O
OtBu
N2
Rh2(S-TBPTTL)4 (1.75) (1 mol%)
CH2Cl2, -78 °C, 51% O
1.90
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OtBu
1.96
135 
tert-Butyl (R)-1-methyl-2-methylenecyclopropane-1-carboxylate (S-1.7). An oven 
dried three neck flask fitted with a nitrogen inlet, a dry-ice condenser and septum was charged 
with Rh2(S-TBPTTL)4 (1.75) (0.00803 g, 0.00320 mmol) and CH2Cl2 (3.2 mL) under an 
atmosphere of nitrogen. The resulting clear, green solution was cooled to ca. -98 °C (external 
temperature, 2:1 Et2O/pentane liquid N2 bath) and treated dropwise with condensed allene (7 
drops). The reaction was then treated with a solution of tert-butyl 2-diazopropanoate 1.90 
(0.0500 g, 0.320 mmol) in CH2Cl2 (0.9 mL) slowly at a rate of ~ 1 mL/ h maintaining the 
external temperature between -95 to -98 °C. The resulting solution was stirred for 1 h 
maintaining the external temperature below -95 °C after which time TLC indicated major diazo 
starting material. The reaction was allowed to warm to -80 °C at which point TLC indicated 
some desired product formation. The reaction was let stir at this temperature for a further 2 h 
then allowed to warm slowly to room temperature, and concentrated. The resulting residue was 
filtered through a pad of florisil washing with 10% Et2O/petroleum ether to deliver 
methylenecyclopropane S-1.7 (0.025 g, 47%) as a clear and colorless oil: 1H NMR (400 MHz; 
CDCl3) δ 5.42 (ap. t, J = 2.6 Hz, 1 H), 5.37 (ap. t, J = 2.0 Hz, 1 H), 1.94 (dt, J = 8.8, 2.4 Hz, 1 
H), 1.41 (s, 9 H), 1.34 (s, 3 H), 1.25 (dt, J = 8.8, 2.1 Hz, 1 H) 
•
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2,5-Dioxopyrrolidin-1-yl 1-methyl-2-methylenecyclopropane-1-carboxylate (±)-(S-
1.8). An oven-dried three neck flask fitted with a nitrogen inlet, a dry-ice condenser and septum 
was charged with Rh2TPA4•2EtOAc (1.83)  (0.00388 g, 0.00254 mmol) and CH2Cl2 (2.5 mL) 
and the resulting green solution cooled to -78 °C (dry ice/ acetone bath) and treated dropwise 
with an excess of condensed allene gas 1.96 (0.500 g, 12.5 mmol). The resulting purple/ maroon 
solution was then treated with a solution of 2,5-dioxopyrrolidin-1-yl 2-diazopropanoate 1.98 
(0.100 g, 0.507 mmol) in anhydrous CH2Cl2 (0.7 mL) via syringe pump at a rate of 1 mL/h 
during which time the solution turned a yellow/brown color. After the addition was complete, the 
mixture was allowed to warm to room temperature, concentrated and the resulting green oil 
purified by chromatography on SiO2 (60% Et2O/hexanes) to deliver methylenecyclopropane (±)-
S-1.8 (0.0873 g, 82%) as a clear and pale yellow oil: IR (ATR) 2993, 2984, 1771, 1728, 1428,
1364, 1199, 1064, 1023, 813 cm-1; 1H NMR (300 MHz; CDCl3) δ 5.68 (t, J = 2.7 Hz, 1 H), 5.56 
(t, J = 2.0 Hz, 1 H), 2.81 (s, 4 H), 2.32 (dt, J = 9.3, 2.4 Hz, 1 H), 1.59 (dt, J = 9.3, 2.4 Hz, 1 H), 
1.51 (s, 3 H); 13C NMR (125 MHz) δ 169.2, 169.1, 135.3, 105.0, 25.7, 21.3, 20.8, 18.4; DEPT-
135 (CDCl3) δ 105.0 (CH2), 25.7 (CH2), 20.8 (CH2), 18.4 (CH3); HRMS (ASAP) m/z calcd for 
C10H11NO4 209.0688, found 209.0710.  
•
(±)-S-1.81.96
O
OSu
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Rh2(TPA)4 (1.83)
CH2Cl2, -78 °C to rt, 82% O
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2,5-Dioxopyrrolidin-1-yl (R)-1-methyl-2-methylenecyclopropane-1-carboxylate (S-
1.8). An oven-dried three neck flask fitted with a nitrogen inlet, a dry-ice condenser and septum 
was charged with Rh2(S-TBPTTL)4 (1.75) (0.0140 g, 0.00560 mmol) and CH2Cl2 (2.75 mL) and 
the resulting green solution cooled to -87°C (acetone/cryocool) and treated dropwise with an 
excess of condensed allene gas (0.700 g, 17.5 mmol). The resulting solution was then treated 
with a solution of 2,5-dioxopyrrolidin-1-yl 2-diazopropanoate (1.98) (0.110 g, 0.558 mmol) in 
anhydrous CH2Cl2 (0.8 mL) via syringe pump at a rate of 1 mL/h during which time the solution 
became yellow/green in color. After the addition was complete, the solution was stirred at -87 °C 
for 4 h during which time no conversion occurred. The reaction was then allowed to warm to -78 
°C for 2 h after which time 1H NMR analysis showed minor conversion to product. Additional 
catalyst was added (0.00700 g) and the reaction was allowed to warm to room temperature. The 
reaction was concentrated and purified by chromatography on SiO2 (25-30% EtOAc/hexanes) to 
deliver 2,5-dioxopyrrolidin-1-yl 1-methyl-2-methylenecyclopropane-1-carboxylate S-1.8 (0.0310 
g, 27%) as a clear and pale yellow oil: 1H NMR analysis of the diastereomeric Mosher ester 
derivatives showed an er ~77:23. 1H-NMR (400 MHz; CDCl3) δ 5.67 (t, J = 2.8 Hz, 1 H), 5.55 
(t, J = 2.2 Hz, 1 H), 2.80 (s, 4 H), 2.30 (dt, J = 9.2, 2.4 Hz, 1 H), 1.58 (dt, J = 9.4, 2.5 Hz, 1 H), 
1.50 (s, 3 H). 
Rh2(S-TBPTTL)4 (1.75) (1.5 mol%)
CH2Cl2, -78 °C to rt, 27%
•
1.96
O
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N2
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 Perchlorophenyl (R)-1-methyl-2-methylenecyclopropane-1-carboxylate (1.105). An 
oven-dried three neck flask fitted with a nitrogen inlet, a dry-ice condenser and septum was 
charged with Rh2(S-TBPTTL)4 (1.75) (0.0413 g, 0.0165 mmol) and CH2Cl2 (8.0 mL) and the 
resulting green solution cooled to -78°C and treated dropwise with an excess of condensed allene 
gas 1.96 (0.570 g, 14.2 mmol). The resulting green solution was then treated with a solution of 
perchlorophenyl 2-diazopropanoate (1.100) (0.574 g, 1.65 mmol) in anhydrous CH2Cl2 (2.9 mL) 
via syringe pump at a rate of 1 mL/h. The resulting solution was allowed to stir at -78 °C for 1.5 
h before warming to room temperature. The residue was purified by chromatography on SiO2 (0-
3% Et2O/hexanes) to deliver methylenecyclopropane 1.105 (0.496 g, 84%) as a white solid. 1H 
NMR analysis of the diastereomeric Mosher ester derivatives showed an er ~77:23: MP 106.2-
108.5 °C; IR (ATR) 2973, 2934, 1745, 1442, 1388, 1361, 1288, 1255, 1214, 1134, 1103, 1086, 
1033, 984, 955, 905, 888, 767 cm-1; 1H NMR (500 MHz; CD2Cl2) δ 5.67 (t, J = 2.8 Hz, 1 H), 
5.58 (t, J = 2.0 Hz, 1 H), 2.37 (dt, J = 9.5, 2.5 Hz, 1 H), 1.63 (dt, J = 9.3, 2.5 Hz, 1 H), 1.53 (s, 3 
H); 13C NMR (100 MHz; CD2Cl2) δ 170.0, 144.9, 136.8, 132.4, 131.7, 128.4, 104.5, 23.4, 20.4, 
18.8; DEPT-135 (CD2Cl2, 125 MHz) δ 104.5 (CH2), 20.4 (CH2), 18.8 (CH3); HRMS (ASAP) m/z 
calcd for C12H8O2Cl5 358.8967, found 358.8938. Crystalline 1.105 was submitted for X-ray 
analysis. Recrystallization of enantiomerically enriched 1.105 resulted in enrichment of the 
mother liquor.  After 2 x recrystallization from boiling heptanes and 1x recrystallization from 
boiling 1,2-DCE the mother liquor was enriched to ~90: 10 er as determined by SFC analysis of 
the amide derivative 2.87.  
•
O
OPcp
N2
Rh2(S-TBPTTL)4 (1.75) (1 mol%)
CH2Cl2, -78 °C to rt, 84% O
1.100
1.105
OPcp
1.96
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SFC resolution of racemic 2.87 [Chiralpak IC column (250 x 4.6 mm), gradient elution 
1% iPrOH (hold for 5 min), 2% iPrOH (hold for 5 min), 3% iPrOH (hold for 6 min), 4% iPrOH 
(hold for 3 min), 4.50% iPrOH (hold for 2 min), 5% iPrOH (hold for 3 min), 4 mL/min, 254 nm, 
P=110 (BAR)]:  
Figure 3-6 SFC chromatograms of racemic standard and imide 2.87 derived from enantioenriched mother liquor 
sample of methylenecyclopropane 1.105 
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(R,E)-N,1-Dimethyl-2-methylene-N-(3-oxobut-1-en-1-yl)cyclopropane-1-
carboxamide (2.87). A flask containing vinylogous amide 2.88 (0.0046 g, 0.046 mmol) was 
evacuated and backfilled with nitrogen. Freshly distilled THF (0.40 mL) was added and the 
resulting solution cooled to -78 °C and treated dropwise with n-BuLi (0.020 mL, 2.5 M solution 
in hexanes, 0.049 mmol) stirred for 5 min at -78°C then treated with a solution of 
pentachlorophenol ester 1.105 (0.018 g, 0.051 mmol) in THF (0.25 mL). The resulting solution 
was then treated with DMAP (0.00057 g, 0.0046 mmol) and stirred for 30 min at -78 °C. TLC 
analysis of the reaction mixture indicated product formation. The cold bath was removed and the 
reaction was warmed to room temperature. The reaction was directly subjected to purification by 
chromatography on SiO2 (10-20% EtOAc/Hexanes) to deliver vinylogous amide 2.87 (0.0078 g, 
87%) as a clear and colorless oil: 1H NMR (300 MHz; CDCl3) δ 8.36 (d, J = 13.8 Hz, 1 H), 5.64 
(d, J = 13.8 Hz, 1 H), 5.64 (ap. t, J = 2.7 Hz, 1 H), 5.53 (s, 1 H), 3.15 (s, 3 H), 2.29 (s, 3 H), 1.80 
(dt, J = 9.6, 2.4 Hz, 1 H), 1.49 (s, 3 H), 1.33 (dt, J = 9.6, 2.3 Hz, 1 H). 
Mosher-acid chloride derivatization, representative procedure: 
(1-Methyl-2-methylenecyclopropyl)methyl (2S)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate (1.102 and 1.103). A solution of ethyl 1-methyl-2-methylenecyclopropane-
1-carboxylate (1.65) (0.020 g, 0.14 mmol) in CH2Cl2 (1 mL) was cooled to 0 °C, treated with
O
OPcp
2.87
2.88 O
n-BuLi, DMAP, THF
-78 °C to rt
87%
N
O O
1.105
MeHN
(S)
O
(S)
O
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Ph CF3OR
O
1.1021.65
(R)
O
(S)
O
OMe
Ph CF3
1.103
+1. DIBAL-H, CH2Cl2, 0 °C, 3 h
2. (R)-(-)-MTPA-Cl, NEt3, DMAP, CH2Cl2, rt, 5 h
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DIBAL-H (0.39 mL, 1 M solution in hexanes, 0.39 mmol) and stirred at 0 °C for 3 h. The 
reaction mixture was treated successively with H2O (15 µL), 15% NaOH (15 µL) and H2O (39 
µL), dried (MgSO4) and filtered through a pad of Celite washing with EtOAc and concentrated. 
A solution of crude alcohol in CH2Cl2 (1.1 mL) under an inert atmosphere was treated 
sequentially with a solution of (R)-(−)-MTPA-Cl47 (0.028, 0.11 mmol) in CH2Cl2 (0.5 mL), 
anhydrous NEt3 (0.023 mL, 0.17 mmol) and DMAP (0.00070 g, 0.0055 mmol). The resulting 
clear and colorless solution was stirred at room temperature for 5 h after which time TLC 
analysis indicated complete consumption of the alcohol starting material. The reaction was 
filtered through a small pad of Florisil (washing with 30% Et2O/hexanes) and concentrated. 1H 
NMR analysis of the crude reaction mixture showed a 1:1 mixture of ester diastereomers 1.102 
and 1.103.  
Racemic standard (500 MHz, CDCl3) 
Figure 3-7 Mosher ester derivative: racemic standard 
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Figure 3-8 Enantioenriched Mosher ester derivatives 
a) t-Butyl derivative (Table 1-3, entry 2, 700 MHz, CDCl3); (b) t-butyl derivative (Table 1-3, entry 3, 700 MHz,
CDCl3); (c) succinimide derivative (Table 1-3, entry 6, 700 MHz); (d) pentachlorophenyl derivative (Table 1-3,
entry 7, 600 MHz, CDCl3); pentafluorophenyl derivative (Table 1-3, entry 8, 600 MHz, CDCl3).
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Catalyst Screen: General Protocol for the Asymmetric Cyclopropanation of Allene: 
Perfluorophenyl (R)-1-methyl-2-methylenecyclopropane-1-carboxylate (1.105). An 
oven-dried three neck flask charged with catalyst (0.0056 mmol) and hexanes or CH2Cl2 (2.8 
mL) and the resulting green solution was cooled to -78 °C and treated dropwise with a large 
excess of condensed allene gas (1.96) (14 mmol). The reaction was then treated with a solution 
of perfluorophenyl 2-diazopropanoate (1.99) (0.56 mmol) in hexanes or CH2Cl2 (1.7 mL) via 
syringe pump at a rate of 1 mL/ h. After the addition was complete, the mixture was allowed to 
warm to room temperature. The reaction was concentrated under reduced pressure and the 
resulting residue purified by chromatography on SiO2 (0-2% Et2O/Hex) to deliver 
methylenecyclopropane (1.105):  1H NMR (400 MHz, CD2Cl2) δ 5.64 (t, J = 2.8 Hz, 1 H), 5.56 
(t, J = 2.2 Hz, 1 H), 2.30 (dt, J = 9.2, 2.5 Hz, 1 H), 1.63 (dt, J = 9.2, 2.4 Hz, 1 H), 1.51 (s, 3 H). 
Catalyst Screen: General protocol for the conversion of methylenecyclopropanes to 
vinylogous imide 2.87 to assess enantiomeric excess:    
(R,E)-N,1-Dimethyl-2-methylene-N-(3-oxobut-1-en-1-yl)cyclopropane-1-
carboxamide (2.87). An oven-dried flask charged with vinylogous amide 2.87 (0.18 mmol, 1.0 
eq.) was evacuated and backfilled with nitrogen (3x). Freshly distilled THF (0.6 mL) was added 
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and the resulting solution was cooled to -78 °C and treated dropwise with n-BuLi (2.29 M 
solution in hexanes, 0.19 mmol, 1.05 eq.). The resulting clear, pale yellow solution was stirred 
for 5 min at -78 °C, then treated with a solution of ester 1.105 (0.19 mmol, 1.05 eq) in THF (1 
mL). The resulting bright yellow solution was treated with DMAP (0.19 mmol, 0.1 eq.) and 
stirred for 10 min at -78 °C. The cold bath was removed and the reaction mixture was allowed to 
stir, warming to room temperature. The reaction was quenched with sat. NaHCO3. After addition 
of EtOAc, the aqueous layer was extracted with EtOAc (3x) and the combined organic layers 
were dried (Na2SO4) and concentrated. The crude product was purified by chromatography on 
SiO2 (10-15% EtOAc/hexanes) to deliver vinylogous imide 2.87 as a clear, pale yellow oil: 1H 
NMR (300 MHz, CDCl3) δ 8.36 (d, J = 13.8 Hz, 1 H), 5.71 (d, J = 13.8 Hz, 1 H), 5.69 (ap. t, J = 
3.0 Hz, 1 H), 5.53 (ap. s, 1 H), 3.15 (s, 3 H), 2.29 (s, 3 H), 1.79 (dt, J = 9.6, 2.2 Hz, 1 H), 1.49 (s, 
3 H), 1.32 (dt, J = 9.6, 2.2 Hz, 1 H). 
 
Figure 3-9 SFC chromatogram of imide 2.87 derived from the reaction with Rh2(R-DOSP)4 
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Figure 3-10 SFC chromatogram of imide 2.87 derived from the reaction with Rh2(R-BTCP)4 
 
 
 
 
Figure 3-11 SFC chromatogram of imide 2.87 derived from the reaction with Rh2(S-PTTL)4 
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Figure 3-12 SFC chromatogram of imide 2.87 derived from the reaction with Rh2(S-PTAD)4 
 
 
4,7-Diphenyl-3a,4,7,7a-tetrahydroisobenzofuran-1,3-dione (1.113). A clear, yellow 
solution of butadiene 1.111 (2.0 g, 9.6 mmol) and maleic anhydride 1.112 (1.1 g, 11 mmol) in 
xylenes (25 mL) was heated at 140 °C for 16 h. After this time, the reaction was cooled to 0 °C 
and the resulting white precipitate filtered to afford Diels-Alder adduct 1.113 (2.29 g, 78%) as a 
white solid:1H NMR (500 MHz, CDCl3) δ 7.43 (ap. t, J = 7.3 Hz, 4 H), 7.39-7.36 (m, 6 H), 6.56 
(s, 2 H), 3.84 (d, J = 4.0 Hz, 2 H), 3.74, dd, J = 4.5, 2.0 Hz, 2 H). The experimental data was 
consistent with the literature-reported data.133  
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4,7-Diphenylisobenzofuran-1,3-dione (1.114). A red solution of anhydride 1.113 (1.0 g, 
3.3 mmol) and DDQ (1.5 g, 6.6 mmol) in toluene (10 mL) was heated at 110 °C for 17 h. The 
reaction was concentrated and filtered washing with copious amounts of EtOH to deliver crude 
4,7-diphenylisobenzofuran-1,3-dione 1.114 (0.832 g, 84%) as a light pink solid that was used 
directly: 1H NMR (300 MHz, CDCl3) δ 7.85 (s, 2 H), 7.61-7.57 (m, 4 H), 7.54-7.51 (m, 6H). The 
experimental data was consistent with the literature-reported data.133 
 
 
 
(S)-2-(1,3-Dioxo-4,7-diphenylisoindolin-2-yl)-3,3-dimethylbutanoic acid (1.116). An 
oven-dried microwave vial was charged sequentially with 4,7-diphenylisobenzofuran-1,3-dione 
(1.114) (0.300 g, 1.00 mmol), L-tert-leucine (0.199 g, 1.50 mmol) and triethylamine (0.0283 mL, 
0.200 mmol) and the resulting heterogeneous brown solution heated at reflux for 19 h. The 
solution was cooled to room temperature, treated with 5% HCl and EtOAc. The separated 
aqueous layer was extracted with EtOAc (3x) and the combined organic layers, dried (Na2SO4), 
filtered and concentrated. The resulting residue was purified by chromatography on SiO2 (0-20% 
Acetone/CH2Cl2) to deliver carboxylic acid 1.116 (0.128 g, 31%) as a white foam: M.p. 142.7-
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145 °C; [α]D19 –10.6 (c 0.17, CHCl3); IR (ATR) 2963, 1770, 1710, 1603, 1475, 1382, 1122, 903, 
752, 698 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.67 (s, 2 H), 7.56 (ap. dd, J = 7.6, 1.9 Hz, 4 H), 
7.52-7.45 (m, 6 H), 4.68 (s, 1 H), 1.14 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 172.3, 167.3, 
140.4, 136.5, 136.3, 129.6, 128.9, 128.3, 128.1, 60.0, 35.8, 28.2; HRMS (LCMS ESI+) m/z calcd 
for C26H24NO4 (M+H) 414.1700, found 414.1698.  
 
 
Tetrakis(S)-2-(1,3-dioxo-4,7-diphenylisoindolin-2-yl)-3,3-dimethylbutanoic acid 
dirhodium(II) complex (1.117). A microwave vial was charged with (S)-2-(1,3-dioxo-4,7-
diphenylisoindolin-2-yl)-3,3-dimethylbutanoic acid 1.116 (0.090 g, 0.22 mmol), Rh2(OAc)4 
(0.016 g, 0.036 mmol) and chlorobenzene (0.5 mL) and the resulting green solution heated at 
145 °C (external temperature, oil bath). After heating overnight, the reaction was cooled and 
concentrated. The resulting green residue was purified by chromatography on SiO2 (0-2% 
acetone/CH2Cl2) to deliver a green residue which was taken up in EtOAc and concentrated to 
deliver the bis EtOAc adduct 1.117 (35.5 mg, 48%) as an emerald green crystalline solid: M.p. 
280-282.9 °C (dec.); [α]D20 +217 (c 0.03, CHCl3); IR (ATR) 2944, 1716, 1606, 1509, 1353, 
1226, 1046, 737 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.52 (bs, 8 H), 7.44-7.33 (m, 40 H), 4.20 (s, 
4 H), 4.12 (q, J = 7.3 Hz, 4 H, EtOAc), 2.04 (s, 6 H, EtOAc), 1.23 (t, J = 7.0 Hz, 6 H, EtOAc), 
0.84 (s, 36 H); 13C NMR (125 MHz, CDCl3) δ187.4 (8C), 171.9 (4C), 166.3 (4C), 166.1 (4C), 
140.0 (4C), 139.3 (4C), 136.8 (8C), 136.3 (4C), 135.3 (4C), 129.9 (8 C), 128.2 (16C), 127.8 
N
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(16C), 60.7 (EtOAc), 60.6 (4C), 35.6 (4C), 28.2 (12C), 21.2 (EtOAc), 14.3 (EtOAc); HRMS 
(ESI+) m/z calcd for C104H89O16N4Rh2 (M+H) 1855.43782, found 1855.43183. 
 
Perfluorophenyl (S)-1-methyl-2-methylenecyclopropane-1-carboxylate (1.109). An 
oven-dried three neck flask was charged with dirhodium catalyst 1.117 (0.0114 g, 0.00562 
mmol) and CH2Cl2 (2.8 mL) and the resulting green solution was cooled to -78 °C (acetone/ dry 
ice bath) and treated dropwise with an large excess of condensed allene gas (10 drops, ~0.99 g 
removed from lecture bottle, 24.7 mmol). The light grey reaction was then treated with 
perfluorophenyl 2-diazopropanoate 1.99 (0.150 g, 0.562 mmol) in CH2Cl2 (1.7 mL) via syringe 
pump at a rate of 1 mL/h maintaining the temperature at -78 °C. After the addition was complete 
TLC analysis showed starting material. The reaction was allowed to stir for a further hour at -78 
°C after which time TLC showed major starting material. Starting material was also observed 
after warming to -60 °C for 30 min. After warming to -40 °C for 30 min some conversion to a 
new spot was observed. After a further 30 min at -40 °C full conversion was observed by TLC. 
The reaction was removed from the cold bath and allowed to warm to room temperature. The 
solvent was removed under reduced pressure and the residue was purified by chromatography on 
SiO2 (0-2% Et2O/hexanes) to deliver perfluorophenyl 1-methyl-2-methylenecyclopropane-1-
carboxylate 1.109 (0.121 g, 78%) as a clear and colorless oil: 1H NMR (300 MHz, CDCl3) δ 5.64 
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(ap.t J = 2.7 Hz, 1 H), 5.57 (ap. t, J = 2.1 Hz, 1 H), 2.31 (dt, J = 9.1, 2.5 Hz, 1 H), 1.61 (dt, J = 
9.1, 2.5 Hz, 1 H), 1.53 (s, 3 H).  
(S,E)-N,1-Dimethyl-2-methylene-N-(3-oxobut-1-en-1-yl)cyclopropane-1-
carboxamide (2.87). An oven-dried round bottom flask charged with vinylogous amide 2.88 
(0.020 g, 0.20 mmol) was evacuated and backfilled with nitrogen (3x). Freshly distilled THF (1 
mL) was added and the solution was cooled to -78 °C (dry ice/acetone bath) and treated dropwise 
with n-BuLi (0.085 mL, 2.5 M solution in hexanes, 0.21 mmol) and stirred for 5 min at -78 °C. 
The reaction was then treated dropwise with a solution of perfluorophenyl 1-methyl-2-
methylenecyclopropane-1-carboxylate 1.109 (0.059 g, 0.21 mmol) in THF (0.5 mL) and then 
DMAP (0.0025 g, 0.020 mmol) and stirred for 10 min at -78 °C. The cold bath was removed, 
allowing the reaction to warm to room temperature. The reaction was quenched with NaHCO3 
and EtOAc was added. The separated aqueous phase was extracted with EtOAc (3x) and the 
combined organic phases were dried (Na2SO4) and concentrated. The resulting residue was 
purified by chromatography on SiO2 (10-15% EtOAc/hexanes) to deliver ((S,E)-N,1-dimethyl-2-
methylene-N-(3-oxobut-1-en-1-yl)cyclopropane-1-carboxamide 2.87 (0.0266 g, 0.138 mmol, 
68%, er 45:55, 10% ee) as a clear and pale yellow oil: 1H NMR (300 MHz, CDCl3) δ 8.37 (d, J = 
13.8 Hz, 1 H), 5.71 (d, J = 13.8 Hz, 1 H), 5.70 (ap. d, J = 2.7 Hz, 1 H), 5.53 (s, 1 H), 3.16 (s, 3 
H), 2.29 (s, 3 H), 1.80 (dt, J = 9.6, 2.4 Hz, 1 H), 1.50 (s, 3 H), 1.33 (dt, J = 9.7, 2.3 Hz, 1 H). 
SFC conditions: Chiralpak-IC semi-prep column (250 x 10mm), gradient elution: 5-15% (rate 
1.0), 7 mL/min, 254 nm, P=100 (BAR).  
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Figure 3-13 SFC chromatograms of racemic standard and imide 2.87 derived from the cyclopropanation with 
dirhodium catalyst 1.117 
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3.2.2 CHAPTER TWO EXPERIMENTAL PART: (±)-2.1 
 
  
Ethyl 2-bromo-2-methylcyclopropanecarboxylate (S-2.3). An oven dried flask was 
charged with Rh2(OAc)4 (0.0695 g, 0.157 mmol) and 2-bromopropene S-2.1 (30.4 mL, 343 
mmol) under an atmosphere of nitrogen was treated with ethyl diazoacetate S-2.2 (19.0 mL, 87% 
purity, 157 mmol) via syringe pump at a rate of 0.2 mL/ h. After the addition was complete the 
crude product was filtered through a pad of silica, washed with Et2O and concentrated under 
reduced pressure to yield ester S-2.3 (31.7 g, 98%) as a clear and yellow oil and mixture of 
diastereomers which was used directly: 1H NMR (400 MHz, CDCl3) δ 4.21 (dq, J = 7.1, 1.3 Hz, 
2 H), 4.16 (q, J = 7.1 Hz, 2 H), 2.30 (dd, J = 9.6, 6.8 Hz, 1 H), 1.87 (s, 3 H), 1.84 (s, 3 H), 1.80-
1.74-1.57 (m, 3 H), 1.44 (t, J = 6.6 Hz, 1 H), 1.30 (t, J = 7.2 Hz, 3 H), 1.29 (t, J = 7.0 Hz, 3 H), 
1.23  (dd, J = 6.4, 4.4 Hz, 1 H); 13C NMR (125 MHz) δ 170.4, 169.5, 61.3, 61.2, 33.5, 33.1, 30.9, 
29.8, 28.9, 24.5, 24.0, 23.1, 14.5, 14.4. The experimental 1H NMR was consistent with the 
literature-reported data.93 
  
 
Ethyl 2-methylenecyclopropanecarboxylate (2.89). An oven-dried flask was charged 
with NaH (4.21 g, 158 mmol) and anhydrous diethyl ether (110 mL) under an atmosphere of 
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nitrogen and treated dropwise with carboxylic acid S-2.3 (18.5 g, 89.1 mmol). The resulting light 
brown slurry was heated to reflux and treated dropwise with a catalytic amount of freshly 
distilled ethanol (1.15 mL, 19.6 mmol) upon the addition of which the solution immediately 
turned deep red/ brown in color. The resulting mixture was let stir at reflux overnight. The 
reaction was diluted with Et2O, filtered through a pad of Celite and concentrated under reduced 
pressure in an ice bath. The crude product was then distilled under reduced pressure (oil bath 
temperature ca. 130 °C, house vacuum ca. 100-120 mmHg) to yield the desired 
methylenecyclopropane ethyl ester 2.89 (9.98 g, 89% (96% pure), 85% yield) as a brown oil 
which was used directly without further purification: 1H NMR (300 MHz, CDCl3) δ 5.52 (d, J = 
1.8 Hz, 2 H), 4.15 (q, J = 7.0 Hz, 2 H) 2.25 (ap. bs, 1 H), 1.81 (ap. bs, 1 H), 1.63 (ap t, J = 9.2 
Hz, 1 H), 1.26 (t, J = 7.2 Hz, 3 H); 13C NMR (100 MHz) δ 172.1, 130.28, 104.6, 60.7, 18.1, 14.2, 
11.5. The experimental 1H NMR was consistent with the literature-reported data.93 
 
  
Ethyl 1-methyl-2-methylenecyclopropanecarboxylate (S-2.4). LDA was prepared in 
situ by the dropwise addition of n-BuLi (34.4 mL, 2.5 M solution of hexanes, 86.1 mmol) to a 
solution of diisopropylamine (13.3 mL, 93.9 mmol) in THF (136 mL) at -78 °C. The resulting 
solution was stirred at -78 °C for 20 min and 15 min at 0 °C before it was cooled to -78 °C and 
treated dropwise with ester 2.89 (9.87 g, 78.3 mmol). The resulting solution was stirred for 0.5 h 
at -78 °C and treated dropwise with CH3I (14.7 mL, 235 mmol). The solution was allowed to 
warm slowly to 0 °C over 4.5 h, quenched with a saturated solution of NH4Cl, extracted with 
Et2O, washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was 
OEt
O
LiN(i-Pr)2, THF, -78 °C, 0.5 h
then CH3I, -78 °C to rt, 45 h; 73% OEt
O
2.89 S-2.4
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purified by chromatography on SiO2 (97:3 hexanes/ether) to deliver ester (±)-S-2.4 (8.02 g, 73%) 
as a clear and pale yellow oil: IR (ATR) 2982, 2932, 2876, 1719, 1467, 1297, 1146 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 5.45 (ap. t, J =2.8 Hz, 1 H), 5.42 (ap. t, J = 2.0 Hz, 1 H), 4.15-4.08 
(m, 2 H), 2.01 (dt, J = 8.7, 2.4 Hz, 1 H), 1.39 (s, 3 H), 1.31 (dt, J = 8.7, 2.4 Hz, 1 H), 1.23, (t, J = 
7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 173.7, 137.8, 102.7, 60.8, 23.2, 19.0, 18.9, 14.3; 
HRMS (LCMS) m/z calcd for C8H13NO2(M+H) 141.0916, found 141.0552.  
 
 
1-Methyl-2-methylenecyclopropanecarboxylic acid (2.90). A solution of 
methylenecyclopropane ethyl ester S-2.4 (8.03 g, 57.3 mmol) in MeOH/H2O 4:1 (357 mL) was 
treated with lithium hydroxide monohydrate (12.0 g, 286 mmol). The resulting cloudy yellow 
solution was stirred at room temperature for 5 days, acidified by dropwise treatment with 2N 
HCl (pH 1-2), diluted with CH2Cl2 and the resulting aqueous phase was extracted with CH2Cl2. 
The combined organic phases were dried (Na2SO4), filtered and concentrated under reduced 
pressure to yield carboxylic acid 2.90 (5.8 g, 90%) as a clear, orange oil which was used directly: 
IR (ATR) 2986, 2831, 1687, 1310, 1176, 911 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.49 (ap. t, J = 
2.8 Hz, 1 H), 5.45 (ap. t, J = 2.0 Hz, 1 H), 2.10 (dt, J = 9.2, 2.4 Hz, 1 H), 1.40 (dt, J  = 9.2, 2.7 
Hz, 1 H), 1.38 (s, 3 H)13C NMR (125 MHz, CDCl3) δ 180.6, 137.4, 103.2, 77.2, 23.0, 19.8, 
18.3l; HRMS (ESI-) m/z calcd for C6H7O2 (M–H) 111.04406, found 111.04413. 
 
LiOH•H2O,  MeOH/ H2O
(4:1), rt, 5 d, 90% OH
O
2.90
OEt
O
S-2.4
 155 
   
1-Methyl-2-methylenecyclopropanecarbonyl chloride (S-2.5). A solution of carboxylic 
acid 2.90 (1.38 g, 12.3 mmol) in CH2Cl2 (24 mL) was cooled to 0 °C and treated with oxalyl 
chloride (1.13 mL, 12.9 mmol) and then DMF (0.0489 mL, 0.0481 mmol) upon the addition of 
which gas evolution was observed. The resulting solution was allowed to stir warming to room 
temperature. 1H NMR analysis of an aliquot (CDCl3) indicated the presence of the desired acid 
chloride. The resulting solution was concentrated to yield crude acid chloride S-25 (1.61 g, 
quantitative), which was used directly. Characteristic 1H NMR signals of acid chloride in crude 
spectrum (300 MHz, CDCl3) δ 5.64 (ap t, J = 2.7 Hz, 1 H), 5.59 (ap. t, J = 2.3 Hz, 1 H), 2.37 (dt, 
J = 9.6, 2.4 Hz, 1 H), 1.62 (dt, J = 9.6, 2.6 Hz, 1 H), 1.49 (s, 3 H) 
N,1-Dimethyl-2-methylene-N-(3-oxobut-1-en-1-yl)cyclopropanecarboxamide (±)-
(2.87). A flame-dried flask containing vinylogous amide 2.88 (1.02 g, 10.3 mmol) was evacuated 
and backfilled with an atmosphere of nitrogen. Anhydrous THF (34 mL) was added and the 
resulting solution was cooled to -78 °C and treated sequentially with n-BuLi (4.3 mL, 2.5 M 
solution in hexanes, 10.9 mmol), acyl chloride S-25 (1.62 g, 12.4 mmol) and DMAP (0.126 g, 
1.03 mmol). The cold bath was removed and the reaction let stir warming to room temperature. 
The reaction was concentrated and purified by chromatography on SiO2 (gradient elution 10% to 
20% EtOAc/hexanes) to obtain amide (±)-2.87 (1.58 g, 79%) as a clear and yellow oil: IR (ATR) 
2975, 1676, 1614, 1577, 1247, 1074, 967 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 14.0, 
1 H), 5.69 (d, J = 13.6 Hz, 1 H), 5.69 (ap. d, J = 2.8 Hz, 1 H), 5.51 (ap t, J = 2.0 Hz, 1 H), 3.13 
(s, 3 H), 2.27 (s, 3 H), 1.78 (dt, J = 9.6, 2.4 Hz, 1 H), 1.48 (s, 3 H), 1.31 (dt, J = 9.6, 2.4 Hz, 1 
2.88 O
n-BuLi, DMAP, THF 
-78 °C to rt; 79%
MeHN
N
O
O
(±)-2.87
(COCl)2, DMF
CH2Cl2, 1.5 h
quant.OH
O
2.90
Cl
O
S-2.5
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H); 13C NMR (100 MHz, CDCl3) δ 196.9, 172.3, 142.9, 134.8, 108.4, 104.9, 30.8, 28.9, 24.9, 
21.8, 15.9; HRMS (LCMS) m/z calcd for C11H16NO2 (M+H) 194.1176, found 194.1174 
 
 
N-(3-((tert-Butyldimethylsilyl)oxy)buta-1,3-dien-1-yl)-N,1-dimethyl-2-
methylenecyclopropanecarboxamide (±)-(2.91). A flame dried flask was charged with 
NaHMDS (0.782 g, 4.05 mmol) followed by anhydrous THF (40 mL) under an atmosphere of 
nitrogen. The resulting clear and colorless solution was stirred for 15 min at room temperature, 
cooled to -78 °C and treated with vinylogous imide (±)-2.87 (0.712 g, 3.69 mmol) in THF (7.4 
mL) slowly via syringe pump at a rate of 2 mL/h. During the slow addition of the amide the 
solution changed color from clear pale yellow, to clear and deep orange. The resulting clear, 
orange solution was stirred for 1 h warming to -50 °C, cooled to -78 °C and treated dropwise 
with a solution of TBSCl (0.673 g, 4.42 mmol) in THF (15 mL) over a period of 5 minutes. The 
solution was allowed to stir for 5 min at -78 °C before the cold bath was removed and the 
solution allowed to reach room temperature. The reaction was concentrated to yield crude TBS 
enol ether (±)-2.91 (1.13 g, quantitative conversion), as an orange oil, which was used directly.  
Diels Alder adducts (±)-2.92 and (±)-epi-2.92.  A solution of crude enol ether (±)-2.91  
(assumed 1.13 g, 3.69 mmol) in THF (11 mL) was heated under microwave irradiation at 100 °C 
for 25 min, concentrated under reduced pressure to obtain the Diels-Alder adducts (±)-2.92 and 
(±)-epi-2.92 which were used directly in the next reaction without purification.   
 
N
O
O
(±)-2.87
NaHMDS, THF, -78
to -50 °C then TBSCl
-78 °C to rt N
O
OTBS
(±)-2.91
THF, 100 °C
µw, 25 min
N
OTBS
H
O
N
OTBS
H
O
+
(±)-2.92 (±)-epi-2.92
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trans-1a,3-Dimethylhexahydro-2H-cyclopropa[c]indole-2,5(3H)-dione (±)-(2.86) and 
cis-1a,3-dimethylhexahydro-2H-cyclopropa[c]indole-2,5(3H)-dione (±)-epi-2.86. The Diels-
Alder adducts (±)-2.92 and (±)-epi-2.92 (assumed 1.13 g, 3.69 mmol) were immediately taken up 
in THF (37 mL) and treated with TBAF (3.87 mL, 1 M solution in THF, 3.87 mmol). The 
resulting solution was stirred for 30 min at room temperature. The resulting residue was purified 
by chromatography on SiO2 (gradient elution: 40% to 80% EtOAc/Hex) to deliver ketone (±)-
2.86 (0.373 g, 52% over two steps from (±)-2.87) as a yellow solid and ketone (±)-epi-2.86 
(0.0930 g, 13% over two steps from (±)-2.87) in an isolated dr of 4:1, (±)-2.86: (±)-epi-2.86. 
 trans-1a,3-Dimethyl-3a,4-dihydro-1H-cyclopropa[c]indole-2,5(1aH,3H)-dione (±)-
(2.86) . Ketone (±)-2.86 was obtained as an oil which solidified at -20 °C to provide crystals of 
sufficient quality for X-ray analysis.   
IR (ATR) 2951, 2933, 1705, 1676, 1359, 1230, 925 cm-1; 1H NMR (400 MHz, CDCl3) δ 
3.41 (dd, J = 13.0, 3.8 Hz, 1 H), 2.80 (ddd, J = 13.3, 4.1, 1.5 Hz, 1 H), 2.69 (ddt, J = 15.5, 5.0, 
1.5 Hz, 1 H), 2.67 (s, 3 H), 2.54 (ddd, J = 15.4, 12.2, 7.2 Hz, 1 H), 2.35 (ap. t, J = 13.2 Hz, 1 H), 
2.17-2.09 (m, 1 H), 1.72 (ddd, J = 13.1, 7.3, 1.9 Hz, 1 H),1.38 (s, 3 H), 0.95 (d, J = 4.0 Hz, 1 H), 
0.66 (d, J = 4.0 Hz, 1 H); 13C NMR (100 MHz, CDCl3) 207.5, 178.9, 60.2, 45.1, 41.5, 31.9, 30.7, 
27.2, 25.9, 22.8, 11.0; HRMS (LCMS) m/z calcd for C11H16NO2 (M+H) 194.1176, found 
194.1174. 
cis-1a,3-Dimethyltetrahydro-1H-cyclopropa[c]indole-2,5(1aH,3H)-dione (±)-epi-
2.86). 1H NMR (500 MHz, CDCl3) δ 3.73 (ap. t, J = 6.5 Hz, 1 H), 2.84 (ddd, J = 15.3, 6.8, 0.7 
N
OTBS
H
O
N
OTBS
H
O
+
(±)-2.92 (±)-epi-2.92 (±)-2.86 (±)-epi-2.86
N
O
H
O
TBAF, THF, rt, 30 min
d.r. 4:1 (C5)
52%
+
N
O
H
O
13%
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Hz, 1 H), 2.72 (s, 3 H), 2.50 (dt, J = 16.6, 5.3 Hz, 1 H), 2.43-2.36 (m, 2 H), 2.30 (ddd, J = 14.8, 
10.0, 5.0 Hz, 1 H), 1.83 (dt, J = 14.5, 5.8 Hz, 1 H), 1.34 (s, 3 H), 0.93 (d, J = 4.5 Hz, 1 H), 0.84 
(d, J = 4.6 Hz, 1 H). The experimental 1H NMR was consistent with the literature-reported 
data.134 
 
  
1a,3-Dimethyl-3a,4-dihydro-1H-cyclopropa[c]indole-2,5(1aH,3H)-dione (±)-(2.85). A 
microwave flask equipped with a stir bar was charged with Pd(TFA)2 (0.0129 g, 0.0384 mmol). 
The flask and the balloon were purged and filled with O2, followed by the addition of DMSO 
(5.45 µL, 0.0767 mmol) and AcOH (3.8 mL). The resulting brown solution was stirred at 55 °C 
under an atmosphere of oxygen (balloon) for 20 h prior to the addition of ketone (±)-2.86 (0.148 
g, 0.767 mmol). The resulting black solution was stirred for a further 7 days during which time 
two more portions of Pd(TFA)2 catalyst were added (2 x 0.1 equiv). The reaction was 
concentrated and purified by chromatography on SiO2 (50% EtOAc/Hex) to obtain enone (±)-
2.85 (0.098 g, 67%) as a white solid: IR (ATR) 2956, 2918, 2850, 1663, 1588, 1390, 1228, 1117 
cm-1; 1H NMR (500 MHz) δ 6.97 (d, J = 9.5 Hz, 1 H), 6.13 (d, J = 10.0 Hz, 1 H), 3.80 (dd, J = 
14.0, 3.5 Hz, 1 H), 2.89 (dd, J = 15.5, 3.5 Hz, 1 H), 2.70 (s, 3 H), 2.43 (dd, J = 15.5, 14.0 Hz, 1 
H), 1.45 (s, 3 H), 1.33 (dd, J = 4.0 Hz, 1 H), 0.85 (dd, J = 4.0 Hz, 1 H); 13C NMR (100 MHz) δ 
197.0, 177.8, 148.4, 131.4, 58.6, 41.9, 32.9, 32.1, 27.3, 23.5, 10.9; HRMS (LCMS) m/z calcd for 
C11H14NO2 (M+H) 192.1019, found 192.1019. 
(±)-2.86
N
O
H
O
(±)-2.85
Pd(TFA)2 (5 mol%), DMSO
O2 (1 atm), AcOH, 55 °C, 20 h
then ketone (±)-2.86, Pd(TFA)2 
(10 mol% x 2)
55 °C, 7 d;  67%
N
O
H
O
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Alcohol (±)-2.83. A flame-dried flask was charged with furanylamino stannane 2.34 
(0.277 g, 0.570 mmol) and evacuated for 15 min under high vacuum prior to the introduction of a 
nitrogen atmosphere. THF (1.2 mL) was added and the solution cooled to -78 °C and treated 
dropwise with n-BuLi (0.228 mL, 2.5 M solution in hexanes, 0.570 mmol). The resulting clear 
and colorless solution was stirred at -78 °C for 10 min, cooled to -95 °C (acetone/liquid nitrogen) 
and treated with a solution of ketone (±)-2.85 (0.0738 g, 0.386 mmol) in THF (1.5 mL) over a 
period of 15 min. The resulting clear and yellow solution was stirred for a further 5 min at -95 
°C, diluted with EtOAc (2 mL) and quenched with saturated NH4Cl (2 mL). The separated 
aqueous phase was extracted with EtOAc (3x) and the combined organic phases dried (Na2SO4) 
and concentrated. The crude residue was filtered through SiO2 and washed with 15% EtOAc/Hex 
to elute tin byproducts then EtOAc to elute product. The EtOAc fraction was concentrated to 
yield crude alcohol (±)-2.83 as a yellow oil, which was used directly without purification. 
The tertiary alcohol (±)-2.83 can be purified by chromatography on SiO2 (gradient 
elution 15% EtOAc/Hex to remove tin by-product and then 30% to 50% EtOAc/Hex) to deliver 
the desired tertiary alcohol (±)-2.83 for full characterisation: IR (ATR) 3390, 2969, 2932, 2869, 
1681, 1694, 1612, 1392, 1374, 1292, 1154, 733 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.19 (s, 1 
H), 6.35 (d, J = 2.0 Hz, 1 H), 6.01 (s, 1 H), 5.83 (d, J = 9.6 Hz, 1 H), 5.66 (d, J = 9.6 Hz, 1 H), 
3.86 (d, J = 14.8 Hz, 1 H), 3.72 (d, J = 14.4 Hz, 1 H), 3.66 (dd, J = 12.8, 2.4 Hz, 1 H), 2.70 (s, 3 
H), 2.19 (d, J = 12.0 Hz, 1 H), 1.59 (ap. t, J = 12.6 Hz, 1 H), 1.44 (s, 9 H), 1.35 (s, 3 H), 0.88 (d, 
O
NBu3Sn
2.34
(±)-2.85
then enone, -95 °C, 20 min
N
O
H
O
N H
O
OH
N Ot-Bu
O
O(±)-2.83
O
Ot-Bu
n-BuLi (1.5 eq), THF, -78 °C, 10 min
(1.5 eq)
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J = 3.6 Hz, 1 H), 0.58 (d, J = 3.6 Hz, 1 H); 13C NMR (125 MHz, CDCl3) δ 179.5, 149.1, 138.4, 
131.1, 129.4, 111.3, 102.0, 82.6, 73.9, 59.5, 57.2, 37.3, 36.8, 32.3, 31.9, 28.2, 27.3, 23.5, 10.8; 
HRMS (LCMS ESI)+ m/z calcd for C21H29N2O5 (M+H) 389.2071, found 389.2071. 
 
       
Indole (±)-2.110. A solution of crude alcohol (±)-2.83 (0.148 g, 0.381 mmol) in 
trifluorotoluene (3.5 mL) was treated with 4,4'-thiobis(6-tert-butyl-o-cresol) (0.0136 g, 0.0381 
mmol) and heated at 185 °C under microwave irradiation for 1 h, The reaction mixture was 
concentrated under reduced pressure and the resulting crude product purified by chromatography 
on SiO2 (60% EtOAc/Hex) to deliver the desired indole (±)-2.110 (0.036 g, 37% over two steps): 
IR (ATR) 3292, 2937, 2850, 1681, 1446, 1372, 1238, 1074, 738 cm-1; 1H NMR (400 MHz) δ 
8.06 (bs, 1 H), 7.22 (d, J = 8.4 Hz, 1 H), 7.12 (ap. t, J = 7.6 Hz, 1 H), 7.0 (t, J = 1.6 Hz, 1 H), 
6.81 (d, J = 7.2 Hz, 1 H), 3.83 (dd, J = 12.0, 4.0 Hz, 1 H), 3.29 (dd, J = 14.0, 4.0 Hz, 1 H), 2.84 
(s, 3 H), 2.71 (ddd, J = 13.6, 12.0, 1.6 Hz, 1 H), 1.85 (s, 3 H), 1.17 (d, J = 3.2 Hz, 1 H), 0.90 (d, J 
= 3.6 Hz, 1 H); 13C NMR (100 MHz) δ 179.0, 133.8, 133.2, 128.3, 123.3, 119.2, 111.3, 110.5, 
109.2, 61.7, 32.8, 32.4, 29.1, 27.6, 25.5, 12.5;  HRMS (LCMS) m/z calcd for C16H17N2O (M+H) 
253.1335, found 253.1335 
  
N H
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N Ot-Bu
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HO
S
OH
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H
N H
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PhCF3, 185 °C, 1h; 37% (2 steps)
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(±)-Cycloclavine (±)-(2.1). A solution of indole (±)-2.110 (0.0088 g, 0.035 mmol) in 
THF (0.2 mL) was treated with LiAlH4 (0.28 mL, 1 M solution in diethyl ether, 0.28 mmol) and 
heated at reflux in a sealed tube overnight. The solution was cooled to room temperature and 
treated sequentially with water (0.1 mL), 15% aqueous NaOH (0.1 mL), and water (0.3 mL). the 
mixture was filtered through Celite, and concentrated in vacuo. The crude product was purified 
by chromatography on SiO2 (0-2% MeOH/CH2Cl2) to deliver cycloclavine (0.0078 g, 94%) as a 
yellow film: IR (ATR) cm-1; 3057, 3027, 2934, 2816, 1629, 1450, 1193, 1163, 982, 727 cm-1; 1H 
NMR (300 MHz) δ 7.93 (bs, 1 H), 7.14 (d, J  = 7.5 Hz, 1 H), 7.09 (ap. t, J = 7.5 Hz, 1 H), 6.90 
(s, 1 H), 6.83 (d, J = 6.9 Hz, 1 H), 3.19-3.12 (m, 2 H), 2.81 (dd, J = 11.7, 3.3 Hz, 1 H), 2.63 (ap. 
t, J = 12.5 Hz, 1 H), 2.42 (d, J = 8.7 Hz, 1 H), 2.38 (s, 3 H), 1.70 (s, 3 H), 1.63 (d, J = 3.0 Hz, 1 
H), 0.46 (d, J = 3.6 Hz, 1 H); 13C NMR (125 MHz) δ 135.6, 133.7, 128.9, 123.1, 118.2, 113.4, 
110.5, 108.1, 69.8, 65.7, 40.1, 34.6, 27.9, 25.1, 24.4, 16.6; HRMS (LCMS) m/z calcd for 
C16H19N2 (M+H) 239.1543, found 239.1541. 
 
  
1,6-Dihydro-[1,1'-biphenyl]-3(2H)-one (2.95) and 5,6-dihydro-[1,1'-biphenyl]-3(4H)-
one (2.96). 3-phenyl cyclohexanone 2.94 was prepared according to a literature protocol.135 A 
microwave flask was charged with Pd(TFA)2 (0.0039 g, 0.012 mmol) and 3-phenyl 
LiAlH4, THF, reflux, 12 h; 94%
(±)-2.1(±)-2.110
N
H
N H
O
N
H
N H
2.94
O O O
+
2.95 2.96
Pd(TFA)2 (0.05 equiv), O2 (1 atm)
AcOH (0.2 M), DMSO (0.1 equiv)
80 °C, 12  h
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cyclohexanone 2.94 (0.040 g, 0.23 mmol). The flask was purged with O2 and a balloon of 
oxygen attached. DMSO (1.6 µL, 0.023 mmol) and acetic acid (1.15 mL) were added. The 
resulting black solution was stirred at 80 °C under an atmosphere of O2 for 12 h. 1H NMR 
analysis of an aliquot (CDCl3) showed a diastereomeric ratio of 1.7: 1 2.95: 2.96.  
The reaction was concentrated and purified by chromatography on SiO2 (gradient elution 
0-20% EtOAc/Hex) to obtain cyclohexenones 2.95 and 2.96 as yellow oils for a characterisation 
standard: 1,6-Dihydro-[1,1'-biphenyl]-3(2H)-one (2.95). 1H NMR (400 MHz) δ 7.34 (ap. d, J = 
7.2 Hz, 2 H), 7.28-7.25 (m, 3 H), 7.05 (ddd, J = 10.1, 5.8, 2.5 Hz), 6.13 (dd, J = 10.0, 2.9 Hz 1 
H) 3.36-3.34 (m, 1 H), 2.71-2.2.51 (m, 4 H). The experimental 1H NMR was consistent with the 
literature-reported data.98 
5,6-Dihydro-[1,1'-biphenyl]-3(4H)-one (2.96). 1H NMR (400 MHz) δ 7.50 (dd, J = 7.0, 
3.1 Hz, 2 H), 7.41 (ap. t, J = 3.3 Hz, 3 H), 6.43 (ap. t, J = 1.4 Hz, 1 H), 2.80-2.77 (m, 2 H), 2.49 
(t, J = 6.7 Hz, 2 H), 2.16 (dt, J = 12.9, 6.4 Hz, 2 H). The experimental 1H NMR was consistent 
with the literature-reported data.98 
 
     
1,6-Dihydro-[1,1'-biphenyl]-3(2H)-one (2.95) and 5,6-dihydro-[1,1'-biphenyl]-3(4H)-
one (2.96). A flame dried microwave flask equipped with a stir bar and cooled under an 
atmosphere of nitrogen was charged with Pd(TFA)2 (0.00393 g, 0.0115 mmol). The flask was 
purged with O2 and a balloon of O2 attached, followed by the addition of DMSO (1.63 µL, 
0.0230 mmol) and AcOH (1.15 mL, 0.2 M w.r.t. ketone). The resulting black solution was stirred 
2.94
O O O
+
2.95 2.96
1. Pd(TFA)2 (0.05 eq), O2 (1 atm), AcOH (0.2 M)
    DMSO (0.1 eq) 55 °C, 20 h
2. ketone 2.94, 55 °C, 2 d
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at 55 °C under an atmosphere of oxygen for 20 h. After 20 h ketone 2.94 (0.0400 g, 0.230 mmol) 
was added and the resulting black solution stirred at 55 °C for 2 days. 1H NMR analysis of an 
aliquot (CDCl3) showed a regioisomeric ratio of 2.17: 1.  
 
 
 1a,3-Dimethyl-1,1a,6,7-tetrahydro-2H-cyclopropa[c]indole-2,5(3H)-dione (2.93). A 
microwave flask was charged with Pd(TFA)2 (0.0092 g, 0.027 mmol). The flask was purged and 
filled with O2, followed by the addition of DMSO (1.9 µL) and AcOH (1.3 mL). The resulting 
brown solution was stirred at 55 °C under an atmosphere of oxygen (balloon) for 20 h then 
treated with ketone (±)-epi-2.86 (0.052, 0.27 mmol). After 3 days 1H NMR analysis of an aliquot 
(CDCl3) indicated exclusive formation of the undesired regioisomer. The reaction was 
concentrated and purified by chromatography on SiO2 (50% EtOAc/Hex) to deliver vinylogous 
amide 2.93 (0.029 g, 56%) as a white solid: IR (ATR) 2956, 1732, 1607, 1458, 1241, 1074 cm-1; 
1H NMR (300 MHz, CDCl3) δ 5.49 (s, 1 H), 2.93 (s, 3 H), 2.68-2.65 (m, 1 H), 2.63 (d, J = 5.0 
Hz, 1 H), 2.35 (td, J = 12.4, 6.8 Hz, 1 H), 1.73 (ddd, J = 13.0, 4.7, 2.8 Hz, 1 H), 1.41 (s, 3 H), 
1.33 (d, J = 4.2 Hz, 1 H), 1.17 (d, J = 4.2 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 197.2, 177.1, 
164.4, 101.4, 36.9, 30.1, 29.9, 29.2, 26.2, 24.5, 10.4; HRMS (LCMS ESI)+ m/z calcd for 
C11H14O2N (M+H) 192.1019, found 192.1020. The experimental 1H NMR was consistent with 
the literature-reported data.134  
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3.2.3 CHAPTER TWO EXPERIMENTAL PART: (–)-2.1 
 
Perfluorophenyl (R)-1-methyl-2-methylenecyclopropane-1-carboxylate (1.109). An oven-
dried three-neck flask fitted with a nitrogen inlet, a dry-ice condenser, and septum was charged 
with Rh2(S-TBPTTL)4 (1.75)55 (0.236 g, 0.0939 mmol) and CH2Cl2 (51 mL) and the resulting 
green solution was cooled to -78°C and treated dropwise with an excess of condensed allene gas 
(1.96, 2.23 g, 55.6 mmol). A solution of perfluorophenyl 2-diazopropanoate (1.99) (2.50 g, 9.39 
mmol) in anhydrous CH2Cl2 (9.0 mL) was then added slowly via syringe pump at a rate of ca.1 
mL/h, allowing the solution to run down the side of the flask into the reaction mixture. After the 
addition was complete, the mixture was allowed to stir at -78 °C for 1 h before warming to room 
temperature. The solution was concentrated and the resulting green residue was purified by 
chromatography on SiO2 (0-1% Et2O/hexanes) to deliver methylenecyclopropane 1.109 (2.24 g, 
86%) as a clear and pale yellow oil: [α]D20 -2.6 (c 1, CHCl3); IR (ATR) 2985, 2939, 1770, 1655, 
1517, 1459, 1283, 1070, 1028, 993 cm-1; 1H NMR (400 MHz, CD2Cl2) δ 5.64 (t, J = 2.8 Hz, 1 
H), 5.56 (t, J = 2.2 Hz, 1 H), 2.30 (dt, J = 9.2, 2.5 Hz, 1 H), 1.63 (dt, J = 9.2, 2.4 Hz, 1 H), 1.51 
(s, 3 H); 13C NMR (100 MHz, CD2Cl2) δ 170.4, 143.2-143.0 (m), 141.3-141.0 (m), 140.7-140.5 
(m), 139.9-139.5 (m), 137.4-137.0 (m), 136.8, 126.2-123.8 (m), 104.5, 23.2, 20.6, 18.8; DEPT-
135 (100 MHz, CD2Cl2) δ 104.5 (CH2), 20.6 (CH2), 18.8 (CH3); 19F NMR (471 MHz, CD2Cl2) δ 
-153.9 (m, 2 F), -59.4 (t, JF = 21.2 Hz, 1 F), -163.5 to -163.6 (m, 2 F); HRMS (APCI+) m/z calcd 
for C12H8O2F5 (M+H) 279.04390, found 279.04312.  
O
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(R,E)-N,1-Dimethyl-2-methylene-N-(3-oxobut-1-en-1-yl)cyclopropane-1-carboxamide 
(2.87). An oven-dried flask charged with vinylogous amide 2.8841 (0.700 g, 7.06 mmol) was 
evacuated and backfilled with nitrogen (3x). Freshly distilled THF (24 mL) was added and the 
resulting solution was cooled to -78 °C and treated dropwise with n-BuLi (3.24 mL, 2.29 M 
solution in hexanes, 7.42 mmol). The resulting clear, pale yellow solution was stirred for 5 min 
at -78 °C, then treated with a solution of ester 1.109 (2.06 g, 7.41 mmol) in THF (4 mL). The 
resulting bright yellow solution was treated with DMAP (0.0862 g, 0.706 mmol) and stirred for 
10 min at -78 °C. The cold bath was removed and the reaction mixture was allowed to stir, 
warming to room temperature. The reaction was quenched with sat. NaHCO3. After addition of 
EtOAc, the aqueous layer was extracted with EtOAc (3x) and the combined organic layers were 
dried (Na2SO4) and concentrated. The crude product was purified by chromatography on SiO2 
(10-15% EtOAc/hexanes) to deliver the vinylogous imide 2.87 (1.03 g, 75%) as a clear, pale 
yellow oil: [α]D20 +214.4 (c 1, CHCl3); IR (ATR) 2968, 2932, 1680, 1615, 1578, 1516, 1355, 
1262, 1247, 1072, 968 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.36 (d, J = 13.6 Hz, 1 H), 5.73-5.69 
(m, 2 H), 5.53 (ap. s, 1 H), 3.15 (s, 3 H), 2.29 (s, 3 H), 1.79 (dt, J = 9.6, 2.2 Hz, 1 H), 1.49 (s, 3 
H), 1.32 (dt, J = 9.6, 2.2 Hz, 1 H); 13C NMR (125 MHz, CDCl3) δ 196.9, 172.4, 142.9, 134.9, 
108.4, 104.9, 30.9, 28.9, 24.9, 21.8, 15.9; HRMS (ESI)+ m/z calcd for C11H16O2N (M+H) 
194.1176, found 194.1174.  
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The er of the imide product 2.87 was determined using chiral SFC. The following conditions 
were developed for resolution of the amide using a) a Chiralpak-IC analytical column and b) a 
Chiralpak-IC semi preparative column:  
a) Chiralpak-IC analytical column (250 x 4.6 mm), gradient elution: 1% iPrOH (hold for 5 
min), 2% iPrOH (hold for 5 min), 3% iPrOH (hold for 6 min), 4% iPrOH (hold for 3 min), 
4.50% iPrOH (hold for 2 min), 5% iPrOH (hold for 3 min), 4 mL/min, 254 nm, P=110 
(BAR)] 
b) Chiralpak-IC semi prep column (250 x 10 mm), gradient elution: 5-15% (rate 1.0), 7 
mL/min, 254 nm, P=100 (BAR).	 
  
  
Figure 3-14 Representative SFC chromatogram showing racemic standard and enantiomerically enriched imide 2.87 
using conditions b) 
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(1aR,3aS,7aS)-5-((tert-Butyldimethylsilyl)oxy)-1a,3-dimethyl-1,1a,3,3a,6,7-
hexahydro-2H-cyclopropa[c]indol-2-one (2.92) and (1aR,3aR,7aS)-5-((tert-
butyldimethylsilyl)oxy)-1a,3-dimethyl-1,1a,3,3a,6,7-hexahydro-2H-cyclopropa[c]indol-2-
one (epi-2.92). An oven-dried flask was charged with NaHMDS (0.611 g, 3.17 mmol) followed 
by anhydrous THF (31.5 mL) under an atmosphere of nitrogen. The resulting clear, colorless 
solution was stirred for 15 min at room temperature, cooled to -78 °C and stirred for a further 15 
min prior to treatment with a solution of vinylogous amide 2.87 (0.556 g, 2.88 mmol) in THF 
(6.0 mL) that was added slowly via syringe pump at a rate of ca. 2 mL/h. During the slow 
addition of the amide, the solution changes color from clear pale yellow, to clear and gold to 
clear and deep orange. The resulting clear, orange solution was allowed to stir for 1 h while 
warming to -50 °C, cooled to -78 °C and treated dropwise with a solution of TBSCl (0.526 g, 
3.45 mmol) in THF (11.5 mL) over a period of 5 min. The solution was allowed to stir for 5 min 
at -78 °C before the cold bath was removed and the solution allowed to reach room temperature. 
1H NMR analysis of an aliquot (CDCl3) indicated formation of the desired TBS enol ether. The 
reaction mixture was concentrated under reduced pressure to obtain crude enol ether as an orange 
gel, which was immediately taken up in THF (8.4 mL) and heated under microwave irradiation 
in a sealed vial at 95 °C for 30 min (3 x 2.8 mL batches). The combined batches were 
concentrated to deliver a mixture of crude enol ethers 2.92 and epi-2.92 (assumed full conversion 
0.885 g, 2.88 mmol).  
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(1aR,3aS,7aS)-1a,3-Dimethylhexahydro-2H-cyclopropa[c]indole-2,5(3H)-dione 
(2.86) and (1aR,3aR,7aS)-1a,3-dimethylhexahydro-2H-cyclopropa[c]indole-2,5(3H)-dione 
(epi-2.86). The crude enol ethers 2.92 and epi-2.92 (0.885 g, 2.88 mmol) were taken up in THF 
(29 mL), treated dropwise with TBAF (2.88 mL, 1 M solution in THF, 2.88 mmol) and allowed 
to stir at room temperature for 30 min. The reaction mixture was filtered through a pad of Celite 
and concentrated. The resulting residue was purified by chromatography on SiO2 (20% 
EtOAc/hexanes to elute recovered vinylogous amide 2.87, then 50-70% EtOAc/hexanes to elute 
ketone 2.86 and then 90-100% EtOAc/hexanes to elute epi-2.86) to deliver recovered vinylogous 
amide 2.87 (0.0153 g) as a yellow oil along with trans-ketone 2.86 (0.339 g, 61% over two steps 
from amide 2.87, (63% brsm)) as a yellow crystalline solid and cis-ketone epi-2.86 (0.0711 g, 
13% over two steps from amide 2.87 (13% brsm)) as a yellow oil.  
trans-Ketone 2.86: [α]D20 +83.9 (c 1, CHCl3); Mp 95.5-98.4 °C; IR (ATR) 2955, 1706, 
1676, 1414, 1395, 1359, 1292, 1230, 1123, 1072, 1042, 865 cm-1; 1H NMR (300 MHz, CDCl3) δ 
3.40 (dd, J = 13.1, 4.1 Hz, 1 H), 2.80 (ddd, J = 13.5, 4.1, 1.4 Hz, 1 H), 2.72-2.66 (m, 4 H), 2.53 
(ddd, J = 15.2, 12.1, 7.3 Hz, 1 H), 2.35 (ap. t, J = 13.4 Hz, 1 H), 2.18-2.08 (m, 1 H), 1.72 (ddd, J 
= 13.2, 7.2, 1.8 Hz, 1 H), 1.38 (s, 3 H), 0.95 (d, J = 3.6 Hz, 1 H), 0.66 (d, J = 3.9 Hz, 1 H); 13C 
NMR (100 MHz, CDCl3) δ 207.6, 178.9, 60.1, 45.1, 41.5, 31.8, 30.7, 27.2, 25.8, 22.7, 11.0; 
HRMS (LCMS-ESI) m/z calcd for C11H16O2N (M+H) 194.1176, found 194.1175.   
cis-Ketone epi-2.86: [α]D18 -9.1 (c 1, CHCl3); 1H NMR (300 MHz; CDCl3) δ 3.73 (ap. t, 
J = 6.6 Hz, 1 H), 2.83 (dd, J =15.0, 6.3 Hz, 1 H), 2.72 (s, 3 H), 2.55-2.25 (m, 4 H), 1.82 (dt, J = 
N
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13.8, 5.1 Hz, 1 H), 1.34 (s, 3 H), 0.92 (d, J = 4.5 Hz, 1 H), 0.84 (d, J = 4.5 Hz, 1 H). The 
experimental 1H NMR was consistent with the literature-reported data.134 
 
 
(1aR,3aS,7aR)-1a,3-Dimethyl-1,1a,3a,4-tetrahydro-2H-cyclopropa[c]indole-2,5(3H)-
dione (2.85).  A solution of Pd(TFA)2 (0.00940 g, 0.0274 mmol) and DMSO (3.90 µL, 0.0549 
mmol) in AcOH (2.74 mL) was heated at 55 °C under an atmosphere of O2 (balloon) to pre-
activate the catalyst system. After 19.5 h, ketone 2.86 (0.106 g, 0.549 mmol) was added and the 
reaction was allowed to stir at 55 °C under an atmosphere of O2 (balloon). Additional Pd(TFA)2  
was added at 48 h (4.7 mg) and 72 h (4.7 mg) after the addition of the ketone in order to drive the 
reaction to completion. After 5 d, 1H NMR of an aliquot (CDCl3) showed that the conversion 
was complete and the reaction mixture was concentrated and purified by chromatography on 
SiO2 (3-5% acetone/CH2Cl2) to deliver enone 2.85 (0.0796 g, 76%) as a cream crystalline solid.  
Protocol for the enantiomeric enrichment by recrystallization: Enone 2.85 (0.0610 g, 
0.320 mmol) was dissolved in a 15:1 mixture of 1,2-dichloroethane: boiling MTBE (c 0.08 M) 
and allowed to cool to room temperature prior to the addition of a seed crystal. The resulting 
solution was allowed to stand overnight at -20 °C during which time white needle-shaped 
crystals formed. The mother liquor was removed via pipette transfer and the crystals were 
washed with MTBE (2x) and placed under vacuum to remove trace solvents. The first 
recrystallization provided crystals of 100:0 er, the second recrystallization crystals were 99.5:0.5 
er and the third recrystallization provided crystals of 96:4 er. Three rounds of recrystallization 
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H
O
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delivered enone 2.85 (29.7 mg, 56% of theoretical maximum yield) as white, needle-shaped 
crystals. Only samples with er >98:2 were carried on in the subsequent reaction. The er of the 
combined material was >99.5:0.5 er by SFC analysis: [α]D18 -103.4 (c 1, CHCl3); Mp 131.7-
134.1 °C; IR (ATR) 2966, 2929, 1683, 1664, 1618, 1585, 1452s, 1389, 1235, 1071, 688, 796 cm-
1; 1H NMR (500 MHz, CDCl3) δ 6.97 (d, J = 9.5 Hz, 1 H), 6.14 (d, J = 9.5 Hz, 1 H), 3.81 (dd, J 
= 13.8, 3.8 Hz, 1 H), 2.90 (dd, J = 15.5, 4.0 Hz, 1 H), 2.71 (s, 3 H), 2.44 (dd, J = 15.8, 14.3 Hz, 1 
H), 1.46 (s, 3 H), 1.33 (d, J = 4.0 Hz, 1 H), 0.86 (d, J = 4.0 Hz, 1 H); 13C NMR (125 MHz, 
CDCl3) δ 197.0, 177.8, 148.4, 131.4, 58.6, 41.9, 32.9, 32.1, 27.3, 23.5, 10.9; HRMS (ESI)+ m/z 
calcd for C11H14O2N (M+H) 192.1019, found 192.1017. SFC conditions to separate enone 2.85 
[Chiralpak-IC semi preparative column (250 x 10 mm), gradient elution: 1-30% iPrOH (rate 1.0), 
5.5 mL/min, 254 nm, P=100 (BAR)]  
   
   
Figure 3-15 SFC chromatograms of the racemic standard and enantioenriched enone 2.85 after recrystallization  
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2,2,6,6-Tetramethylpiperidin-1-yl furan-2-yl(((1aR,3aS,5R,7aR)-5-hydroxy-1a,3-
dimethyl-2-oxo-1a,2,3,3a,4,5-hexahydro-1H-cyclopropa[c]indol-5-yl)methyl)carbamate 
(2.111) and 2,2,6,6-tetramethylpiperidin-1-yl furan-2-yl(((1aR,3aS,5S,7aR)-5-hydroxy-1a,3-
dimethyl-2-oxo-1a,2,3,3a,4,5-hexahydro-1H-cyclopropa[c]indol-5-yl)methyl)carbamate 
(epi-2.111). An oven-dried 2-neck flask equipped with a septum fitted with a nitrogen inlet and a 
stopper was charged with stannane 2.149 (0.107 g, 0.188 mmol) and evacuated under high 
vacuum, then backfilled with nitrogen (3x). The stopper was exchanged for a thermocouple 
thermometer under a positive flow of nitrogen, and anhydrous Et2O (0.60 mL) was added. The 
clear, colorless solution was cooled to -74 °C (Et2O/dry ice), stirred for 10 min, then treated 
dropwise with n-BuLi (0.0753 mL, 2.5 M solution in hexanes, 0.188 mmol) during the slow 
addition of which the temperature increased to -71.4 °C. The resulting clear and colorless 
solution was stirred at -73 °C for 15 min then cooled to -94 °C (N2(l)/ Et2O) over a period of 10 
min and treated dropwise with a solution of enone 2.85 (0.0300 g, 0.157 mmol) in THF/Et2O 
(1:1 , 600 µL). During this addition the temperature rose to -88 °C and the solution became clear 
yellow. The mixture was stirred for 1 h while the internal temperature was kept between -89 to -
95 °C. The solution was then allowed to warm slowly to -75 °C over 20 min, diluted with EtOAc 
(0.50 mL) and quenched with sat. NH4Cl(aq) (1.0 mL), keeping the internal temperature below -
50 °C. The cold bath was removed and the reaction mixture was warmed to room temperature. 
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The aqueous layer was extracted with EtOAc (3x). The combined organic layers were dried 
(Na2SO4) and concentrated. The resulting residue was purified by chromatography on SiO2 (5-
10% acetone/CH2Cl2) to deliver recovered starting material 71 (7.8 mg) as a white solid along 
with allylic alcohols 2.111 (0.026 g, 35%) and epi-2.111 (0.0176 g, 24%) as a white foams.  
 Allylic alcohol 2.111: [α]D17 -22.8 (c  1, CHCl3); IR (ATR) 3415, 2932, 1736, 1676, 
1614, 1504, 1380, 1365, 1287, 1124, 915, 730 cm-1; 1H NMR (400 MHz, C6D6) δ 6.81 (dd, J = 
2.0, 0.8 Hz, 1 H), 5.99 (dd, J = 3.2, 2.4 Hz, 1 H), 5.90 (dd, 3.2, 0.8 Hz, 1 H), 5.43 (dd, J = 9.8, 
0.6 Hz, 1 H), 5.36 (d, J = 9.6 Hz, 1 H), 3.76 (d, J = 14.8 Hz, 1 H), 3.54 (d, J = 14.0 Hz, 1 H), 
3.37 (s, 1 H), 2.98 (dd, J = 13.2, 2.4 Hz, 1 H), 2.54 (s, 3 H), 2.42 (dd, J = 12.0, 0.8 Hz, 1 H), 1.68 
(ap. t, J = 12.2 Hz, 1 H), 1.58-1.55 (m, 2 H), 1.31 (s, 3 H), 1.27-1.23 (m, 9 H), 1.08-1.05 (m, 1 
H), 0.93 (s, 3 H), 0.92 (s, 3 H),  0.75 (d, J = 3.6 Hz, 1 H), 0.23 (d, J = 3.6 Hz, 1 H); 13CNMR 
(100 MHz, CDCl3) δ 179.2, 159.0, 148.9, 139.5, 132.3, 128.8, 111.5, 103.1, 75.1, 60.9, 60.8, 
59.5, 58.2, 39.1 (2C), 35.8, 32.4, 32.1, 31.9, 31.7, 27.2, 24.6, 20.5 (2C), 16.9, 10.8; HRMS 
(LCMS ESI+) m/z calcd for C26H38O5N3 (M+H) 472.2806, found 472.2807. The relative 
configuration of allylic alcohol 2.111 was established through a combination of X-ray and 1H 
NMR data. An X-ray crystal structure of (±)-2.111 confirmed the assigned relative configuration. 
Crystals were grown by slow evaporation at room temperature from a mixture of Et2O/hexanes 
(1:1): Mp 91.4-94.3 °C.  
Allylic alcohol epi-2.111: [α]D24 -1.0 (c 0.5, CHCl3); IR (ATR) 3413, 2932, 1744, 1677, 
1611, 1504, 1451, 1381, 1364, 1287, 1177, 924, 736 cm-1; 1H NMR (400 MHz, C6D6) δ 6.86 (dd, 
J = 2.0, 0.8 Hz, 1 H), 6.03 (dd, J = 3.2, 2.0 Hz, 1 H), 5.87 (dd, J = 3.2, 0.8 Hz, 1 H), 5.66 (dd, J = 
9.8, 0.6 Hz, 1 H), 5.48 (d, J = 10.0 Hz, 1 H), 3.84, 3.80 (ABq, J = 14.4 Hz, 2 H), 3.53 (dd, J = 
12.6, 2.6 Hz, 1 H), 3.48 (bs, 1 H), 2.47 (s, 3 H), 2.12 (ddd, J = 12.0, 2.8, 1.2 Hz, 1 H), 1.66-1.55 
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(m, 3 H), 1.33-1.28 (m, 12 H), 1.13-1.07 (m, 1 H), 0.93 (s, 6 H), 0.78 (d, J = 3.6 Hz, 1 H), 0.25 
(d, J = 3.6 Hz, 1 H); 13C NMR (150 MHz, CDCl3) δ 179.5, 158.8, 148.7, 139.6, 131.0, 129.6, 
111.4, 103.4, 74.0, 61.0, 60.9, 60.8, 57.1, 39.1 (2 C), 37.2, 32.3, 31.9, 31.8, 31.7, 27.2, 23.6, 20.5 
(2 C), 17.0, 10.8; HRMS (LCMS ESI+) m/z calcd for C26H38O5N3 (M+H) 472.2806, found 
472.2803. 
                                  
 
(−)-Cycloclavine (1). A solution of tertiary alcohol 2.111 (0.0140 g, 0.0297 mmol) in dry 
degassed PhMe (2.0 mL) was heated at 135 °C in a sealed tube for 68 h. The reaction mixture 
was filtered through a pad of SiO2 washing with EtOAc and concentrated. The crude indole 
2.110 was dissolved in anhydrous THF (0.4 mL), treated with LiAlH4 (0.24 mL, 1.0 M solution 
in Et2O, 0.240 mmol) and stirred at reflux (66 °C) in a sealed tube overnight. The reaction 
mixture was cooled to 0 °C and diluted with Et2O (1 mL), then treated successively with H2O (9 
µL), 15% NaOH (9 µL) and H2O (27 µL). The suspension was stirred for 15 min while warming 
to room temperature, then treated with MgSO4 and stirred for a further 15 min. The mixture was 
filtered through a pad of Celite and concentrated. The crude product was purified by 
chromatography on SiO2 (20% acetone/ CHCl3) to deliver (−)-(2.1) (0.0034 g, 48% (2 steps)) as 
a white solid: [α]D21 -56.0 (c 0.096, CHCl3); IR (ATR) 3413, 2930, 2879, 1591, 1443 1322, 
1165, 1093, 738 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.90 (bs, 1 H), 7.14 (dd, J = 8.0, 0.8 Hz, 1 
H), 7.09 (dd, J = 8.0, 6.8 Hz, 1 H), 6.90 (ap. t, J = 1.6 Hz, 1 H), 6.82 (dd, J = 6.8, 0.4 Hz, 1 H), 
3.17-3.11 (m, 2 H), 2.78 (dd, J = 11.6, 4.0 Hz, 1 H), 2.63-2.57 (m, 1 H), 2.40 (d, J = 8.4 Hz, 1 
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H), 2.36 (s, 3 H), 1.69 (s, 3 H), 1.60 (d, J = 3.6 Hz, 1 H), 0.45 (d, J = 3.6 Hz, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 135.6, 133.7, 128.8, 123.1, 118.2, 113.5, 110.5, 108.1, 69.8, 65.8, 40.1, 
34.5, 27.9, 25.1, 24.4, 16.6; HRMS (LCMS ESI+) m/z calcd for C16H19N2 (M+H) 239.1543, 
found 239.1541. 
 
 
1a,3-Dimethyl-2-thioxo-1,1a,2,3,3a,4-hexahydro-5H-cyclopropa[c]indol-5-one 
(2.116). A solution of enone (±)-2.85 (0.020 g, 0.11 mmol) in THF (2 mL) was treated with 
Belleau's reagent 2.117 (0.061 g, 0.12 mmol) and stirred at 66 °C under an atmosphere of 
nitrogen for 3 h. The reaction was quenched with Na2CO3 and extracted with EtOAc (3x). The 
combined organic layers were dried (Na2SO4), filtered and concentrated. The resulting residue 
was purified by chromatography on SiO2 (0-20% EtOAc/hexanes) to deliver thioamide 2.116 
(0.016 g, 76%) as a yellow oil: IR (ATR) 2970, 2932, 2850, 1713, 1668, 1581, 1480, 1398, 1310, 
1109 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 9.6 Hz, 1 H), 6.17 (d, J = 9.6 Hz, 1 H), 
4.10 (dd, J = 14.0, 4.0 Hz, 1 H), 3.12 (s, 3 H), 3.03 (dd, J = 15.6, 4.0 Hz, 1 H), 2.53 (ap. t, J = 
14.8 Hz, 1 H), 1.63 (s, 3 H), 1.20 (d, J = 4.0 Hz, 1 H), 1.03 (d, J = 4.0 Hz, 1 H); 13C NMR (100 
MHz, CDCl3) δ 208.1, 196.6, 148.1, 131.4, 64.3, 43.0, 42.1, 34.4, 32.3, 26.5, 14.1; HRMS 
(LCMS ESI)+ m/z calcd for C11H14NOS (M+H) 208.0791, found 208.0790.   
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N-(2-Oxo-2H-pyran-3-yl)benzamide (2.120). An oven-dried flask containing 3-
dimethylaminoacrolein (2.119) (0.225 g, 2.27 mmol) in acetic anhydride (10 mL) was treated 
with hippuric acid (2.118) (0.407 g, 2.27 mmol) and the resulting orange solution heated to for 4 
h during which time the solution became dark purple/black in color. The reaction was cooled to 
100 °C and H2O (10 mL) was added and the reaction was allowed to stir overnight cooling to 
room temperature. The resulting orange oil was concentrated under reduced pressure and filtered 
through a pad of SiO2 (washing with 20% EtOAc/hexanes), concentrated and purified by 
chromatography on SiO2 (10-25% EtOAc/hexanes) to deliver pyrone 2.120 (0.225 g, 46%) as a 
yellow solid: 1H NMR (400 MHz; DMSO-d6) δ 9.56 (bs, 1 H), 8.07 (dd, J = 7.2, 2.0 Hz, 1 H), 
7.93 (d, J = 6.8 Hz, 2 H), 7.68 (dd, J = 5.0, 1.8 Hz, 1 H), 7.61 (d, J = 7.2 Hz, 1 H), 7.54 (ap. t, J = 
6.8 Hz, 2 H), 6.54 (dd, J = 7.0, 5.0 Hz, 1 H); HRMS (LCMS ESI)+ m/z calcd for C12H10O3N 
(M+H) 216.0655, found 216.0654. The experimental 1H NMR was consistent with the literature-
reported data.136  
 
 
N-(2-Oxo-2H-pyran-3-yl)-N-((tributylstannyl)methyl)benzamide (2.121). A solution 
of pyrone 2.120 (0.040 g, 0.19 mmol) in DMF (0.5 mL) at 0 °C was treated with NaH (0.0090 g, 
60% dispersion in mineral oil, 0.22 mmol). The resulting mixture was stirred at 0 °C for 0.5 h 
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then treated with (iodomethyl)tributyltin (S-2.6) (0.084 g, 0.20 mmol) and stirred for 2 h 
warming to room temperature. The resulting brown solution reaction was diluted with Et2O and 
quenched with saturated aq. NH4Cl and the separated aqueous layer extracted with Et2O (2 x) 
and the combined organic layers dried (Na2SO4) and concentrated. The resulting residue was 
purified by chromatography on SiO2 (0-15% EtOAc/hexanes) to deliver stannane 2.121 (0.024 g, 
25%, 42% brsm) as a clear, yellow oil: IR (ATR) 2952, 2921, 2869, 2850, 1728, 1627, 1446, 
1374, 911, 742 cm-1; 1H NMR (400 MHz; CDCl3) δ 7.34 (dd, J = 5.1, 2.0 Hz, 1 H), 7.34-7.23 
(m, 5 H), 6.74 (dd, J = 6.8, 1.8 Hz, 1 H), 5.99 (dd, J = 6.8, 5.2 Hz, 1 H), 3.22 (bs, 2 H), 1.57-1.49 
(m, 6 H), 1.30 (dt, J = 14.7, 7.3 Hz, 6 H), 0.90 (ap. t, J = 8.2 Hz, 6 H), 0.88 (t, J  = 7.3 Hz, 9 H); 
13C NMR (100 MHz; CDCl3) δ 170.4, 159.4, 150.4, 138.9, 135.6, 133.8, 130.2, 128.4, 127.7, 
105.7, 36.4, 29.2, 27.6, 13.9, 11.1; HRMS (LCMS, ESI)+ m/z calcd for C25H38O3NSn (M+H) 
520.18682, found 520.18690. 
 
 
N-(8-Oxo-4,4a,5,6,7,8-hexahydronaphthalen-1-yl)benzamide (2.124) & N-(8-oxo-
5,6,7,8-tetrahydronaphthalen-1-yl)benzamide (2.125). A solution of pyrone 2.120 (0.028 g, 
0.13 mmol) in PhCF3 (0.5 mL) was treated with cyclohexenone (0.065 mL, 065 mmol) and the 
resulting solution heated under microwave irradiation in a sealed tube at 170 °C for 3 h. The 
reaction was concentrated and purified by chromatography on SiO2 (5-10% EtOAc/ Hex) to 
O
PhCF3, 170 °C, µw; 29%
O
HN
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deliver dienone 2.124 (0.0040 mg, 12%, 23% brsm) as a white solid and protected aniline 2.125 
(0.0060 mg, 17%, 35% brsm) as a yellow solid along with recovered starting material (14 mg). 
N-(8-Oxo-4,4a,5,6,7,8-hexahydronaphthalen-1-yl)benzamide (2.124): IR (ATR) 2986, 
2977, 2954, 2945, 2939, 2900, 2869, 1678, 1640, 1577, 1527, 1463, 1407, 1277, 1266, 1241, 
1176, 1143 cm-1; 1H-NMR (400 MHz; CDCl3): δ 13.81 (s, 1 H), 8.04-8.01 (m, 2 H), 7.57-7.47 
(m, 3 H), 5.74-5.69 (m, 1 H), 5.66 (dtd, J = 9.9, 2.0, 0.84 Hz, 1 H), 4.08 (dddd, J = 23.8, 6.6, 4.0, 
0.80 Hz, 1 H), 3.68 (ddt, J = 24.1, 9.7, 2.4 Hz, 1 H), 3.23-3.13 (m, 1 H), 2.61 (dtd, J = 17.3, 6.6, 
0.98 Hz, 1 H), 2.46 (ap. dt, J = 17.3, 7.6 Hz, 1 H), 2.05 (dqd, J = 12.9, 4.7, 2.0 Hz, 1 H), 1.94-
1.87 (m, 2 H), 1.53-1.47 (m, 1 H); 13C-NMR (100 MHz, CDCl3) δ 203.6, 166.5, 150.2, 134.5, 
132.4, 128.9, 128.7, 128.0, 121.6, 112.8, 39.2, 35.5, 30.9, 29.7, 20.7; HRMS (LCMS) m/z calcd 
for C17 H18 O2 N (M+H) = 268.1332, found 268.1330. 
N-(8-Oxo-5,6,7,8-tetrahydronaphthalen-1-yl)benzamide (2.125): IR (ATR) 2951, 
2930, 2921, 2902, 2882, 2852, 1720, 1663, 1638, 1607, 1558, 1459, 1353, 1344, 1260, 1241, 
1213, 1143, 1072, 794 cm-1; 1H-NMR (400 MHz; CDCl3): δ 13.13 (s, 1 H), 8.85 (dd, J = 8.4, 1.1 
Hz, 1 H), 8.11-8.08 (m, 2 H), 7.54-7.52 (m, 4 H), 6.99 (dq, J = 7.6, 1.2 Hz, 1 H), 3.02 (t, J = 6.0 
Hz, 2 H), 2.76 (dd, J = 6.9, 6.1 Hz, 2 H), 2.14 (dq, J = 12.4, 6.0 Hz, 2 H); 13C-NMR (125 MHz, 
CDCl3); δ 203.9, 166.4, 146.3, 142.5, 135.5, 135.2, 132.1, 128.9, 127.7, 123.4, 118.9, 118.6, 
41.0, 31.2, 22.9; HRMS (LCMS) m/z calcd for C17 H16 O2 N (M+H) = 266.1176, found 
266.1173.  
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3-Ethylpentan-3-yl furan-2-yl((tributylstannyl)methyl)carbamate (2.140). A solution of 
sodium azide (0.39 g, 6.0 mmol) in toluene (4.8 mL) was treated with 2-furoyl chloride (0.53 
mL, 5.3 mmol) and let stir at room temperature for 24 h. The resulting clear light yellow solution 
was treated with 3-ethyl-3-pentanol (1.85 g, 16 mmol) and stirred at 85 °C for 12 h during which 
time the solution became yellow then brown. The reaction was diluted with ethyl acetate and 
washed with NaHCO3. The separated aqueous layer was extracted (3x EtOAC) and the combined 
organic layers dried (Na2SO4) and concentrated. The resulting residue was purified by 
chromatography on SiO2 (gradient elution 0-5% EtOAc/Hex) to deliver furan S-2.7 (0.47 g, ca 
40%, 81% pure, yield ~32%) with minor impurities as a yellow oil, which was used directly 
without further purification.1H NMR (300 MHz) δ 7.05 (s, 1 H), 6.61 (bs, 1 H), 6.33 (d, J = 2.1 
Hz, 1 H), 6.02 (s, 1 H), 1.86 (q, J = 7.4 Hz, 6 H), 0.85 (t, J = 7.5 Hz, 9 H). A solution of furan S-
2.7 (0.072 g, 0.32 mmol) in dry DMF (1.3 mL) at 0 °C was treated with NaH (0.0077 g, 0.32 
mmol) in portions. The reaction mixture was stirred at 0 °C for 1 h, at which time 
(iodomethyl)tributyltin S-2.6 (0.15 g, 0.35 mmol) was added dropwise. The solution was stirred 
at 0 °C for 2 h, diluted with Et2O and quenched with saturated aq. NH4Cl. The separated aqueous 
layer was extracted with Et2O (2 x) and the combined organic layers were washed with brine, 
dried (Na2SO4) and concentrated. The resulting residue was purified by chromatography on SiO2 
(0-5% EtOAc/Hex) to deliver stannane 2.140 (0.055 g, 33%) as a clear and colorless oil): 1H 
NMR (300 MHz) δ 7.14 (d, J = 1.2 Hz, 1 H), 6.32 (dd, J = 3.2, 2.3 Hz, 1 H), 5.92 (bs, 1 H), 3.35 
O
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O
O NH
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(bs, 2 H), 1.79 (q, J = 7.2 Hz, 6 H), 1.48-1.42 (m, 6 H), 1.27 (sextet, J = 7.2 Hz, 6 H), 0.87 (t, J = 
7.2 Hz, 9 H), 0.86-0.76 (m, 15 H) 
 
(3s,5s,7s)-Adamantan-1-yl furan-2-yl((tributylstannyl)methyl)carbamate (2.139). A stirred 
solution of 2-furoyl chloride (0.405 g, 3.10 mmol) in toluene (4.00 mL) was treated with sodium 
azide (0.230 g, 3.53 mmol) in one portion. After stirring the reaction mixture at room 
temperature for 24 h 1-adamantanol (1.42 g, 9.31 mmol) was added and the resulting solution 
was heated at reflux overnight. The reaction was diluted with ethyl acetate then treated with 
NaHCO3. The separated aqueous phase was extracted with ethyl acetate (3x) and the combined 
organic layers dried (Na2SO4), filtered and concentrated under reduced pressure. The residue was 
purified by chromatography on SiO2 (gradient elution 0-5% EtOAc/Hex) to deliver carbamate S-
2.8 (0.376 g, 46%) as clear oil: IR (ATR) 3294, 2910, 2852, 1703, 1612, 1530, 1353, 1251, 
1185, 1061 cm-1; 1H NMR (300 MHz) δ 7.05 (dd, J = 2.0, 1.1 Hz, 1 H), 6.60 (bs, 1 H), 6.33 (dd, 
J = 3.2, 2.3 Hz, 1 H), 6.02 (bs, 1 H), 2.18 (s, 3 H), 2.15 (s, 6 H), 1.67 (s, 6 H); 13C NMR (125 
MHz) δ 151.5, 145.6, 136.1, 111.5, 95.0, 41.6, 36.3, 31.0. A solution of carbamate S-2.8 (0.10 g, 
0.38 mmol) in dry DMF (1 mL) at 0 °C was treated with NaH (0.012 g, 0.46 mmol). The 
reaction mixture was stirred at 0 °C for 1 h, at which time (iodomethyl)tributyltin S-2.6 (0.18 g, 
0.42 mmol) was added dropwise. The solution was stirred at 0 °C for 2 h, diluted with Et2O and 
quenched with saturated aq. NH4Cl. The separated aqueous layer was extracted with Et2O (3x) 
and the combined organic extracts were dried (Na2SO4) and concentrated under reduced 
pressure. The resulting residue was purified by chromatography on SiO2 (0-5% EtOAc/Hex) to 
O
O
Cl NaN3, PhMe, 24 h, rt
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deliver stannane 2.139 (0.12 g, 57%) as a clear and colorless oil: 1H NMR (300 MHz) δ 7.12 (d, 
J = 0.9 Hz, 1 H), 6.31 (dd, J = 3.2, 2.3 Hz, 1H), 5.91 (bs, 1 H), 3.38 (bs 2 H), 2.15 (bs, 3 H), 2.10 
(bs, 6 H), 1.65 (s, 6 H), 1.48−1.42 (m, 6 H), 1.27 (sextet, J = 7.2 Hz, 6 H), 0.8 (t, J = 7.2 Hz, 9 
H), 0.84 (t, J = 8.1 Hz, 6 H) 
 
N-(Furan-2-yl)pyrrolidine-1-carboxamide (S-2.9). A solution of furan-2-carbonyl 
azide111 (2.145) (0.500 g, 3.65 mmol) in anhydrous toluene (18 mL) was heated to reflux for 2.5 
h. The reaction was cooled to 0 °C and treated with pyrrolidine (0.306 mL, 3.65 mmol) upon the 
addition of which a white gas evolved. The resulting solution was filtered through neutral 
alumina and concentrated to deliver urea S-2.9 (0.650 g, 99%) as a pale yellow solid: Mp 129.2-
134.8 °C; IR (ATR) 3219, 3174, 2867, 1646, 1532, 1519, 1471, 1349, 1234, 1204, 1003, 772 cm-
1; 1H NMR (400 MHz; CDCl3) δ 7.05 (dd, J = 2.0, 0.8 Hz, 1 H), 6.38 (bs, 1H), 6.34 (dd, J = 3.2, 
2.0 Hz, 1 H), 6.13 (dd, J = 3.2, 0.8 Hz, 1 H), 3.43 (t, J = 5.8 Hz, 4 H), 1.96 (t, J = 6.6 Hz, 4H); 
13C NMR (100 MHz; CDCl3) δ 152.6, 146.5, 135.8, 111.6, 95.4, 46.0, 25.7; HRMS (ESI)+ m/z 
calcd for C9H13O2N2 (M+H) 181.09715, found 181.09663. 
 
 
N-(Furan-2-yl)-N-((tributylstannyl)methyl)pyrrolidine-1-carboxamide (2.141). A 
solution of furanyl urea S-2.9 (0.500 g, 2.77 mmol) in DMF (4.5 mL) at 0 °C was treated with 
NaH (0.0888 g, 90% dispersion in mineral oil, 3.33 mmol). The resulting mixture was stirred at 0 
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°C for 0.5 h then treated with (iodomethyl)tributyltin S-2.6 (1.26 g, 2.91 mmol) and stirred for 1 
h warming to room temperature. The reaction was diluted with Et2O and quenched with saturated 
aq. NH4Cl. The separated aqueous layer was extracted with Et2O (2 x) and the combined organic 
layers dried (Na2SO4) and concentrated. The resulting residue was purified by chromatography 
on SiO2 (0-5% EtOAc/hexanes) to deliver stannane 2.141 (0.981 g, 73%) as a clear and colorless 
oil: IR (ATR) 2951, 2919, 2869, 2850, 1631, 1603, 1504, 1452, 1392, 1074, 999, 913, 733 cm-1; 
1H NMR (300 MHz; CDCl3) δ 7.18 (dd, J = 2.0, 1.1 Hz, 1 H), 6.31 (dd, J = 3.0, 2.1 Hz, 1 H), 
5.82 (dd, J = 3.2, 0.8 Hz, 1 H), 3.19 (s, 2 H), 3.06 (t, J = 6.6 Hz, 4 H), 1.71 (t, J = 6.6 Hz, 4 H), 
1.50-1.41 (m, 6 H), 1.28 (sextet, J = 7.2 Hz, 6 H), 0.87 (t, J = 7.2 Hz, 9 H), 0.88-0.83 (m, 6 H); 
13C NMR (100 MHz, CDCl3) δ 158.6, 152.2, 138.2, 111.1, 101.1, 47.7, 37.8, 29.2, 27.6, 25.6, 
13.9, 10.4; HRMS (ESI) m/z calcd for C22H41O2N2Sn (M+H) 485.21845, found 485.21635. 
                   
 
2,2,6,6-Tetramethylpiperidin-1-ol (2.147). Prepared based on protocols reported by 
Paleos and Dais137 and Wipf138. A solution of TEMPO (2.00 g, 96% purity, 12.3 mmol) in 
deoxygenated MeOH (104 mL) was treated with ascorbic acid (2.60 g, 14.8 mmol) upon the 
addition of which the solution immediately changed color from clear and orange to a clear pale 
yellow solution. The solution was allowed to stir for 30 min, then concentrated under reduced 
pressure. The resulting residue was diluted with deoxygenated Et2O (60 mL) and water (60 mL) 
and transferred to a separatory funnel. The aqueous phase was further extracted with 
deoxygenated Et2O (4 x 30 mL) and the combined organic layers were dried (MgSO4) under 
N
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O
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H
O
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PhMe, reflux, 1 h, 87%
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nitrogen, filtered and concentrated to deliver crude 2,2,6,6-tetramethylpiperidin-1-ol (2.147) 
(1.55 g, 80% crude yield), which was carried on without further purification.  
2,2,6,6-Tetramethylpiperidin-1-yl furan-2-ylcarbamate (2.148). A solution of acyl 
azide 2.145111 (0.800 g, 5.84 mmol) in PhMe (45 mL) was heated at reflux for 1 h then cooled to 
room temperature. IR analysis of the reaction mixture indicated isocyanate formation (νNCO 2265 
cm-1). The reaction mixture was then treated with a solution of 2,2,6,6-tetramethylpiperidin-1-ol 
(2.147) (1.55 g, 9.86 mmol) in PhMe (12 mL). The resulting orange/brown solution was stirred 
for 1 h and concentrated. The residue was purified by chromatography on SiO2 (0-4% 
EtOAc/hexanes) to deliver TEMPO-carbamate 2.148 (1.35 g, 87%) as a white solid: Mp 101.4-
102.8 °C; IR (ATR) 3256, 2936, 2924, 2921, 1715, 1620, 1506, 1439, 1379, 1251, 1154, 1010, 
719 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.00 (bs, 1 H), 7.10 (d, J = 1.0 Hz, 1 H), 6.38 (dd, J = 
3.3, 2.3 Hz, 1 H), 6.17 (d, J = 3.0 Hz, 1 H), 1.71-1.55 (m, 5 H), 1.48-1.44 (m, 1 H), 1.26 (s, 6 H), 
1.19 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ 154.6, 144.9, 136.4, 111.7, 95.6, 61.5, 39.9, 31.7, 
20.9, 16.9; HRMS (ESI+) m/z  calcd for C14H23O3N2 (M+H) 267.17032, found 267.17137. 
 
                                       
2,2,6,6-Tetramethylpiperidin-1-yl furan-2-yl((tributylstannyl)methyl)carbamate 
(2.149). A solution of furan 2.148 (0.150 g, 0.563 mmol) in DMF (0.9 mL) was cooled to 0 °C 
and treated with NaH (0.0270 g, 60% dispersion in mineral oil, 0.675 mmol). The resulting 
solution was stirred at 0 °C for 0.5 h then treated with (iodomethyl)tributyltin S-2.6139 (0.255 g, 
0.591 mmol). The resulting brown solution was stirred for 1 h while warming to room 
I SnBu3
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temperature, diluted with Et2O and quenched with sat. NH4Cl(aq). The aqueous layer was 
extracted with Et2O (2x) and the combined organic layers were dried (Na2SO4) and concentrated. 
The resulting residue was purified by chromatography on SiO2 (0-3% EtOAc/hexanes) to deliver 
stannane 2.149 (0.223 g, 70%) as a clear, pale yellow oil: IR (ATR) 2947, 2926, 2923, 2869, 
1728, 1609, 1502, 1430, 1377, 1349, 1185, 1072, 986 cm-1; 1H NMR (400 MHz, C6D6) δ 6.90 
(dd, J = 2.0, 0.80 Hz, 1 H), 6.05 (dd, J = 3.2, 2.0 Hz, 1 H), 5.93 (bs, 1 H), 3.35 (s, 2 H, 
2J117/119Sn-1H = 27.6 Hz), 1.69-1.54 (m, 9 H), 1.44-1.35 (m, 7 H), 1.33 (s, 6 H), 1.27-1.23 (m, 2 
H), 1.09-1.05 (m, 6 H), 0.97-0.94 (m, 15 H); 13C NMR (100 MHz, C6D6) δ 157.2, 151.1, 138.8, 
111.3, 101.5, 60.4, 39.4, 36.7, 32.0, 29.6 (J117/119Sn-13C = 20 Hz), 27.9 (J 117/119Sn-13C = 57 Hz), 
20.6, 17.2, 14.0, 11.0 (1J119Sn-13C = 334 Hz, 1J 117Sn-13C = 319 Hz); HRMS (ESI+) m/z calcd for 
C27H51O3N2Sn (M+H) 571.29162, found 571.28963.  
 
 
2,2,6,6-Tetramethylpiperidin-1-ylfuran-2-yl((1-hydroxycyclohex-2-en-
1yl)methyl)carbamate (2.150). A flame-dried flask cooled under an inert atmosphere was 
charged with stannane 2.149 (0.142 g, 0.250 mmol) and evacuated under high vacuum then 
backfilled with nitrogen (3x). THF (0.5 mL) was added and the resulting clear and colorless 
solution cooled to -78 °C, stirred for 10 min and treated dropwise with n-BuLi (0.100 mL, 2.5 M 
solution in hexanes, 0.250 mmol). The resulting clear, very pale yellow solution was stirred at -
78 °C for 15 min then treated dropwise with enone (0.0201 mL, 0.208 mmol). The reaction was 
stirred for 30 min at -78 °C, diluted with EtOAc (2 mL) and quenched with NH4Cl (2 mL). The 
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N
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SnBu3
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separated aqueous layer was extracted (3 x EtOAc), dried (Na2SO4) and concentrated. The 
residue was purified by chromatography on SiO2 (10-15% EtOAc/Hexanes) to yield allylic 
alcohol 2.150 (0.0691 g, 88%) as a white solid: Mp 114.8-116.5 °C; IR (ATR) 3443, 2967, 2930, 
2883, 1730, 1610, 1502, 1363, 1284, 1172, 984, 733; 1H NMR (500 MHz; CDCl3) δ 7.24 (d, J = 
1.5 Hz, 1 H), 6.37 (dd, J = 3.3, 2.3 Hz, 1 H), 6.10 (d, J = 3.0 Hz, 1 H), 5.81 (dt, J = 10.0, 3.5 Hz, 
1 H), 5.62 (d, J = 10.0 Hz, 1 H), 3.75 (d, J = 14.5 Hz, 1 H), 3.67 (d, J = 14.5 Hz, 1H), 3.50 (bs, 1 
H), 2.03 (dd, J = 18.0, 5.0 Hz, 1 H), 1.91 (dd, J = 17.9, 3.1 Hz, 1 H), 1.78-1.53 (m, 7 H), 1.47 
(dt, J = 13.2, 2,3 Hz, 2 H), 1.36 (dt, J = 13.3, 3.0 Hz, 1 H), 1.13 (s, 6 H), 0.92 (s, 6 H); 13C NMR 
(100 MHz; CDCl3) δ 158.7, 149.1, 139.3, 130.6, 130.2, 111.2, 103.1, 70.9, 60.7, 60.7, 39.1, 33.9, 
31.8, 31.8, 25.3, 20.4, 19.1, 17.0; HRMS (LCMS) m/z calcd for C21H33O4N2 (M+H) 377.2435, 
found 377.2437. 
 
 
2,2,6,6-Tetramethylpiperidin-1-yl 4,5-dihydrobenzo[cd]indole-1(3H)-carboxylate 
(2.151). Allylic alcohol 2.150 (0.050 g, 0.13 mmol) in dry degassed toluene (10 mL) was heated 
in a sealed tube at reflux, during which time the solution became clear and brown. The reaction 
was stirred for 10 days and filtered through a pad of florisil (2% EtOAc/Hex) to deliver crude 
indole (0.039 g). The brown residue was purified by chromatography on SiO2 (0-5% 
EtOAc/Hex) to deliver indole 2.151 (0.023 g, 51%) as a white film: IR (ATR) 2969, 2928, 2889, 
2865, 1756, 1437, 1377, 1355, 1230, 1131, 1094, 753 cm-1; 1H NMR (300 MHz; CD2Cl2) δ 7.81 
(d, J = 8.1 Hz, 1 H), 7.30 (s, 1 H), 7.23 (t, J = 7.8 Hz, 1 H), 6.98 (d, J = 7.2 Hz, 1 H), 2.91 (t, J = 
N
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N
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HO
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10 d, 51%
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6.0 Hz, 2 H), 2.82 (t, J = 6.1 Hz, 2 H), 2.03 (p, J = 6.1 Hz, 2 H), 1.73-1.61 (m, 6 H), 1.31 (s, 6 
H), 1.15 (s, 6 H); 13C NMR (100 MHz, C6D6, 70 °C) δ 152.3, 134.8, 132.6, 130.1, 125.6, 120.3, 
119.2, 118.6, 113.4, 60.8, 39.9, 31.9 (broad), 27.5, 24.5, 22.1, 21.5 (broad) 17.4; HRMS (LCMS, 
ESI+) m/z calcd for C21H29O2N2 (M+H) 341.22235, found 341.22141. 
 
 
1,3,4,5-Tetrahydrobenzo[cd]indole (138). A solution of protected indole 2.151 (0.0040 
g, 0.012 mmol) in PhCF3 (1 mL) was heated at 180 °C in the microwave for 1 h 20 min. The 
reaction was concentrated & purified by chromatography on SiO2 (2% EtOAc/hexanes) to 
deliver indole 2.152 (0.0016 g, 87%) as a white film: 1H NMR (500 MHz; CDCl3) δ 7.80 (bs, 1 
H), 7.15 (d, J = 8.5, 1 H), 7.10 (ap. t, J = 7.5 Hz, 1 H), 6.85 (d, J = 1.0 Hz, 1 H), 6.83 (dd, J = 
6.8, 0.8 Hz, 1 H), 2.94 (t, J = 6.0 Hz, 2 H), 2.87 (t, J = 6.2 Hz, 2 H), 2.07 (ap. quintet, J = 6.1 Hz, 
2 H). The experimental 1H NMR was consistent with the literature-reported data.83  
3.2.4 CHAPTER TWO EXPERIMENTAL PART: (+)-2.1 
 
N-Tetrabromophthaloyl-(R)-tert-leucine (2.157). An oven-dried round bottom flask 
topped with a Dean Stark apparatus and condenser was charged sequentially with D-tert-leucine 
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2.155 (0.500 g, 3.77 mmol), tetrabromophthalic anhydride 2.156 (1.79 g, 3.77 mmol), anhydrous 
toluene (10 ml) and triethylamine (0.0536 mL, 0.377 mmol) and the resulting heterogeneous 
mixture heated at reflux while the solvent was removed at a rate of ~ 1 mL/h. The resulting 
solution was cooled to room temperature and treated with 5% HCl (6 mL) and EtOAc (15 mL). 
The separated aqueous layer was extracted with EtOAc (6 mL) and the combined organic layers 
were dried (Na2SO4) and concentrated to deliver N-tetrabromophthaloyl-(R)-tert-leucine (2.157) 
(2.11 g, 97%) as a white solid: [α]D20 +22.3 (c 0.40, EtOH); 1H NMR (300 MHz, acetone-d6) δ 
4.68 (s, 1 H), 1.19 (s, 9 H). The experimental 1H NMR was consistent with the literature-reported 
data for the enantiomer.55  
 
       
Dirhodium(II) tetrakis[N-tetrabromophthaloyl-(R)-tert-leucinate] [Rh2(R-
TBPTTL)4] (ent-1.75). An oven dried flask topped with a dean stark apparatus and condenser 
was charged with Rh2(OAc)4 (0.130 g, 0.294 mmol) and N-tetrabromophthaloyl-(R)-tert-leucine 
2.157 (0.933 g, 1.62 mmol) and a solution of chlorobenzene/ CH3CN (9:1, 13 mL). The resulting 
dark purple mixture was heated at reflux while the solvent was removed at a rate of ~ 1 mL/ h for 
5 h during which time the solution becomes emerald green. After 5 h the reaction was cooled to 
room temperature and treated sequentially with toluene (40 mL) and sat. NaHCO3 (40 mL). The 
separated organic layer was washed with NaHCO3 (1x 40mL), brine (1 x 40mL), filtered and 
dried (Na2SO4) to deliver Rh2(R-TBPTTL)4 ent-1.75 (0.555 g, 75%) as a green solid which was 
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used directly without further purification: 1H NMR (300 MHz, benzene-d6) δ 5.37 (s, 4 H), 1.45 
(s, 36 H). The experimental 1H NMR was consistent with the literature-reported data for the 
enantiomer.55 
 
        
Perfluorophenyl (S)-1-methyl-2-methylenecyclopropane-1-carboxylate (ent-1.109). 
An oven-dried three neck flask fitted with a nitrogen inlet, a dry-ice condenser and a septum was 
charged with Rh2(R-TBPTTL)4 (ent-1.75) (0.566 g, 0.226 mmol) and CH2Cl2 (141 mL) and the 
resulting green solution cooled to -78 °C (dry ice/acetone bath) and treated dropwise with an 
excess of condensed allene gas (1.96) (~65 drops, approx. 5.14 g, ~ 5.52 mmol). The resulting 
solution was then treated with a solution of perfluorophenyl 2-diazopropanoate (1.99) (6.00 g, 
22.6 mmol) in CH2Cl2 (12 mL) via syringe pump at a rate of ~ 2 mL/h. The resulting solution 
was allowed to stir at -78 °C for 1 h before warming to room temperature. The resulting green 
residue was purified by chromatography on SiO2 (0-1% Et2O/Hex) to deliver 
methylenecyclopropane ent-1.109 (5.41 g, 86%) as a clear and pale yellow oil: [α]D19 +2.8 (c 
7.6, CHCl3); 1H NMR (500 MHz, CD2Cl2) δ 5.64 (ap. t, J = 2.8 Hz, 1 H); 5.56 (ap. t, J = 2.3 Hz, 
1 H), 2.30 (dt, J = 9.5, 2.5 Hz, 1 H), 1.63 (dt, J = 9.2, 2.4 Hz, 1 H), 1.51 (s, 3 H); HRMS (ESI+) 
m/z calcd for C12H8O2F5 (M+H) 279.04390, found 279.04502. The experimental data was 
consistent with the reported data for the enantiomer.140 
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(S,E)-N,1-Dimethyl-2-methylene-N-(3-oxobut-1-en-1-yl)cyclopropane-1-
carboxamide (ent-2.87). An oven-dried round bottom flask was charged with vinylogous amide 
2.88 (2.77 g, 27.9 mmol) and evacuated and backfilled with nitrogen (3x). Distilled THF (93 
mL) was added and the resulting solution cooled to -78 °C and treated dropwise with n-BuLi 
(11.7 mL, 2.5 M solution of hexanes, 29.3 mmol) and stirred for 5 min at -78 °C then treated 
dropwise with a solution of perfluorophenyl (S)-1-methyl-2-methylenecyclopropane-1-
carboxylate ent-1.109  (8.15 g, 29.3 mmol) in THF (15 mL). The resulting solution was then 
treated with DMAP (0.0341 g, 0.279 mmol) and stirred for 10 min at -78 °C. The cold bath was 
removed and the reaction was allowed to warm to room temperature. The reaction was treated 
with sat. NaHCO3 and EtOAc was added. The separated aqueous layer was extracted with 
EtOAc (3 x) and the combined organic layers dried and concentrated. The crude product was 
purified by chromatography on SiO2 (10-15% EtOAc/Hex) to deliver (S,E)-N,1-dimethyl-2-
methylene-N-(3-oxobut-1-en-1-yl)cyclopropane-1-carboxamide (ent-2.87) (4.30 g, 80%, er 
87:13) as a clear and pale yellow oil: [α]D19 –243.2 (c 2.24, CHCl3); 1H NMR (500 MHz, CDCl3) 
δ 8.37 (d, J = 14.0 Hz, 1 H), 5.73 (d, J = 13.5 Hz, 1 H), 5.71 (ap. t, J = 2.8 Hz, 1 H), 5.53 (s, 1 
H), 3.15 (s, 3 H), 2.29 (s, 3 H), 1.80 (dt, J = 9.8, 2.4 Hz, 1 H), 1.50 (s, 3 H), 1.33 (dt, J = 9.7, 2.4 
Hz, 1 H); HRMS (ESI)+ m/z calcd for C11H16O2N (M+H) 194.1176, found 194.1175.  
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SFC conditions: Chiralpak-IC semi-prep column (250 x 10mm), gradient elution: 5-15% (rate 
1.0), 7 mL/min, 254 nm, P=100 (BAR). 
 
 
Figure 3-16 SFC chromatogram of racemic standard and enantioenriched amide ent-2.87 (87:13 er) 
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(1aS,3aR,7aR)-5-((tert-Butyldimethylsilyl)oxy)-1a,3-dimethyl-1,1a,3,3a,6,7-
hexahydro-2H-cyclopropa[c]indol-2-one (ent-2.92) and (1aS,3aS,7aR)-5-((tert-
butyldimethylsilyl)oxy)-1a,3-dimethyl-1,1a,3,3a,6,7-hexahydro-2H-cyclopropa[c]indol-2-
one (epi-ent-2.92). An oven-dried flask was charged with NaHMDS (2.50 g, 12.9 mmol) 
followed by anhydrous THF (150 mL) under an atmosphere of nitrogen. The resulting clear and 
colorless solution was stirred for 15 min at room temperature then cooled to -78 °C and stirred 
for a further 15 min at this temperature prior to treatment with vinylogous amide ent-2.87 (2.75 
g, 14.2 mmol) in THF (20 mL) slowly at a rate of ~4 mL/h maintaining the temperature of the 
acetone/dry ice bath below -50 °C. During the slow addition of the amide the solution changes 
color from clear and pale yellow to clear and orange. The resulting clear, orange solution was 
allowed to warm to -50 °C over 1 h, cooled to -78 °C and treated dropwise with a solution of 
TBSCl (2.36 g, 15.5 mmol) in THF (52 mL). The reaction was allowed to stir for a further 5 min 
at -78 °C before the cold bath was removed and the reaction allowed to reach room temperature. 
1H NMR analysis of an aliquot (CDCl3) indicated conversion to enol ether ent-2.91. The reaction 
was concentrated and directly subjected to the following reaction: 1H NMR (300 MHz, CDCl3) δ 
7.65 (d, J = 13.5 Hz, 1 H), 5.67 (ap. s, 1 H), 5.52 (d, J = 13.8 Hz, 1 H), 5.45 (ap. s, 1 H), 4.23 (s, 
2 H), 3.13 (s, 3 H), 1.73 (dt, J = 9.6, 2.1 Hz, 1 H), 1.47 (s, 3 H), 1.25 (dt, J = 9.4, 2.2 Hz, 1 H), 
1.00 (s, 9 H), 0.24 (d, J = 2.7 Hz, 6 H). A solution of crude amide ent-2.91 (assumed 3.98 g, 12.9 
mmol) in THF (28 mL, 3.5 mL x 8 batches) was heated under microwave irradiation at 95 °C for 
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30 min then concentrated to deliver the crude Diels-Alder adducts ent-2.92 and epi-ent-2.92 
(assumed 3.98 g, 12.9 mmol) as orange oils which were used directly in the next reaction.  
 
    
(1aS,3aR,7aR)-1a,3-Dimethylhexahydro-2H-cyclopropa[c]indole-2,5(3H)-dione (ent-
2.86) & (1aS,3aS,7aR)-1a,3-dimethylhexahydro-2H-cyclopropa[c]indole-2,5(3H)-dione (epi-
ent-2.86). The crude enol ether adducts ent-2.92 and epi-ent-2.92 (assumed 3.98 g, 12.9 mmol) 
were immediately taken up in THF (130 mL) was treated dropwise with TBAF (12.9 mL, 1M 
solution in THF, 12.9 mmol) and stirred at room temperature for 30 min. The reaction mixture 
was filtered through a pad of florisil (washing with EtOAc) and concentrated. The resulting 
residue was purified by chromatography on SiO2 (20% to elute RSM, then 50-70% EtOAc/Hex 
to elute trans-diastereomer, then 90-100% EtOAc/Hexanes to elute cis-diastereomer) to deliver 
trans-ketone ent-2.86 (1.64 g, 66%) as a pale yellow solid and cis-ketone epi-ent-2.86 (0.371 g, 
15%) as a yellow oil.   
trans-Ketone (ent-2.86): [α]D19 –104.3 (c 0.93 CHCl3); 1H NMR (400 MHz, CDCl3) δ 
3.41 (dd, J = 12.8, 4.0 Hz, 1 H), 2.80 (ddd, J = 13.6, 4.0, 1.6 Hz, 1 H), 2.69 (ddt, J = 15.5, 4.8, 
1.6 Hz, 1 H), 2.66 (s, 3 H), 2.54 (ddd, J = 15.4, 12.2, 7.2 Hz, 1 H), 2.35 (ap.t, J = 13.4 Hz, 1 H), 
2.13 (tdd, J = 12.6, 5.0, 1.4 Hz, 1 H), 1.72 (ddd, J = 13.1, 7.3, 1.9 Hz, 1 H), 1.38 (s, 3 H), 0.95 
(d, J = 3.6 Hz, 1 H), 0.66 (d, J =4.0 Hz, 1 H); HRMS (ESI)+ m/z calcd for C11H16O2N (M+H) 
194.11756, found 194.11786. 
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cis-ketone (epi-ent-2.86): [α]D19 +11.0 (c 0.15 CHCl3); 1H NMR (300 MHz, CDCl3) δ 
3.73 (ap. t, J = 6.5 Hz, 1 H), 2.84 (dd, J = 15.0, 6.0 Hz, 1 H), 2.72 (s, 3 H), 2.53-2.25 (m, 4 H), 
1.83 (dt, J = 14.2, 5.2 Hz, 1 H), 1.34 (s, 3 H), 0.93 (d, J = 4.5 Hz, 1 H), 0.84 (d, J = 4.5 Hz, 1 H); 
HRMS (ESI)+ m/z calcd for C11H16O2N (M+H) 194.11756, found 194.11777  
 
           
(1aS,3aR,7aS)-1a,3-Dimethyl-1,1a,3a,4-tetrahydro-2H-cyclopropa[c]indole-2,5(3H)-
dione (ent-2.85). A solution of Pd(TFA)2 (0.0441 g, 0.129 mmol) and DMSO (0.0184 mL, 0.259 
mmol) in AcOH (13 mL) was heated at 55 °C under an atmosphere of oxygen (balloon). After 
stirring at 55 °C overnight ketone ent-2.86 (0.500 g, 2.59 mmol) was added and the reaction 
allowed to stir at room 55 °C for 4 days during which time additional catalyst (2x 0.11 g) was 
added after 24 and 48 h to drive the reaction to completion. The reaction was concentrated and 
purified by chromatography (50-70% EtOAc/Hexanes) to deliver enone ent-2.85 (0.320 g, 65%) 
as a pale yellow solid.  
Representative protocol for the enantiomeric enrichment by recrystallization: Enone ent-
2.85 (0.110 g, 0.573 mmol) was dissolved in boiling MTBE (9.5 mL) and 1,2-dichloroethane 
(0.4 mL) and allowed to cool to room temperature. The resulting solution was allowed to stand 
overnight at -20 °C during which time white needle-shaped crystals formed. The mother liquor 
was removed via pipette transfer and the crystals were washed with MTBE (2x) and placed 
under vacuum to remove trace solvents. The first recrystallization provided crystals of >99.5:0.5 
er, the second recrystallization provided crystals of 95.4:4.6 er and the third recrystallization 
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provided crystals of 98:2 er to deliver a combined yield of enone ent-2.85 (0.0654 g, 60%, 69% 
of theoretical maximum) as a white crystalline solid. Only combined samples with er >97.5:2.5 
were carried on in the subsequent reaction: [α]D17 + 111.1 (c 0.484, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 6.98 (d, J = 9.6 Hz, 1 H), 6.15 (d, J = 9.6 Hz, 1 H), 3.82 (dd, J = 14.2. 3.8 Hz, 1 H), 
2.91 (dd, J = 15.9, 3.6 Hz, 1 H), 2.72 (s, 3 H), 2.44 (dd, J  = 15.6, 14.0 Hz, 1 H), 1.47 (s, 3 H), 
1.34 (d, J = 4.0 Hz, 1 H), 0.86 (d, J = 4.0 Hz, 1 H); HRMS (ESI)+ m/z calcd for C11H14O2N 
(M+H) 192.1019, found 192.1018. SFC analysis: Chiralpak-IC semiprep column (250 x 10 mm), 
gradient elution: 1-30% iPrOH (rate 1.0), 5.5 mL/min, 254 nm, P=100 (BAR).  
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Figure 3-17 Representative SFC chromatograms of a) racemic standard b) enone ent-2.85 before recrystallization 
and c) enantioenriched enone ent-2.85 after recrystallization (batch 1) 
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Allylic alcohols ent-2.111 and epi-ent-2.111. An oven-dried 3-neck 25 mL flask fitted 
with two stoppers and nitrogen inlet was charged with stannane 2.149 (0.893 g, 1.57 mmol) and 
evacuated under high vacuum then backfilled with nitrogen (3x). A stopper was exchanged for a 
thermocouple thermometer and anhydrous Et2O (5 mL) was added. The clear, pale yellow 
solution was cooled to -70.5 °C (Et2O/dry ice) and stirred for 10 min then treated dropwise with 
n-BuLi (0.628 mL, 2.5 M solution in hexanes, 1.57 mmol) during which time the temperature 
rose to -67.4 °C. The resulting clear, yellow solution was stirred for 15 min maintaining the 
internal temperature between -67.4 and -74.5 °C then cooled to -93.1°C (liquid nitrogen/Et2O 
bath) and treated with enone ent-2.85 (0.250 g, 1.31 mmol) in anhydrous THF/Et2O 1:1 (3.5 mL) 
slowly over 10 min in 0.4 mL portions during which time the temperature rose to -86 °C. The 
reaction was stirred for 30 min maintaining the temperature below -90 °C, then stirred for a 
further hour warming to -76 °C, The reaction was then diluted with EtOAc and quenched with 
NH4Cl maintaining the internal temperature below -50 °C. The separated aqueous layer was 
extracted (5 x EtOAc), dried (Na2SO4) and concentrated. The residue was purified by 
chromatography on SiO2 (gradient elution 5% acetone/CH2Cl2 to elute enone ent-2.85 recovered 
starting material then alcohol ent-2.111, then 10% acetone/CH2Cl2 to elute alcohol epi-ent-2.111) 
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to deliver enone ent-2.85 (3 mg) as a white solid, alcohol ent-2.111 (0.250 g, 41%) as a white 
foam and alcohol epi-ent-2.111 (0.196 g, 32%) as a white foam. 
Allylic alcohol ent-2.111: [α]D18 +30.1 (c  0.2, CHCl3); 1H NMR (500 MHz, C6D6) δ 
6.81 (d, J = 1.0 Hz, 1 H), 5.98 (dd, J = 3.3, 2.3 Hz, 1 H), 5.89 (d, J = 2.5 Hz, 1 H), 5.43 (d, J 
=9.5 Hz, 1 H), 5.36 (d, J = 9.5 Hz, 1 H), 3.74 (d, J =14.5 Hz, 1 H), 3.54 (d, J = 15.0 Hz, 1 H), 
3.30 (s, 1 H), 2.97 (dd, J = 13.3, 2.3 Hz, 1 H), 2.53 (s, 3 H), 2.40 (ap. t, J = 10.8 Hz, 1 H), 1.67 
(ap. t, J = 12.3 Hz, 1 H), 1.54 (ap. t, J = 13.0 Hz, 2 H), 1.31 (s, 3 H), 1.27-1.23 (m, 9 H), 1.06 (dt, 
J = 13.5, 2.8 Hz, 1 H), 0.93 (s, 3 H), 0.92 (s, 3 H), 0.75 (d J = 3.5 Hz, 1 H), 0.23 (d, J = 3.5 Hz, 1 
H); HRMS (ESI+) m/z calcd for C26H38O5N3 (M+H) 472.28060, found 472.28102. 
Allylic alcohol epi-ent-2.111: [α]D18 +2.0 (c 0.3, CHCl3); 1H NMR (300 MHz, C6D6) δ 
6.84 (dd, J =1.8, 0.9 Hz, 1 H), 6.02 (dd, J = 3.2, 2.0 Hz, 1 H), 5.86 (dd, J = 3.2, 0.8 Hz, 1 H), 
5.60 (d, J = 9.6 Hz, 1 H), 5.45 (d, J = 9.6 Hz, 1 H), 3.74 (ap. s, 2 H), 3.45 (d, J = 13.2 Hz, 1 H), 
3.12 (ap. d, J = 9.4 Hz, 1 H), 2.46 (s, 3 H), 2.08 (d, J = 13.8 Hz, 1 H), 1.58 (t, J = 13.0 Hz, 3 H), 
1.30-1.23 (m, 12 H), 1.08 ( ap. dd, J = 11.5, 3.4 Hz, 1 H), 0.93 (ap. s, 6 H), 0.76 (d, J = 3.3 Hz, 1 
H), 0.21 (d, J = 3.6 Hz, 1 H); HRMS (ESI+) m/z calcd for C26H38O5N3 (M+H) 472.28060, found 
472.28147. 
 
 
(+)-Cycloclavine (+)-(2.1). A solution of allylic alcohol ent-2.111 (0.128 g, 0.272 mmol) 
in anhydrous, degassed toluene (10 mL) was heated to 135 °C in a sealed tube for 3 d 18 h. The 
reaction was cooled, concentrated and filtered through a pad of SiO2 washing with 2-5% 
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acetone/CH2Cl2 to deliver crude indole ent-2.110 (27 mg, 39%) which was used directly: 1H 
NMR (400 MHz, CD2Cl2) δ 8.14 (bs, 1H), 7.21 (d, J = 8.0 Hz, 1 H), 7.09 (dd, J = 8.0, 7.2 Hz, 1 
H), 7.02 (ap. s, 1 H), 6.80 (d, J = 6.8 Hz, 1 H), 3.78 (dd, J = 11.8, 4.2 Hz, 1 H), 3.29 (dd, J = 
13.6, 4.0 Hz, 1 H), 2.79 (s, 3 H), 2.71-2.64 (m, 1 H), 1.80 (s, 3 H), 1.14 (d, J = 3.6 Hz, 1 H), 0.84 
(d, J = 3.2 Hz, 1 H). A microwave vial was charged with crude indole ent-2.110 (0.0270 g, 0.107 
mmol) in anhydrous THF (1.2 mL) under an atmosphere of nitrogen was cooled to 0 °C and 
treated dropwise with LiAlH4 (0.535 mL, 1M solution in Et2O, 0.535 mmol) and the resulting 
solution stirred at reflux in a sealed tube for 16 h. The reaction was diluted with Et2O, cooled to 
0 °C and treated sequentially with DI H2O (0.020 mL), 15% NaOH(aq) (0.020 mL) and DI H2O 
(0.061 mL), warmed to room temperature and stirred for 15 min. Anhydrous MgSO4 was then 
added and the solution allowed to stir rigorously for 15 min, then filtered through a pad of Celite. 
The crude residue was purified by chromatography on SiO2 (pre-washed column with 0.1% 
NEt3/CH2Cl2 then gradient elution 0-2% MeOH/CH2Cl2 with 0.1% NEt3 added to each eluent) to 
deliver (+)-cycloclavine (+)-2.1 (21.95 mg, 86% or 34% 2 steps) as a white solid. [a]D18 +61.4 (c 
0.2, CHCl3); literature [α]D20 +63 (c 1, CHCl3)72; M.p. 161.1 to 163.8 °C (dark brown liquid, 
dec.); IR (ATR) 3409, 3166, 3103, 3062, 2942, 2885, 2843, 2788, 1617, 1590, 1442, 1322, 1165, 
1095, 922, 749 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.89 (bs, 1 H), 7.13 (dd, J = 8.0, 0.5 Hz, 1 
H), 7.09 (ap. t, J = 7.8 Hz, 1 H), 6.90 (ap. t, J = 1.8 Hz, 1 H), 6.82 (dd, J = 7.0, 0.5 Hz, 1 H), 3.15 
(d, J = 9.0 Hz, 1 H), 3.13 (dd, J = 13.8, 3.8 Hz, 1 H), 2.78 (dd, J = 11.5, 4.0 Hz, 1 H), 2.63-2.57 
(m, 1 H), 2.40 (d, J = 8.5 Hz, 1 H), 2.36 (s, 3 H), 1.69 (s, 3 H), 1.60 (d, J = 3.5 Hz, 1 H), 0.45 (d, 
J = 3.5 Hz, 1 H); 13C NMR (150 MHz, CDCl3) δ 135.6, 133.7, 128.8, 123.1, 118.2, 113.5, 110.5, 
108.1, 69.8, 65.7, 40.1, 34.5, 27.9, 25.1, 24.4, 16.6; DEPT-135 (100 MHz, CDCl3) δ123.1 (CH), 
118.2 (CH), 110.5 (CH), 108.1 (CH), 69.8 (CH), 65.8 (CH2), 40.1 (N-CH3), 25.1 (CH2), 24.4 
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(CH2), 16.6 (CH3); HRMS (LCMS ESI+) m/z calcd for C16H19N2 (M+H) 239.1543, found 
239.1544. 
 
Figure 3-18 Overlayed CD spectra of (–)- and (+)-cycloclavine  
 
 
 
trans-N,N-Diethyl-2-(p-tolyl)cyclopropane-1-carboxamide (2.167). A suspension of 
CrCl2 (2.33 g, 18.4 mmol) in THF (46 mL) was treated dropwise with (E)-N,N-diethyl-3-(p-
tolyl)acrylamide141 2.166 (1.00 g, 4.60 mmol) in THF (23 mL) followed by CH2ICl (1.28 mL, 
17.3 mmol) at room temperature under an inert atmosphere. After stirring for 17.5 h at reflux, the 
reaction was quenched with 1.0 M HCl and extracted with diethyl ether. The combined organic 
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layers were washed with sat. NH4Cl(aq), H2O and dried (Na2SO4) and concentrated. The residue 
was purified by chromatography on SiO2 (0-15% Hex/EtOAc) to deliver trans-N,N-diethyl-2-
phenylcyclopropane-1-carboxamide 2.167 (0.64 g, 60%) as a clear, yellow oil: IR (ATR) 2974, 
2931, 1629, 1518, 1481, 1459, 1427, 1362, 1254, 1139, 1074, 809 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.09 (d, J = 8.1 Hz, 2 H), 7.02 (d, J = 8.1 Hz, 2 H), 3.40 (q, J = 7.0 Hz, 4 H), 2.44 (qd, 
J = 6.9, 4.2 Hz, 1 H), 2.32 (s, 3 H), 1.89 (dt, J = 8.2, 4.8 Hz, 1H), 1.63 (ap. p, J = 4.7 Hz, 1 H), 
1.22-1.14 (m, 1 H), 1.18 (t, J = 7.1 Hz, 3 H), 1.13 (t, J = 7.4 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 171.3, 138.3, 135.9, 129.2, 126.2, 42.3, 41.1, 25.3, 23.3, 21.1, 16.2, 15.1, 13.4; HRMS 
(LCMS, ESI+) m/z calcd for C15H22NO (M+H) 232.1696, found 232.1694 
 
        
(E)-N,N-Diethyl-3-(p-tolyl)acrylamide (2.168). An oven-dried Schlenck tube cooled 
under an atmosphere of argon was charged sequentially with (trans)-N,N-diethyl-2-
phenylcyclopropane-1-carboxamide 2.167 (0.0607 g, 0.262 mmol), HPLC grade H2O (0.0378 
mL, 2.10 mmol) and THF (1.0 mL). The clear yellow solution was subjected to 6 cycles of 
freeze pump thaw (liquid nitrogen). After the last cycle an atmosphere of argon was introduced. 
The reaction was then treated with SmI2 (7.87 mL, 0.1 M solution in THF, 0.787 mmol, syringe 
flushed 3x with argon) and the resulting dark blue solution stirred under an atmosphere of argon 
at room temperature. After stirring at room temperature for 1 h, no reaction had occurred. The 
reaction was then treated with degassed NEt3 (0.293 mL, 0.210 mmol, degassed by freeze pump 
thaw) after the addition of which the solution became a dark green color. The solution was 
stirred for 1 h during which time the reaction turned color from dark to light green and then an 
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O
1. Cyclopropyl amide, H2O (8 equiv.)
    THF (freeze pump thaw), then SmI2 (3 equiv.), 1 h
2. then, NEt3 (8 equiv. degassed freeze pump thaw), 1 h
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 200 
aliquot was taken and analyzed by 1H NMR (CDCl3) indicating consumption of the starting 
material. The excess Sm(II) was oxidized by bubbling through compressed air then the reaction 
was diluted with CH2Cl2 and NaOH (1N) was added. The separated aqueous layer was extracted 
with CH2Cl2 (3x) and the combined organic layers dried, filtered and concentrated. 1H NMR 
analysis of the crude (~64 mg crude) showed ~ 4:1 ratio of acyclic amide 2.168: cyclopropane 
starting material 2.167). The crude reaction mixture was purified by chromatography on SiO2 (0-
15% EtOAc/Hex) to deliver an inseparable 4:1 mixture (0.047 g, ~77%) of amide product 2.168: 
cyclopropane 2.167. Characterization data for the major amide product 2.168 of the mixture: IR 
(ATR) 2973, 2932, 2872, 1634, 1515, 1480, 1449, 1428, 1258, 1137, 808 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.08 (s, 4 H), 3.37 (q, J = 7.1 Hz, 2 H), 3.24 (q, J = 7.2 Hz, 2 H), 2.41 (t, J = 7.2 
Hz, 2 H), 2.31 (s, 3 H), 2.29 (ap. d, J = 7.6 Hz, 2 H),  1.97 (ap. pentet, J = 7.6 Hz, 2 H), 1.12 (t, J 
= 7.2 Hz, 3 H), 1.11 (t, J = 7.0 Hz, 3 H); 1H NMR (100 MHz, CDCl3) δ 172.0, 139.0, 135.4, 
129.2, 128.5, 42.1, 40.2, 35.1, 32.4, 27.1, 21.1, 14.5, 13.3; HRMS (ASAP) m/z calcd for 
C15H24NO (M+H) 234.1858, found 234.1830.  
 
(6aR,9aR)-7,9,9a-Trimethyl-4,6,6a,7,9,9a-hexahydro-8H-indolo[6,5,4-cd]indol-8-one.  
Conditions A. An oven-dried flask containing a stir bar was charged with a dark blue solution of 
SmI2 in THF (1.9 mL, 0.1 M solution, 1.9 mmol, 8 Eq.) under an atmosphere of nitrogen, 
followed by degassed Et3N (0.24 mL, 1.7 mmol, 72 Eq.) and degassed water (0.031 mL, 1.7 
mmol, 72 Eq.) and stirred vigorously. The resulting dark brown solution was treated dropwise 
N
H
N H
O
N
H
N H
O
2.160ent-2.110
Conditions A:    SmI2 (24 eq.), NEt3 (72 eq.)
                          H2O (72 eq.), THF, 4 h, ~12.5% 2.160
Conditions B:     Li (~ 12 eq), anhydrous EtNH2 
                          0 °C, 5 min; ~36% 2.160
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with a solution of amide ent-2.110 (0.0060 g, 0.024 mmol, 1 Eq.) in THF (0.2 mL) and the 
resulting reaction stirred at room temperature for 30 min during which time the solution became 
a light green color then white. LCMS indicated mostly starting material amide ent-2.110. The 
reaction was stirred at room temperature for an additional 3.5 h during which time additional 
equivalence of SmI2 (2 x 1.9 mL, 2 x 8 equiv) was added. After which time LCMS showed 
consumption of starting material. Excess SmI2 was quenched by bubbling compressed air 
through solution, which turned yellow. The reaction was diluted with CH2Cl2 and 1M NaOH. 
The separated aqueous layer was extracted (3x CH2Cl2) and the combined organic layers dried 
(Na2SO4) and concentrated. The resulting reside was purified by chromatography to deliver the 
tentatively assigned cyclopropane cleavage product 2.160 (0.75 mg, ~12.5%) as a white film: 1H 
NMR (500 MHz, CD2Cl2) δ 8.16 (bs, 1 H), 7.23 (d, J = 8.0 Hz, 1 H), 7.11 (ap. t, J = 7.8 Hz, 1 
H), 7.03 (s, 1 H), 6.96 (d, J = 7.0 Hz, 1 H), 3.52 (dd, J = 12.8, 4.8 Hz, 1 H), 3.32 (dd, J = 14.0, 
4.5 Hz, 1 H), 2.88 (s, 3 H), 2.84 (ap. td, J = 13.5, 2.4 Hz, 1 H), 2.69 (q, J = 7.0 Hz, 1 H), 1.47 (d, 
J = 7.0 Hz, 3 H), 1.00 (s, 3 H); HRMS (LCMS ESI+) m/z calcd for C16H19NO2 (M+H) 255.1492, 
found 255.1489.  
Conditions B: A solution of amide ent-2.110 (0.0060 g, 0.024 mmol) in anhydrous ethylamine 
(1.2 mL) was cooled to 0 °C under an atmosphere of argon and treated with approx. 2 mg of Li 
and stirred until the solution color remained dark blue. After 5 min the solution was quenched 
with a small amount of sat. NH4Cl solution and Et2O, stirred for 30 min then evaporated to 
dryness, suspended in CH2Cl2, dried with Na2SO4, filtered and concentrated. The resulting 
residue was purified by chromatography on SiO2 (0-5% MeOH/CH2Cl2) delivering the 
tentatively assigned amide 2.160 (~2.16 mg, 36%) and an unidentified byproduct.   
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2,2,6,6-Tetramethylpiperidin-1-yl 1H-indole-1-carboxylate (2.171). An oven-dried 
round bottom flask charged with 90% NaH (0.147 g, 5.49 mmol) in THF (30 mL) was cooled to 
0 °C, stirred at this temperature for 5 min and then treated with a solution of indole 2.169 (0.500 
g, 4.23 mmol) in THF (2 mL). The off-white, cloudy mixture was stirred for 30 min at 0 °C then 
treated with a solution of mixed anhydride 2.170 (1.64 g, 5.07 mmol) in THF (10 mL). The 
bright orange reaction was then stirred for 1 h while allowing the solution to slowly warm to 
room temperature. After 1 h the reaction was quenched with DI H2O. EtOAc and Na2CO3 were 
added. The separated organic layer was extracted with EtOAc (2x) and the combined organic 
layers washed with brine, dried and concentrated under reduced pressure to afford a yellow 
residue which was purified by chromatography on SiO2 (0-2% EtOAc/Hex) to afford protected 
indole 2.171 (1.14 g, 90%) as a white solid: 1H NMR (300 MHz, CD2Cl2) δ 8.21 (d, J = 8.4 Hz, 
1 H), 7.68 (d, J = 3.9 Hz, 1 H), 7.60 (d, J = 7.2 Hz, 1 H), 7.34 (td, J = 7.7, 1.3 Hz, 1 H), 7.25 (td, 
J = 7.5, 1.4 Hz, 1 H), 6.65 (dd, J = 3.8, 0.8 Hz, 1 H), 1.75-1.62 (m, 5 H), 1.49-1.47 (m, 1 H), 
1.32 (s, 6 H), 1.16 (s, 6 H); HRMS (LCMS ESI+) m/z calcd for C18H25N2O2 (M+H) 301.1911, 
found 301.1906. 
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Thermolysis of TEMPOC-protected indole 
 
Thermolysis Experiment 1 (Entry 1): A microwave vial was charged with protected 
indole 2.171 (0.150 g, 0.499 mmol) in C6D5CD3 (0.5 mL) was heated in a sealed tube in an oil 
bath maintaining the external temperature at 150 C °C. After 20 h, the brown reaction was 
removed from the oil bath and allowed to cool to room temperature. 1H NMR analysis of the 
crude reaction showed ~ 3.6: 1 ratio of pyrrolidine 2.173: tetramethylpiperidine 2.172.   
 
Figure 3-19 Thermolysis experiment 1: crude 1H NMR spectrum 
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Thermolysis Experiment 2 (Entry 2): A microwave vial charged with protected indole 
2.171 (0.150 g, 0.499 mmol) in C6D5CD3 (0.5 mL) was subjected to 4 cycles of freeze pump 
thaw and on the last cycle an atmosphere of nitrogen introduced and the capped microwave vial 
sealed with additional teflon and parafilm. The reaction was then heated in a silicone oil bath 
maintaining the external temperature at 150 C °C for 9 h during which time the reaction turned 
from clear and colorless to dark brown. The reaction was cooled to room temperature. TLC 
indicated reaction completion. 1H NMR analysis of the crude reaction showed 1.0: 2.3: 0.98 ratio 
of tetramethylpiperidine 2.169: pyrrolidine 2.172: pyrrolidine enamine 2.175. 
 
Figure 3-20 Thermolysis experiment 2: crude 1H NMR spectrum  
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Thermolysis Experiment 3 (Entry 3): A microwave vial charged with protected indole 
2.171 (0.100 g, 0.332 mmol) and HPLC grade water (0.024 mL, 1.33 mmol) in C6D5CD3 (0.33 
mL). The reaction was then heated in a silicone oil bath in the sealed microwave tube 
maintaining the external temperature at 150 °C. After heating 21.5h the brown reaction was 
cooled to room temperature and 1H NMR analysis of the reaction showed conversion to indole 
2.169 and a ~ 3.4: 1 ratio of pyrrolidine 2.173: tetramethylpiperidine 2.172.  The reaction was 
concentrated and the resulting brown residue purified by chromatography on SiO2 (0-10% 
EtOAc/Hex) to deliver indole 2.169 (0.034 g, 87%) as a tan solid: 1H NMR (400 MHz, CDCl3) δ 
8.15 (bs, 1 H), 7.66 (d, J = 7.2 Hz, 1 H), 7.41 (d, J = 8.0 Hz, 1 H), 7.40-7.18 (m, 2 H), 7.1407.10 
(m, 1 H), 6.57 (t, J = 2.2 Hz, 1 H). 
 
Figure 3-21 Thermolysis experiment 3: crude 1H NMR spectrum 
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Thermolysis Experiment 4 (Entry 4): A microwave vial was charged with protected 
indole 2.171 (0.100 g, 0.332 mmol) in C6D5CD3 (0.33 mL). The reaction was then heated in a 
silicone oil bath maintaining the external temperature between 135-140 °C for 32. 5 h during 
which time the reaction turns from clear and colorless to dark brown. After heating for 32.5 h the 
reaction was cooled to room temperature. 1H NMR analysis of the crude reaction showed ~ 1.8: 
1 ratio of pyrrolidine 2.173: tetramethylpiperidine 2.172. 
 
Figure 3-22 Thermolysis experiment 4: crude 1H NMR spectrum 
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2,2-Dimethylpyrrolidine Standard. A solution of commercially available 2,2-
dimethylpyrrolidine•HCl (0.050 g, 0.35 mmol) in NaOH (1.25 mL, 12N) was stirred vigorously 
at room temperature. After 1.5 h the solution was treated with tol-d8 (1 mL) and stirred 
vigorously. The separated organic layer was dried (Na2SO4). 1H NMR analysis of the organic 
layer showed full conversion to the free base 2.173: 1H NMR (400 MHz, PhMe-d8) δ 2.77 (t, J = 
7.0 Hz, 2 H), 1.57 (p, J = 7.3 Hz, 2 H), 1.30 (t, J = 7.6 Hz, 2 H), 1.01 (s, 6 H); 13C NMR (100 
MHz, tol-d8) δ 58.8, 46.3, 39.9, 28.9, 26.4  
 
 
Tetramethylpiperidine Standard. 1H NMR (400 MHz, PhMe-d8) δ 1.55-1.49 (m, 2 H), 
1.23-1.20 (m, 4 H), 1.03 (s, 12 H); 13C NMR (100 MHz, tol-d8) δ 49.6, 38.7, 32.0,18.9  
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APPENDIX A 
X-RAY DATA 
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Figure A-1 ORTEP structure of methylenecyclopropane 1.105.  
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Table A-1 Data Collection and Structure Refinement for Methylenecyclopropane 1.105 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus source, Cu 
Theta range for data collection 4.09 to 68.86° 
Index ranges -9<=h<=8, -10<=k<=10, -13<=l<=13 
Reflections collected 11743 
Independent reflections 4546 [R(int) = 0.0323] 
Absorption correction multi-scan 
Max. and min. transmission 0.6100 and 0.2500 
Structure solution technique direct methods 
Structure solution program SHELXS-97 (Sheldrick, 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-97 (Sheldrick, 2008) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4546 / 3 / 346 
Goodness-of-fit on F2 1.582 
Final R indices 4118 data; I>2σ(I) R1 = 0.0508, wR2 = 0.1505 
 all data R1 = 0.0555, wR2 = 0.1550 
Weighting scheme w=1/[σ
2(Fo2)+(0.0680P)2] 
where P=(Fo2+2Fc2)/3 
Absolute structure parameter 0.1(0) 
Largest diff. peak and hole 0.566 and -0.447 eÅ-3 
R.M.S. deviation from mean 0.063 eÅ-3 
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Table A-2 Atomic Coordinates and Equivalent Isotropic Atomic Displacement Parameters (Å2) for 
Methylenecyclopropane 1.105 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x/a y/b z/c U(eq) 
C1 0.9094(8) 0.0898(7) 0.4000(6) 0.0522(13) 
C2 0.0077(9) 0.1080(8) 0.2794(6) 0.0561(14) 
C3 0.0366(9) 0.2483(9) 0.2261(5) 0.0591(16) 
C4 0.9642(9) 0.3759(8) 0.2934(6) 0.0573(14) 
C5 0.8631(9) 0.3594(7) 0.4130(5) 0.0514(13) 
C6 0.8380(8) 0.2166(7) 0.4665(5) 0.0463(12) 
C7 0.8026(9) 0.2339(7) 0.6823(5) 0.0512(13) 
C8 0.6645(9) 0.2187(7) 0.7977(5) 0.0549(13) 
C9 0.4752(10) 0.2287(9) 0.7897(6) 0.0663(17) 
C10 0.5378(14) 0.0806(11) 0.8090(8) 0.090(3) 
C11 0.7246(14) 0.2727(12) 0.9130(6) 0.089(3) 
C12 0.3468(12) 0.3220(15) 0.7723(7) 0.100(3) 
C13 0.3673(9) 0.6379(8) 0.4052(6) 0.0574(15) 
C14 0.4666(10) 0.6342(9) 0.2870(7) 0.0662(18) 
C15 0.5368(9) 0.7653(10) 0.2269(6) 0.0655(18) 
C16 0.5014(10) 0.9021(9) 0.2879(6) 0.0629(16) 
C17 0.4022(10) 0.9071(8) 0.4086(6) 0.0615(16) 
C18 0.3384(9) 0.7744(8) 0.4670(5) 0.0547(14) 
C19 0.3090(9) 0.7541(8) 0.6820(6) 0.0561(14) 
C20 0.1741(12) 0.7621(12) 0.7997(6) 0.084(2) 
C21 0.9899(12) 0.7618(12) 0.7959(7) 0.086(2) 
C22 0.0345(19) 0.9124(14) 0.8119(11) 0.120(4) 
C23 0.2460(15) 0.7232(12) 0.9130(7) 0.093(3) 
C24 0.863(2) 0.664(2) 0.7811(10) 0.144(6) 
Cl1 0.8717(3) 0.9173(2) 0.4685(2) 0.0826(6) 
Cl2 0.0908(3) 0.9516(3) 0.1955(2) 0.0900(7) 
Cl3 0.1551(3) 0.2691(3) 0.07691(16) 0.0921(7) 
Cl4 0.9979(3) 0.5523(3) 0.2305(2) 0.0940(7) 
Cl5 0.7679(3) 0.5103(2) 0.49704(18) 0.0748(5) 
Cl6 0.2764(4) 0.4812(3) 0.4833(3) 0.1008(8) 
Cl7 0.5065(4) 0.4643(4) 0.2138(3) 0.1213(11) 
Cl8 0.6578(3) 0.7588(5) 0.07831(18) 0.1178(12) 
Cl9 0.5781(4) 0.0647(4) 0.2134(3) 0.1207(11) 
Cl10 0.3587(4) 0.0727(3) 0.4860(3) 0.1085(9) 
O1 0.7294(6) 0.1998(6) 0.5810(4) 0.0594(11) 
 212 
 x/a y/b z/c U(eq) 
O2 0.9540(6) 0.2677(7) 0.6725(4) 0.0685(12) 
O3 0.2320(7) 0.7838(9) 0.5817(4) 0.086(2) 
O4 0.4647(7) 0.7296(6) 0.6689(4) 0.0691(12) 
     
 
Table A-3 Bond Lengths (Å) for Methylenecyclopropane 1.105  
C1-C6 1.394(9) C1-C2 1.396(10) 
C1-Cl1 1.707(7) C2-C3 1.377(11) 
C2-Cl2 1.717(7) C3-C4 1.405(11) 
C3-Cl3 1.717(6) C4-C5 1.393(9) 
C4-Cl4 1.712(7) C5-C6 1.396(9) 
C5-Cl5 1.705(6) C6-O1 1.369(7) 
C7-O2 1.175(8) C7-O1 1.380(7) 
C7-C8 1.483(8) C8-C9 1.461(10) 
C8-C11 1.518(9) C8-C10 1.557(11) 
C9-C12 1.317(12) C9-C10 1.427(13) 
C10-H10A 0.98 C10-H10B 0.98 
C11-H11A 0.97 C11-H11B 0.97 
C11-H11C 0.97 C12-H12A 0.94 
C12-H12B 0.94 C13-C14 1.367(10) 
C13-C18 1.389(11) C13-Cl6 1.711(7) 
C14-C15 1.395(12) C14-Cl7 1.713(8) 
C15-C16 1.392(12) C15-Cl8 1.708(7) 
C16-C17 1.390(10) C16-Cl9 1.708(7) 
C17-C18 1.385(11) C17-Cl10 1.703(7) 
C18-O3 1.358(7) C19-O4 1.181(8) 
C19-O3 1.375(7) C19-C20 1.483(9) 
C20-C21 1.409(13) C20-C23 1.499(11) 
C20-C22 1.688(16) C21-C24 1.343(18) 
C21-C22 1.406(17) C22-H22A 0.98 
C22-H22B 0.98 C23-H23A 0.97 
C23-H23B 0.97 C23-H23C 0.97 
C24-H24A 0.94 C24-H24B 0.94 
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Table A-4 Bond Angles (°) for Methylenecyclopropane 1.105  
C6-C1-C2 118.9(6) C6-C1-Cl1 118.8(5) 
C2-C1-Cl1 122.3(5) C3-C2-C1 121.3(6) 
C3-C2-Cl2 119.6(5) C1-C2-Cl2 119.1(6) 
C2-C3-C4 119.7(6) C2-C3-Cl3 120.9(6) 
C4-C3-Cl3 119.4(6) C5-C4-C3 119.7(6) 
C5-C4-Cl4 119.3(6) C3-C4-Cl4 121.0(5) 
C4-C5-C6 119.9(6) C4-C5-Cl5 121.5(5) 
C6-C5-Cl5 118.6(5) O1-C6-C1 119.6(6) 
O1-C6-C5 119.7(6) C1-C6-C5 120.5(5) 
O2-C7-O1 122.2(6) O2-C7-C8 127.8(5) 
O1-C7-C8 110.0(5) C9-C8-C7 118.5(5) 
C9-C8-C11 120.1(6) C7-C8-C11 114.1(6) 
C9-C8-C10 56.3(6) C7-C8-C10 117.4(6) 
C11-C8-C10 118.5(6) C12-C9-C10 150.8(10) 
C12-C9-C8 143.9(9) C10-C9-C8 65.2(6) 
C9-C10-C8 58.4(5) C9-C10-H10A 117.9 
C8-C10-H10A 117.9 C9-C10-H10B 117.9 
C8-C10-H10B 117.9 H10A-C10-H10B 115.1 
C8-C11-H11A 109.5 C8-C11-H11B 109.5 
H11A-C11-H11B 109.5 C8-C11-H11C 109.5 
H11A-C11-H11C 109.5 H11B-C11-H11C 109.5 
C9-C12-H12A 120.0 C9-C12-H12B 120.0 
H12A-C12-H12B 120.0 C14-C13-C18 119.4(7) 
C14-C13-Cl6 123.3(6) C18-C13-Cl6 117.4(5) 
C13-C14-C15 121.1(7) C13-C14-Cl7 118.8(7) 
C15-C14-Cl7 120.1(6) C16-C15-C14 119.1(6) 
C16-C15-Cl8 120.5(6) C14-C15-Cl8 120.4(7) 
C17-C16-C15 120.3(7) C17-C16-Cl9 119.9(6) 
C15-C16-Cl9 119.7(6) C18-C17-C16 119.2(6) 
C18-C17-Cl10 119.5(6) C16-C17-Cl10 121.3(6) 
O3-C18-C17 117.8(7) O3-C18-C13 121.0(7) 
C17-C18-C13 120.9(6) O4-C19-O3 120.9(6) 
O4-C19-C20 127.7(6) O3-C19-C20 111.4(6) 
C21-C20-C19 119.1(6) C21-C20-C23 123.7(8) 
C19-C20-C23 114.5(8) C21-C20-C22 53.1(7) 
C19-C20-C22 114.7(8) C23-C20-C22 116.0(8) 
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C24-C21-C22 147.4(13) C24-C21-C20 138.9(12) 
C22-C21-C20 73.7(9) C21-C22-C20 53.3(7) 
C21-C22-H22A 118.4 C20-C22-H22A 118.4 
C21-C22-H22B 118.4 C20-C22-H22B 118.4 
H22A-C22-H22B 115.7 C20-C23-H23A 109.5 
C20-C23-H23B 109.5 H23A-C23-H23B 109.5 
C20-C23-H23C 109.5 H23A-C23-H23C 109.5 
H23B-C23-H23C 109.5 C21-C24-H24A 120.0 
C21-C24-H24B 120.0 H24A-C24-H24B 120.0 
C6-O1-C7 117.0(5) C18-O3-C19 117.9(5) 
 
Table A-5 Anisotropic Atomic Displacement Parameters (Å2) for Methylenecyclopropane 1.105. 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 
C1 0.046(3) 0.057(3) 0.055(3) -0.003(3) -0.013(2) -0.002(3) 
C2 0.045(3) 0.071(4) 0.055(3) -0.013(3) -0.016(2) -0.002(3) 
C3 0.047(3) 0.093(5) 0.039(3) 0.002(3) -0.011(2) -0.003(3) 
C4 0.054(4) 0.068(4) 0.050(3) 0.008(3) -0.011(2) -0.003(3) 
C5 0.053(3) 0.053(3) 0.049(3) 0.001(2) -0.011(2) -0.001(3) 
C6 0.040(3) 0.060(3) 0.039(3) -0.005(2) -0.007(2) -0.003(2) 
C7 0.056(4) 0.054(3) 0.046(3) 0.000(2) -0.016(2) -0.003(3) 
C8 0.062(3) 0.061(3) 0.039(3) 0.008(2) -0.004(2) -0.007(3) 
C9 0.070(4) 0.084(5) 0.041(3) 0.004(3) -0.002(3) -0.005(4) 
C10 0.112(7) 0.080(5) 0.070(5) 0.012(4) 0.003(4) -0.035(5) 
C11 0.113(6) 0.117(7) 0.039(3) -0.008(4) -0.018(4) -0.017(6) 
C12 0.078(5) 0.154(10) 0.062(4) -0.004(5) -0.004(4) 0.021(6) 
C13 0.051(3) 0.069(4) 0.054(3) 0.012(3) -0.015(3) -0.011(3) 
C14 0.063(4) 0.076(4) 0.065(4) -0.019(3) -0.027(3) 0.009(3) 
C15 0.048(3) 0.109(6) 0.040(3) 0.007(3) -0.011(2) -0.007(4) 
C16 0.058(4) 0.079(4) 0.057(3) 0.019(3) -0.024(3) -0.009(3) 
C17 0.064(4) 0.062(4) 0.064(4) -0.006(3) -0.027(3) 0.009(3) 
C18 0.045(3) 0.080(4) 0.040(3) 0.002(3) -0.011(2) 0.001(3) 
C19 0.058(4) 0.067(4) 0.044(3) -0.002(2) -0.013(2) -0.003(3) 
C20 0.083(5) 0.128(7) 0.040(3) -0.011(4) -0.005(3) -0.007(5) 
C21 0.075(5) 0.112(7) 0.060(4) -0.001(4) 0.011(3) 0.003(5) 
C22 0.162(11) 0.101(8) 0.086(6) -0.013(6) 0.003(6) 0.025(8) 
C23 0.133(8) 0.103(7) 0.045(3) -0.002(4) -0.022(4) -0.012(6) 
C24 0.127(10) 0.213(18) 0.086(7) -0.017(8) -0.003(6) -0.057(11) 
 215 
 U11 U22 U33 U23 U13 U12 
Cl1 0.0941(14) 0.0611(10) 0.0946(13) 0.0072(8) -0.0234(11) -0.0079(9) 
Cl2 0.0849(14) 0.0986(15) 0.0863(13) -0.0462(12) -0.0164(10) 0.0180(11) 
Cl3 0.0751(11) 0.153(2) 0.0425(8) -0.0028(9) 0.0027(7) -0.0093(12) 
Cl4 0.1016(16) 0.0896(14) 0.0872(13) 0.0377(11) -0.0114(11) -0.0045(12) 
Cl5 0.0804(11) 0.0656(10) 0.0768(10) -0.0124(8) -0.0127(8) 0.0182(9) 
Cl6 0.1095(18) 0.0903(15) 0.1139(16) 0.0408(13) -0.0483(14) -0.0462(13) 
Cl7 0.128(2) 0.112(2) 0.132(2) -0.0714(18) -0.0449(18) 0.0266(17) 
Cl8 0.0748(12) 0.232(4) 0.0412(8) 0.0095(12) 0.0018(7) 0.0085(16) 
Cl9 0.115(2) 0.1187(19) 0.144(2) 0.0796(18) -0.0628(17) -0.0474(16) 
Cl10 0.120(2) 0.0815(14) 0.138(2) -0.0419(14) -0.0598(17) 0.0295(14) 
O1 0.049(2) 0.088(3) 0.039(2) -0.0031(19) -0.0029(16) -0.012(2) 
O2 0.054(3) 0.096(4) 0.057(2) 0.000(2) -0.0156(19) -0.015(3) 
O3 0.058(3) 0.162(6) 0.037(2) 0.000(3) -0.0049(19) 0.013(3) 
O4 0.068(3) 0.087(3) 0.055(2) -0.004(2) -0.018(2) 0.005(3) 
 
Table A-6 Hydrogen Atomic Coordinates and Isotropic Atomic Displacement Parameters (Å2) for 
Methylenecyclopropane 1.105 
 x/a y/b z/c U(eq) 
H10A 0.5545 0.0102 0.7394 0.108 
H10B 0.4986 0.0349 0.8910 0.108 
H11A 0.7418 0.3806 0.9080 0.134 
H11B 0.8369 0.2234 0.9192 0.134 
H11C 0.6336 0.2487 0.9856 0.134 
H12A 0.2322 0.2850 0.7694 0.12 
H12B 0.3697 0.4254 0.7628 0.12 
H22A -0.0059 0.9581 0.8936 0.144 
H22B 0.0452 0.9811 0.7411 0.144 
H23A 0.2965 0.6224 0.9049 0.139 
H23B 0.1492 0.7280 0.9855 0.139 
H23C 0.3386 0.7941 0.9220 0.139 
H24A -0.2539 0.6978 0.7791 0.173 
H24B -0.1092 0.5605 0.7727 0.173 
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Figure A-2 ORTEP structure of ketone (±)-2.86 
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Table A-7 Data Collection and Structure Refinement for Ketone (±)-2.86 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus, Cu 
Theta range for data collection 5.23 to 68.22° 
Index ranges -7<=h<=8, -12<=k<=13, -15<=l<=16 
Reflections collected 6297 
Independent reflections 1762 [R(int) = 0.0394] 
Coverage of independent reflections 96.9% 
Absorption correction multi-scan 
Max. and min. transmission 0.8980 and 0.7200 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2013 (Sheldrick, 2013) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 1762 / 0 / 127 
Goodness-of-fit on F2 3.255 
Final R indices 1639 data; I>2σ(I) R1 = 0.1109, wR2 = 0.2851 
 all data R1 = 0.1135, wR2 = 0.2861 
Weighting scheme w=1/[σ
2(Fo2)+(0.0680P)2] 
where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.650 and -0.432 eÅ-3 
R.M.S. deviation from mean 0.126 eÅ-3 
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Table A-8 Atomic Coordinates and Equivalent Isotropic Atomic Displacement Parameters (Å2) for Ketone (±)-2.86. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x/a y/b z/c U(eq) 
O1 0.0224(4) 0.9844(2) 0.7226(2) 0.0381(7) 
O2 0.9272(4) 0.6922(3) 0.6518(2) 0.0512(9) 
N1 0.3009(4) 0.9050(3) 0.6553(2) 0.0315(7) 
C1 0.1848(5) 0.9371(3) 0.7317(2) 0.0292(8) 
C2 0.4996(5) 0.8724(3) 0.6886(2) 0.0291(8) 
C3 0.5962(6) 0.7631(3) 0.6392(2) 0.0348(9) 
C4 0.7842(5) 0.7290(3) 0.6951(3) 0.0331(9) 
C5 0.7852(5) 0.7314(3) 0.8077(3) 0.0319(8) 
C6 0.6745(5) 0.8406(3) 0.8527(2) 0.0324(8) 
C7 0.4814(5) 0.8480(3) 0.7981(2) 0.0263(8) 
C8 0.3199(5) 0.7594(3) 0.8246(3) 0.0302(8) 
C9 0.2853(5) 0.8985(3) 0.8271(2) 0.0270(8) 
C10 0.2416(6) 0.9656(3) 0.9212(3) 0.0361(9) 
C11 0.2457(7) 0.9283(4) 0.5531(3) 0.0498(11) 
 
Table A-9 Bond Lengths (Å) for Ketone (±)-2.86. 
O1-C1 1.224(4) O2-C4 1.218(5) 
N1-C1 1.362(4) N1-C11 1.439(5) 
N1-C2 1.459(5) C1-C9 1.499(5) 
C2-C7 1.507(4) C2-C3 1.521(4) 
C2-H2A 1.0 C3-C4 1.513(5) 
C3-H3A 0.99 C3-H3B 0.99 
C4-C5 1.516(5) C5-C6 1.540(4) 
C5-H5A 0.99 C5-H5B 0.99 
C6-C7 1.491(5) C6-H6A 0.99 
C6-H6B 0.99 C7-C8 1.514(4) 
C7-C9 1.507(4) C8-C9 1.531(4) 
C8-H8A 0.99 C8-H8B 0.99 
C9-C10 1.500(4) C10-H10A 0.98 
C10-H10B 0.98 C10-H10C 0.98 
C11-H11A 0.98 C11-H11B 0.98 
C11-H11C 0.98   
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Table A-10 Bond Angles (°) for Ketone (±)-2.86 
C1-N1-C11 122.5(3) C1-N1-C2 112.6(3) 
C11-N1-C2 123.5(3) O1-C1-N1 125.2(3) 
O1-C1-C9 126.4(3) N1-C1-C9 108.4(3) 
N1-C2-C7 104.0(2) N1-C2-C3 117.7(3) 
C7-C2-C3 109.8(3) N1-C2-H2A 108.3 
C7-C2-H2A 108.3 C3-C2-H2A 108.3 
C2-C3-C4 110.1(3) C2-C3-H3A 109.6 
C4-C3-H3A 109.6 C2-C3-H3B 109.6 
C4-C3-H3B 109.6 H3A-C3-H3B 108.1 
O2-C4-C5 120.3(4) O2-C4-C3 121.3(3) 
C5-C4-C3 118.2(3) C4-C5-C6 114.7(3) 
C4-C5-H5A 108.6 C6-C5-H5A 108.6 
C4-C5-H5B 108.6 C6-C5-H5B 108.6 
H5A-C5-H5B 107.6 C7-C6-C5 106.4(3) 
C7-C6-H6A 110.4 C5-C6-H6A 110.4 
C7-C6-H6B 110.4 C5-C6-H6B 110.4 
H6A-C6-H6B 108.6 C6-C7-C8 119.1(3) 
C6-C7-C2 113.3(3) C8-C7-C2 115.1(3) 
C6-C7-C9 132.0(3) C8-C7-C9 60.9(2) 
C2-C7-C9 106.8(3) C7-C8-C9 59.34(19) 
C7-C8-H8A 117.8 C9-C8-H8A 117.8 
C7-C8-H8B 117.8 C9-C8-H8B 117.8 
H8A-C8-H8B 115.0 C1-C9-C10 119.4(3) 
C1-C9-C7 105.4(2) C10-C9-C7 126.6(3) 
C1-C9-C8 109.0(3) C10-C9-C8 122.2(3) 
C7-C9-C8 59.8(2) C9-C10-H10A 109.5 
C9-C10-H10B 109.5 H10A-C10-H10B 109.5 
C9-C10-H10C 109.5 H10A-C10-H10C 109.5 
H10B-C10-H10C 109.5 N1-C11-H11A 109.5 
N1-C11-H11B 109.5 H11A-C11-H11B 109.5 
N1-C11-H11C 109.5 H11A-C11-H11C 109.5 
H11B-C11-H11C 109.5   
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Table A-11 Anisotropic Atomic Displacement Parameters (Å2) for Ketone (±)-2.86 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ]   
 U11 U22 U33 U23 U13 U12 
O1 0.0285(13) 0.0263(13) 0.0595(16) 0.0047(9) 0.0047(11) 0.0067(9) 
O2 0.0309(16) 0.0590(18) 0.0644(18) -0.0273(14) 0.0112(13) 0.0050(12) 
N1 0.0289(16) 0.0321(14) 0.0336(14) 0.0020(10) 0.0033(11) 0.0035(11) 
C1 0.0275(17) 0.0176(14) 0.0429(18) -0.0003(11) 0.0059(13) -0.0020(12) 
C2 0.0250(17) 0.0277(16) 0.0350(16) -0.0030(11) 0.0059(12) 0.0020(12) 
C3 0.035(2) 0.0364(18) 0.0336(16) -0.0076(12) 0.0091(14) 0.0029(13) 
C4 0.0255(18) 0.0251(15) 0.0491(19) -0.0113(12) 0.0095(14) -0.0026(12) 
C5 0.0208(17) 0.0279(16) 0.0471(19) -0.0030(12) 0.0025(13) 0.0029(12) 
C6 0.0275(18) 0.0332(17) 0.0369(16) -0.0056(12) 0.0051(13) -0.0010(12) 
C7 0.0227(17) 0.0230(15) 0.0336(15) -0.0033(10) 0.0064(12) 0.0015(11) 
C8 0.0236(17) 0.0238(16) 0.0437(17) 0.0017(11) 0.0068(13) -0.0003(11) 
C9 0.0232(17) 0.0240(15) 0.0341(16) -0.0016(11) 0.0076(12) 0.0021(11) 
C10 0.0364(19) 0.0353(18) 0.0371(17) -0.0047(13) 0.0118(14) 0.0058(13) 
C11 0.050(3) 0.059(3) 0.040(2) 0.0046(16) 0.0004(17) 0.0117(19) 
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Table A-12 Hydrogen Atomic Coordinates and Isotropic Atomic Displacement Parameters (Å2) for Ketone (±)-2.86 
 x/a y/b z/c U(eq) 
H2A 0.5857 0.9460 0.6804 0.035 
H3A 0.6255 0.7840 0.5697 0.042 
H3B 0.5053 0.6921 0.6384 0.042 
H5A 0.9231 0.7335 0.8328 0.038 
H5B 0.7259 0.6540 0.8314 0.038 
H6A 0.6552 0.8270 0.9244 0.039 
H6B 0.7494 0.9178 0.8444 0.039 
H8A 0.3327 0.7155 0.8889 0.036 
H8B 0.2555 0.7118 0.7702 0.036 
H10A 0.2236 1.0533 0.9068 0.054 
H10B 0.3512 0.9550 0.9691 0.054 
H10C 0.1215 0.9324 0.9491 0.054 
H11A 0.1059 0.9489 0.5480 0.075 
H11B 0.2707 0.8546 0.5134 0.075 
H11C 0.3231 0.9971 0.5282 0.075 
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Figure A-3 ORTEP structure of  allylic alcohol (±)-2.111 
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Table A-13 Date Collection and Structure Refinement for Allylic Alcohol (±)-2.111 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus, Cu 
Theta range for data collection 3.76 to 68.50° 
Index ranges -10<=h<=10, -23<=k<=22, -16<=l<=18 
Reflections collected 14241 
Independent reflections 4735 [R(int) = 0.1006] 
Coverage of independent reflections 98.8% 
Absorption correction multi-scan 
Max. and min. transmission 0.9540 and 0.8820 
Structure solution technique direct methods 
Structure solution program SHELXL-2014/6 (Sheldrick, 2014) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014/6 (Sheldrick, 2014) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / parameters 4735 / 0 / 317 
Goodness-of-fit on F2 1.152 
Δ/σmax 0.444 
Final R indices 2672 data; I>2σ(I) R1 = 0.0922, wR2 = 0.1973 
 all data R1 = 0.1407, wR2 = 0.2252 
Weighting scheme w=1/[σ2(Fo2)+(0.0680P)2] where P=(Fo2+2Fc2)/3 
Largest diff. peak and hole 0.544 and -0.279 eÅ-3 
R.M.S. deviation from mean 0.113 eÅ-3 
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Table A-14 Atomic Coordinates and Equivalent Isotropic Atomic Displacement Parameters (Å2) for Allylic Alcohol 
(±)-2.111  
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 x/a y/b z/c U(eq) O1 0.3718(3) 0.71375(13) 0.52526(16) 0.0516(6) 
N1 0.5116(3) 0.64695(15) 0.63095(19) 0.0496(7) 
C1 0.2265(5) 0.81229(19) 0.4733(3) 0.0568(9) 
O2 0.2715(3) 0.67526(13) 0.64034(17) 0.0552(6) 
N2 0.1017(3) 0.51393(16) 0.7153(2) 0.0502(7) 
C2 0.0738(5) 0.8347(2) 0.4110(3) 0.0678(11) 
O3 0.6186(3) 0.50353(15) 0.67015(19) 0.0611(7) 
C3 0.0408(5) 0.8023(2) 0.3182(3) 0.0720(12) 
O4 0.9160(3) 0.48706(15) 0.78893(18) 0.0625(7) 
C4 0.0416(5) 0.7250(2) 0.3283(3) 0.0668(11) 
O5 0.7218(4) 0.7042(2) 0.6037(3) 0.0996(12) 
C5 0.1922(4) 0.69733(19) 0.3868(3) 0.0559(9) 
N3 0.2205(3) 0.73570(14) 0.47447(19) 0.0482(7) 
C7 0.3604(5) 0.8431(2) 0.4429(3) 0.0720(12) 
C8 0.2333(6) 0.8356(2) 0.5698(3) 0.0736(12) 
C9 0.3164(5) 0.7003(2) 0.3358(3) 0.0704(11) 
C10 0.1692(5) 0.6225(2) 0.4119(3) 0.0710(12) 
C11 0.3728(4) 0.67788(17) 0.6028(2) 0.0458(8) 
C12 0.5498(4) 0.61392(19) 0.7211(2) 0.0490(8) 
C13 0.5255(4) 0.53573(18) 0.7206(2) 0.0454(8) 
C14 0.3612(4) 0.51508(18) 0.6747(2) 0.0466(8) 
C15 0.2649(4) 0.52448(17) 0.7410(2) 0.0439(8) 
C16 0.0485(4) 0.48754(19) 0.7840(2) 0.0496(9) 
C17 0.1795(4) 0.45581(19) 0.8527(2) 0.0504(8) 
C18 0.2570(5) 0.40365(19) 0.8060(3) 0.0590(10) 
C19 0.3184(4) 0.47538(17) 0.8191(2) 0.0463(8) 
C20 0.4791(4) 0.48566(19) 0.8650(2) 0.0496(8) 
C21 0.5722(4) 0.51259(19) 0.8194(2) 0.0501(9) 
C22 0.0055(4) 0.5512(2) 0.6400(3) 0.0603(10) 
C23 0.1694(5) 0.4478(2) 0.9491(3) 0.0688(11) 
C24 0.6214(4) 0.6528(2) 0.5824(3) 0.0621(11) 
C25 0.6469(5) 0.6171(3) 0.5111(3) 0.0795(13) 
C26 0.7654(6) 0.6461(4) 0.4848(4) 0.0994(18) 
C27 0.8131(5) 0.6977(4) 0.5412(4) 0.102(2) 
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Table A-15 Bond lengths (Å) for Allylic Alcohol (±)-2.111 
O1-C11 1.368(4) O1-N3 1.462(4) 
N1-C11 1.366(5) N1-C24 1.383(5) 
N1-C12 1.476(4) C1-N3 1.497(5) 
C1-C8 1.521(6) C1-C7 1.525(6) 
C1-C2 1.534(6) O2-C11 1.196(4) 
N2-C16 1.354(5) N2-C15 1.448(4) 
N2-C22 1.452(5) C2-C3 1.505(6) 
C2-H2A 0.98 C2-H2B 0.98 
O3-C13 1.419(4) O3-H3 0.87(5) 
C3-C4 1.517(6) C3-H3A 0.98 
C3-H3B 0.98 O4-C16 1.222(4) 
C4-C5 1.531(6) C4-H4A 0.98 
C4-H4B 0.98 O5-C24 1.339(6) 
O5-C27 1.412(7) C5-N3 1.494(5) 
C5-C9 1.517(6) C5-C10 1.538(6) 
C7-H7A 0.97 C7-H7B 0.97 
C7-H7C 0.97 C8-H8A 0.97 
C8-H8B 0.97 C8-H8C 0.97 
C9-H9A 0.97 C9-H9B 0.97 
C9-H9C 0.97 C10-H10A 0.97 
C10-H10B 0.97 C10-H10C 0.97 
C12-C13 1.542(5) C12-H12A 0.98 
C12-H12B 0.98 C13-C21 1.524(5) 
C13-C14 1.534(5) C14-C15 1.497(5) 
C14-H14A 0.98 C14-H14B 0.98 
C15-C19 1.509(5) C15-H15A 0.99 
C16-C17 1.506(5) C17-C23 1.497(5) 
C17-C18 1.509(5) C17-C19 1.519(5) 
C18-C19 1.502(5) C18-H18A 0.98 
C18-H18B 0.98 C19-C20 1.465(5) 
C20-C21 1.326(5) C20-H20A 0.94 
C21-H21A 0.94 C22-H22A 0.97 
C22-H22B 0.97 C22-H22C 0.97 
C23-H23A 0.97 C23-H23B 0.97 
C23-H23C 0.97 C24-C25 1.354(7) 
C25-C26 1.358(7) C25-H25A 0.94 
C26-C27 1.324(9) C26-H26A 0.94 
C27-H27A 0.94    
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Table A-16 Bond Angles (°) for Allylic Alcohol (±)-2.111 
C11-O1-N3 114.2(2) C11-N1-C24 121.7(3) 
C11-N1-C12 118.1(3) C24-N1-C12 119.8(3) 
N3-C1-C8 106.3(3) N3-C1-C7 115.6(3) 
C8-C1-C7 109.1(3) N3-C1-C2 105.2(3) 
C8-C1-C2 109.0(4) C7-C1-C2 111.4(3) 
C16-N2-C15 112.4(3) C16-N2-C22 122.6(3) 
C15-N2-C22 121.0(3) C3-C2-C1 113.5(4) 
C3-C2-H2A 108.9 C1-C2-H2A 108.9 
C3-C2-H2B 108.9 C1-C2-H2B 108.9 
H2A-C2-H2B 107.7 C13-O3-H3 120.(3) 
C2-C3-C4 109.2(3) C2-C3-H3A 109.9 
C4-C3-H3A 109.8 C2-C3-H3B 109.8 
C4-C3-H3B 109.8 H3A-C3-H3B 108.3 
C3-C4-C5 113.0(3) C3-C4-H4A 109.0 
C5-C4-H4A 109.0 C3-C4-H4B 109.0 
C5-C4-H4B 109.0 H4A-C4-H4B 107.8 
C24-O5-C27 104.2(5) N3-C5-C9 116.8(3) 
N3-C5-C4 105.8(3) C9-C5-C4 111.0(4) 
N3-C5-C10 105.0(3) C9-C5-C10 109.0(3) 
C4-C5-C10 108.8(3) O1-N3-C1 105.5(2) 
O1-N3-C5 104.8(3) C1-N3-C5 119.3(3) 
C1-C7-H7A 109.5 C1-C7-H7B 109.5 
H7A-C7-H7B 109.5 C1-C7-H7C 109.5 
H7A-C7-H7C 109.5 H7B-C7-H7C 109.5 
C1-C8-H8A 109.5 C1-C8-H8B 109.5 
H8A-C8-H8B 109.5 C1-C8-H8C 109.5 
H8A-C8-H8C 109.5 H8B-C8-H8C 109.5 
C5-C9-H9A 109.5 C5-C9-H9B 109.5 
H9A-C9-H9B 109.5 C5-C9-H9C 109.5 
H9A-C9-H9C 109.5 H9B-C9-H9C 109.5 
C5-C10-H10A 109.5 C5-C10-H10B 109.5 
H10A-C10-H10B 109.5 C5-C10-H10C 109.5 
H10A-C10-H10C 109.5 H10B-C10-H10C 109.5 
O2-C11-O1 126.2(3) O2-C11-N1 126.0(3) 
O1-C11-N1 107.8(3) N1-C12-C13 115.3(3) 
N1-C12-H12A 108.5 C13-C12-H12A 108.5 
N1-C12-H12B 108.5 C13-C12-H12B 108.5 
H12A-C12-H12B 107.5 O3-C13-C21 110.0(3) 
O3-C13-C14 106.2(3) C21-C13-C14 111.8(3) 
O3-C13-C12 109.8(3) C21-C13-C12 106.5(3) 
C14-C13-C12 112.6(3) C15-C14-C13 108.9(3) 
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C15-C14-H14A 109.9 C13-C14-H14A 109.9 
C15-C14-H14B 109.9 C13-C14-H14B 109.9 
H14A-C14-H14B 108.3 N2-C15-C14 121.9(3) 
N2-C15-C19 103.2(3) C14-C15-C19 108.9(3) 
N2-C15-H15A 107.4 C14-C15-H15A 107.4 
C19-C15-H15A 107.4 O4-C16-N2 126.3(3) 
O4-C16-C17 125.0(3) N2-C16-C17 108.7(3) 
C23-C17-C16 119.4(3) C23-C17-C18 122.5(3) 
C16-C17-C18 109.3(3) C23-C17-C19 127.7(3) 
C16-C17-C19 103.9(3) C18-C17-C19 59.5(2) 
C19-C18-C17 60.6(2) C19-C18-H18A 117.7 
C17-C18-H18A 117.7 C19-C18-H18B 117.7 
C17-C18-H18B 117.7 H18A-C18-H18B 114.8 
C20-C19-C18 118.9(3) C20-C19-C15 112.1(3) 
C18-C19-C15 116.9(3) C20-C19-C17 133.1(3) 
C18-C19-C17 59.9(2) C15-C19-C17 107.0(3) 
C21-C20-C19 119.4(3) C21-C20-H20A 120.3 
C19-C20-H20A 120.3 C20-C21-C13 125.0(3) 
C20-C21-H21A 117.5 C13-C21-H21A 117.5 
N2-C22-H22A 109.5 N2-C22-H22B 109.5 
H22A-C22-H22B 109.5 N2-C22-H22C 109.5 
H22A-C22-H22C 109.5 H22B-C22-H22C 109.5 
C17-C23-H23A 109.5 C17-C23-H23B 109.5 
H23A-C23-H23B 109.5 C17-C23-H23C 109.5 
H23A-C23-H23C 109.5 H23B-C23-H23C 109.5 
O5-C24-C25 109.8(4) O5-C24-N1 117.9(4) 
C25-C24-N1 132.2(4) C26-C25-C24 108.9(6) 
C26-C25-H25A 125.5 C24-C25-H25A 125.5 
C27-C26-C25 106.4(5) C27-C26-H26A 126.8 
C25-C26-H26A 126.8 C26-C27-O5 110.5(4) 
C26-C27-H27A 124.7 O5-C27-H27A 124.7 
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Table A-17 Anisotropic Atomic Displacement Parameters (Å2) for Allylic Alcohol (±)-2.111 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 O1 0.0494(13) 0.0528(15) 0.0509(14) 0.0085(10) 0.0090(11) 0.0004(11) 
N1 0.0460(16) 0.0529(18) 0.0498(17) 0.0047(13) 0.0115(13) -0.0013(13) 
C1 0.072(2) 0.041(2) 0.054(2) 0.0015(15) 0.0103(18) -0.0050(18) 
O2 0.0563(15) 0.0517(15) 0.0601(15) 0.0054(11) 0.0191(12) 0.0061(11) 
N2 0.0383(14) 0.0550(18) 0.0546(18) 0.0060(13) 0.0064(13) 0.0002(13) 
C2 0.075(3) 0.047(2) 0.076(3) 0.0079(18) 0.008(2) 0.0086(19) 
O3 0.0521(15) 0.0726(19) 0.0608(17) 0.0011(13) 0.0184(13) 0.0117(13) 
C3 0.074(3) 0.071(3) 0.064(3) 0.015(2) 0.004(2) 0.003(2) 
O4 0.0415(14) 0.082(2) 0.0639(17) -0.0004(13) 0.0131(12) -0.0044(12) 
C4 0.069(3) 0.066(3) 0.058(2) -0.0028(19) 0.0009(19) -0.007(2) 
O5 0.078(2) 0.121(3) 0.094(2) 0.024(2) 0.0105(18) -0.035(2) 
C5 0.063(2) 0.049(2) 0.053(2) -0.0044(15) 0.0083(17) -0.0076(17) 
N3 0.0487(16) 0.0405(16) 0.0515(17) 0.0004(12) 0.0051(13) -0.0008(12) 
C7 0.083(3) 0.057(3) 0.070(3) 0.0068(19) 0.010(2) -0.018(2) 
C8 0.097(3) 0.048(2) 0.071(3) -0.0113(18) 0.011(2) -0.003(2) 
C9 0.084(3) 0.072(3) 0.055(2) -0.0025(19) 0.018(2) 0.002(2) 
C10 0.091(3) 0.046(2) 0.073(3) -0.0142(18) 0.014(2) -0.009(2) 
C11 0.0458(18) 0.0427(19) 0.050(2) -0.0045(15) 0.0144(16) -0.0033(15) 
C12 0.0461(18) 0.055(2) 0.0433(19) 0.0024(15) 0.0070(15) -0.0037(16) 
C13 0.0383(16) 0.051(2) 0.0484(19) 0.0062(15) 0.0136(14) 0.0035(15) 
C14 0.0480(18) 0.0424(18) 0.0468(19) 0.0012(14) 0.0069(15) 0.0019(15) 
C15 0.0391(16) 0.0395(18) 0.0505(19) 0.0024(14) 0.0060(14) -0.0005(14) 
C16 0.0396(19) 0.053(2) 0.056(2) -0.0105(16) 0.0111(15) -0.0069(15) 
C17 0.0439(18) 0.052(2) 0.054(2) 0.0026(15) 0.0101(15) -0.0044(16) 
C18 0.063(2) 0.044(2) 0.067(2) 0.0049(16) 0.0109(18) -0.0031(17) 
C19 0.0432(17) 0.0421(19) 0.053(2) 0.0015(14) 0.0109(15) 0.0011(14) 
C20 0.0441(18) 0.054(2) 0.049(2) 0.0071(15) 0.0078(15) 0.0064(16) 
C21 0.0385(17) 0.060(2) 0.049(2) 0.0057(16) 0.0053(15) 0.0041(16) 
C22 0.0469(19) 0.064(3) 0.062(2) 0.0065(18) -0.0016(17) -0.0004(17) 
C23 0.061(2) 0.082(3) 0.063(3) 0.013(2) 0.0139(19) -0.010(2) 
C24 0.0425(19) 0.076(3) 0.066(3) 0.027(2) 0.0112(18) -0.0012(19) 
C25 0.071(3) 0.104(4) 0.074(3) 0.019(3) 0.039(2) 0.014(3) 
C26 0.072(3) 0.142(6) 0.088(4) 0.028(4) 0.026(3) 0.011(3) 
C27 0.048(2) 0.149(6) 0.111(4) 0.057(4) 0.024(3) -0.023(3) 
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Table A-18 Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for allylic alcohol (±)-
2.111. 
 x/a y/b z/c U(eq) H2A -0.0081 0.8228 0.4400 0.081 
H2B 0.0740 0.8846 0.4042 0.081 
H3 0.715(6) 0.498(3) 0.694(3) 0.083(15) 
H3A 0.1181 0.8162 0.2867 0.086 
H3B -0.0588 0.8175 0.2821 0.086 
H4A 0.0219 0.7040 0.2679 0.08 
H4B -0.0412 0.7115 0.3558 0.08 
H7A 0.3642 0.8921 0.4540 0.108 
H7B 0.3479 0.8346 0.3786 0.108 
H7C 0.4544 0.8223 0.4769 0.108 
H8A 0.2218 0.8849 0.5708 0.11 
H8B 0.3307 0.8227 0.6094 0.11 
H8C 0.1519 0.8139 0.5908 0.11 
H9A 0.3026 0.6630 0.2922 0.106 
H9B 0.4151 0.6959 0.3785 0.106 
H9C 0.3110 0.7437 0.3041 0.106 
H10A 0.1255 0.5966 0.3571 0.106 
H10B 0.1009 0.6209 0.4520 0.106 
H10C 0.2666 0.6027 0.4424 0.106 
H12A 0.4879 0.6350 0.7584 0.059 
H12B 0.6568 0.6236 0.7504 0.059 
H14A 0.3220 0.5435 0.6209 0.056 
H14B 0.3581 0.4671 0.6554 0.056 
H15A 0.2833 0.5715 0.7658 0.053 
H18A 0.3161 0.3674 0.8435 0.071 
H18B 0.2043 0.3895 0.7444 0.071 
H20A 0.5159 0.4733 0.9263 0.06 
H21A 0.6750 0.5178 0.8504 0.06 
H22A 0.0136 0.5309 0.5831 0.09 
H22B 0.0381 0.5987 0.6422 0.09 
H22C -0.0994 0.5491 0.6443 0.09 
H23A 0.2653 0.4304 0.9856 0.103 
H23B 0.0883 0.4160 0.9515 0.103 
H23C 0.1481 0.4920 0.9726 0.103 
H25A 0.5916 0.5786 0.4843 0.095 
H26A 0.8055 0.6322 0.4362 0.119 
H27A 0.8963 0.7261 0.5398 0.122 
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APPENDIX B 
SELECTED NMR SPECTRA 
 
 
 
9
8
7
6
5
4
3
2
1
0
ppm
1.100
1.121
1.250
1.274
1.298
1.572
1.698
1.720
1.830
4.133
4.157
4.180
4.204
7.260
1.01
3.36
3.10
1.00
3.15
2.20
231 
Br
OOEt
1.81
C
D
C
l3 , 300 M
H
z 
232 
Br
OOEt
1.81
C
D
C
l3 , 100 M
H
z  
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
14.42
21.63
26.14
28.85
30.41
42.36
61.36
77.15
171.74
SRM
−575
−060
9
8
7
6
5
4
3
2
1
0
ppm
1.250
1.272
1.279
1.302
1.326
1.565
1.948
1.970
3.928
3.969
4.022
4.063
4.156
4.168
4.178
4.192
4.202
4.216
4.225
4.239
4.249
4.261
7.260
1.11
3.00
3.01
0.99
1.04
1.04
2.00
233 
1.82
Cl
OOEt
Cl
C
D
C
l3 , 300 M
H
z  
200
180
160
140
120
100
80
60
40
20
0
ppm
14.23
18.38
29.43
31.67
50.55
54.36
62.02
77.16
171.43
234 
1.82
Cl
OOEt
Cl
C
D
C
l3 , 100 M
H
z  
235 
9
8
7
6
5
4
3
2
1
0
ppm
0.398
0.411
1.209
1.227
1.245
1.294
1.300
1.317
1.323
1.384
2.047
2.052
2.070
2.075
4.076
4.078
4.080
4.094
4.096
4.112
4.114
4.129
4.132
6.093
6.099
7.260
7.346
7.354
7.359
7.360
7.526
7.535
7.543
6.48
3.73
1.44
3.32
1.14
2.12
1.00
3.33
2.29
OEt
O
PhM
e2 Si
S-1.1 *
C
D
C
l3 , 400 M
H
z  
236 
200
180
160
140
120
100
80
60
40
20
0
ppm
−2.16
−1.94
14.29
18.82
19.65
22.81
60.74
77.16
113.34
127.89
129.12
133.93
139.06
147.47
173.64
OEt
O
PhM
e2 Si
S-1.1 *
C
D
C
l3 , 100 M
H
z  
9
8
7
6
5
4
3
2
1
0
ppm
0.399
0.409
1.329
1.336
1.353
1.359
1.414
1.438
2.095
2.102
2.119
2.125
5.041
5.073
5.131
5.163
6.119
6.126
6.132
7.260
7.278
7.292
7.298
7.304
7.314
7.319
7.325
7.332
7.339
7.344
7.357
7.504
7.508
7.523
7.527
6.28
1.16
3.12
1.14
2.20
1.00
8.46
2.05
S
R
M
−699
−007
237 
OBn
O
PhM
e2 Si
S-1.2 *
C
D
C
l3 , 400 M
H
z  
238 
200
180
160
140
120
100
80
60
40
20
0
ppm
−2.15
−1.97
18.81
19.79
22.82
66.29
77.16
113.69
127.65
127.91
128.07
128.60
129.14
133.91
136.44
138.86
147.09
173.45
128
129
130
p
p
m
127.655
127.912
128.069
128.601
129.143
OBn
O
PhM
e2 Si
S-1.2 *
C
D
C
l3 , 100 M
H
z  
239 
9
8
7
6
5
4
3
2
1
0
ppm
0.381
0.399
1.233
1.239
1.256
1.262
1.335
1.403
1.541
1.952
1.958
1.975
1.981
6.061
6.067
6.073
7.260
7.325
7.339
7.347
7.352
7.523
7.532
7.542
7.547
6.40
1.46
3.18
9.45
1.05
1.00
3.03
2.09
C
D
C
l3 , 400 M
H
z  OtB
u
O
PhM
e2 Si
S-1.3 *
240 
200
180
160
140
120
100
80
60
40
20
0
ppm
−2.16
−1.87
18.81
19.51
23.69
28.11
80.27
112.68
127.94
129.11
133.95
139.22
148.11
172.91
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00 Hz
S
S
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
F
 
 
 
 
 
 
 
 
 
 100.6379009 MHz
S
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32768
S
F
O2        400.2316009 MHz
P
L13W        0.00000000 W
P
L12W        0.23137002 W
P
L2W        21.64248466 W
P
L13             120.00 dB
P
L12              15.81 dB
P
L2               
−3.90 dB
P
C
P
D2             90.00 usec
N
U
C2                 1H
C
P
D
P
R
G2         waltz16
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f2 ========
S
F
O1        100.6479773 MHz
P
L1W        39.19395828 W
P
L1               
−0.44 dB
P1                10.00 usec
N
U
C1                13C
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
T
D0                   1
D11          0.03000000 sec
D1           3.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 296.0 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 71.8
AQ            1.3631988 sec
F
I
D
R
E
S
 
 
 
 
 
 
 
 
 0.366798 Hz
S
W
H
 
 
 
 
 
 
 
 
 
 
 24038.461 Hz
D
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10174
S
O
L
V
E
N
T
 
 
 
 
 
 
 
 
 
 
 
C
D
Cl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65536
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
z
g
p
g30
P
R
O
B
H
D
 
 
 5 mm PADUL 13C
I
N
S
T
R
U
M
 
 
 
 
 
 
 
 
 
 
 
s
p
e
c
t
Time               9.23
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20160206
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
N
A
M
E
 
 
 
 
 
S
R
M
−699
−020
−13C
S
R
M
−699
−020
−13C
C
D
C
l3 , 100 M
H
z  
O
tB
u
O
PhM
e2 Si
S-1.3 *
9
8
7
6
5
4
3
2
1
0
ppm 0.380
0.387
0.394
0.404
0.679
0.697
0.745
0.762
0.793
0.811
0.825
0.856
0.870
0.875
0.887
0.893
0.898
0.913
1.032
1.269
1.286
1.292
1.309
1.315
1.330
1.371
1.381
1.540
1.638
1.647
1.653
1.671
1.680
1.687
2.019
2.025
2.042
2.048
4.622
4.633
6.060
6.066
6.073
7.260
7.339
7.343
7.352
7.356
7.519
7.526
7.531
7.538
7.543
6.48
4.31
5.83
1.03
2.20
3.31
2.69
2.02
1.98
1.16
1.09
1.00
3.10
2.15
241 
*
OM
en
O
S-1.4
PhM
e2 Si
C
D
C
l3 , 400 M
H
z  
9
8
7
6
5
4
3
2
1
0
ppm
1.208
1.226
1.243
1.293
1.300
1.305
1.315
1.321
1.327
1.386
1.996
2.002
2.008
2.018
2.024
2.031
4.069
4.078
4.087
4.092
4.096
4.105
4.109
4.114
4.127
4.132
4.136
4.145
4.154
5.411
5.416
5.421
5.446
5.453
5.460
7.260
3.05
1.06
3.03
1.00
2.00
2.00
242 
O
(±)-1.101 OEt
C
D
C
l3 , 400 M
H
z 
243 
200
180
160
140
120
100
80
60
40
20
0
ppm
14.31
18.89
18.99
23.23
60.86
77.16
102.67
137.78
173.73
O
(±)-1.101 OEt
C
D
C
l3 , 100 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
1.224
1.230
1.236
1.246
1.252
1.257
1.338
1.412
5.362
5.367
5.372
5.415
5.422
5.429
7.260
1.15
3.00
9.24
1.03
2.00
244 
O
S-1.7
OtBu
C
D
C
l3 , 400 M
H
z 
200
180
160
140
120
100
80
60
40
20
0
ppm
18.66
18.96
24.11
28.08
77.16
80.43
102.09
138.19
172.91
245 
O
S-1.7
OtBu
C
D
C
l3 , 100 M
H
z 
246 
9
8
7
6
5
4
3
2
1
0
ppm
1.514
1.565
1.573
1.581
1.596
1.604
1.613
2.295
2.303
2.312
2.326
2.334
2.343
2.808
5.558
5.565
5.571
5.673
5.682
5.691
7.260
3.43
1.32
1.05
4.35
0.98
1.00
C
D
C
l3 , 300 M
H
z 
(±)-S-1.8 O O
N
O
O
200
180
160
140
120
100
80
60
40
20
0
ppm
18.43
20.83
21.34
25.73
77.16
105.02
135.33
169.11
169.24
247 
C
D
C
l3 , 125 M
H
z 
(±)-S-1.8 O O
N
O
O
9
8
7
6
5
4
3
2
1
0
ppm
1.533
1.615
1.621
1.625
1.634
1.639
1.644
2.350
2.355
2.360
2.369
2.374
2.379
5.320
5.573
5.577
5.581
5.659
5.665
5.670
3.31
1.01
1.03
1.00
1.00
248 
C
D
2 C
l2 , 500 M
H
z 
O
1.105
OCl
Cl
Cl Cl
Cl
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
18.76
20.39
23.43
54.00
104.48
128.41
131.74
132.37
136.81
144.88
170.04
S
R
M
−713
−029
−13C
249 
C
D
2 C
l2 , 100 M
H
z 
O
1.105
OCl
Cl
Cl Cl
Cl
9
8
7
6
5
4
3
2
1
0
ppm
1.136
4.678
7.260
7.454
7.464
7.469
7.478
7.488
7.499
7.505
7.517
7.547
7.553
7.571
7.579
7.671
9.24
1.01
6.08
4.14
2.00
250 
C
D
C
l3 , 300 M
H
z 
N(S)
HO
OH Ph
Ph
O
O1.116
200
180
160
140
120
100
80
60
40
20
0
ppm
28.21
35.76
60.03
77.16
128.05
128.27
128.86
129.60
136.31
136.48
140.37
167.28
172.26
251 
C
D
C
l3 , 100 M
H
z 
N(S)
HO
OH Ph
Ph
O
O1.116
10
9
8
7
6
5
4
3
2
1
0
ppm
0.838
1.221
1.235
1.249
2.039
4.109
4.123
4.137
4.152
4.197
7.260
7.331
7.441
7.519
35.95
7.03
6.59
4.46
4.00
40.09
8.40
S
R
M
−801
−071, 500 MHz, CDCl3
252 
C
D
C
l3 , 500 M
H
z 
N(S)
HO
O
P
h
P
h
O
O
Rh
Rh
4
1.117
• 2EtOAc
253 
200
180
160
140
120
100
80
60
40
20
0
ppm
14.29
21.16
28.23
35.61
60.57
60.70
77.15
127.81
128.24
129.85
135.34
136.28
136.81
139.32
139.97
166.11
166.34
171.90
187.42
130
135
140
p
p
m
127.811
128.236
129.846
135.335
136.278
136.815
139.317
139.971
C
D
C
l3 , 125 M
H
z 
N(S)
HO
O
P
h
P
h
O
O
Rh
Rh
4
1.117
• 2EtOAc
13
12
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1.378
1.392
1.402
1.408
1.414
2.076
2.082
2.088
2.099
2.105
2.111
5.449
5.454
5.459
5.487
5.494
5.501
7.260
11.987
4.17
1.11
0.96
1.00
1.10
SRM
−545
−088
254 
OH
O
2.90
C
D
C
l3 , 400 M
H
z 
255 
200
180
160
140
120
100
80
60
40
20
0
ppm
18.30
19.76
22.96
77.16
103.18
137.40
180.57
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00 Hz
SSB      0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
SF          125.7653151 MHz
SI                32768
F2 
−
 
P
r
o
c
e
s
sing parameters
SFO2        500.1620006 MHz
P
L
W13    0 W
P
L
W12        0.36736000 W
P
L
W2        18.74300003 W
P
C
P
D2             80.00 usec
N
U
C2                 1H
C
P
D
P
R
G2         waltz16
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f2 ========
SFO1        125.7779080 MHz
P
L
W1       112.58000183 W
P1                 8.80 usec
N
U
C1                13C
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D11          0.03000000 sec
D1           2.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 298.6 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 203
AQ            1.1010548 sec
F
I
D
R
ES         0.454131 Hz
SWH           29761.904 Hz
DS                    4
NS                  254
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65536
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
z
g
p
g30
P
R
O
B
H
D
 
 
 5 mm PABBO BB
−
I
NSTRUM           spect
Time              13.36
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20140128
F2 
−
 
A
c
q
uisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
N
A
M
E
 
 
 
 
 SRM
−545
−088
−13C
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
SRM
−545
−088
−13C
OH
O
2.90
C
D
C
l3 , 125 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
0.570
0.579
0.873
0.882
1.354
1.440
1.553
1.585
1.616
2.178
2.208
2.695
3.636
3.642
3.668
3.703
3.739
3.841
3.878
5.645
5.669
5.819
5.843
6.007
6.350
6.355
7.187
7.260
1.01
1.19
3.05
9.25
1.34
1.03
3.17
1.19
1.13
1.11
1.03
1.07
1.08
1.12
1.00
S
R
M
−575
−009
−1H
256 
N
H
O
OH
N
Ot-Bu
O
O
(±)-2.83
C
D
C
l3 , 400 M
H
z 
200
180
160
140
120
100
80
60
40
20
0
ppm
10.83
23.54
27.27
28.20
31.91
32.33
36.78
37.26
57.18
59.47
73.88
77.16
82.61
101.99
111.29
129.36
131.13
138.44
149.13
179.51
SRM
−575
−009
−13C
257 
N
H
O
OH
N
Ot-Bu
O
O
(±)-2.83
C
D
C
l3 , 125 M
H
z 
Relative	Stereochem
istry	of	Addition	Adduct:	
N
O
ESY	Correlations	
ppm
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
3.2
3.4
3.6
3.8
4.0
ppm
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
3.2
3.4
3.6
3.8
4.0
H
D	
H
D’	H
A	
N
-M
e
	
H
B	
H
C	
H
D	
H
D’	 H
A	
N
-M
e
	
H
B	
H
C	
N
O
CH
3
H
A
HO
BocN
OH
C
H
B
H
D
H
D'
(±)-2.83
key N
O
ESY
 correlations in (±)-2.83 (C
D
C
l3 , 500 M
H
z) 
258 
259 
ppm
3.55
3.60
3.65
3.70
3.75
3.80
3.85
3.90
ppm
3.55
3.60
3.65
3.70
3.75
3.80
3.85
3.90
3.95
N
O
E
S
Y
S
R
M
−545
−082
H
D
H
D’
H
A
H
A
H
D’
H
D
ppm
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
3.2
3.4
3.6
3.8
4.0
ppm
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
3.2
3.4
3.6
3.8
4.0
N
M
e
O
H
A
OH
N
O
OO
H
D'
H
D
Lack of key N
O
ESY
 correlations in (±)-2.83 (C
D
C
l3 , 500 M
H
z) 
9
8
7
6
5
4
3
2
1
0
ppm 1.163
1.177
1.320
1.334
1.418
1.694
1.704
1.709
1.719
1.737
1.746
1.754
1.762
2.089
2.293
2.316
2.334
2.357
2.376
2.398
2.619
2.636
2.648
2.658
2.660
2.670
2.675
2.680
2.932
5.486
7.260
1.03
1.24
3.31
1.20
1.19
2.04
3.29
1.00
S
R
M
−593
−001
260 
2.93
N
O
O
C
D
C
l3 , 300 M
H
z 
200
180
160
140
120
100
80
60
40
20
0
ppm
10.38
24.50
26.24
29.17
29.88
30.11
36.88
77.16
101.38
164.40
177.10
197.21
S
R
M
−593
−001
−13C
261 
2.93
N
O
O
C
D
C
l3 , 100 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
0.406
1.204
7.160
3.00
C
6 D
6 , 300 M
H
z 
262 
O
O
N
2
1.99
F
F
FF
F
S
R
M
-
7
3
5
-
0
3
5
-
1
9
F
,
 
C
6
D
6
,
 
4
7
1
 
M
H
z
-
2
0
0
-
1
8
0
-
1
6
0
-
1
4
0
-
1
2
0
-
1
0
0
-
8
0
-
6
0
-
4
0
-
2
0
0
p
p
m
-163.219
-163.173
-163.128
-158.591
-158.543
-158.496
-154.240
-154.198
2.017
1.000
1.958
C
6 D
6 , 471 M
H
z 
263 
O
O
N
2
1.99
F
F
FF
F
9
8
7
6
5
4
3
2
1
0
ppm
1.514
1.528
1.609
1.615
1.621
1.632
1.638
1.644
2.281
2.288
2.294
2.305
2.311
2.317
5.320
5.558
5.564
5.569
5.637
5.644
5.651
3.44
1.02
1.04
1.00
1.00
C
D
2 C
l2 , 400 M
H
z 
264 
O
1.109
OF
F
F F
F
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
18.77
20.63
23.22
54.00
104.46
125.79
126.16
136.76
137.02
137.38
138.48
138.83
139.51
139.87
140.47
140.72
140.98
141.33
142.96
143.21
170.39
C
D
2 C
l2 , 100 M
H
z 
265 
O
1.109
OF
F
F F
F
-200
-180
-160
-140
-120
-100
-80
-60
-40
-20
0
ppm
-163.60
-163.59
-163.58
-163.55
-163.54
-163.50
-163.49
-163.48
-159.48
-159.43
-159.39
-153.94
-153.94
-153.93
-153.89
-153.88
-153.87
1.99
1.00
2.00
19F-N
M
R
, C
D
2 C
l2 , 471 M
H
z 
266 
O
1.109
OF
F
F F
F
9
8
7
6
5
4
3
2
1
0
ppm
1.308
1.314
1.319
1.332
1.338
1.343
1.494
1.776
1.781
1.787
1.800
1.805
1.811
2.289
3.152
5.527
5.693
5.700
5.707
5.728
7.260
8.346
8.380
1.13
3.12
1.08
3.06
3.07
1.01
2.01
1.00
C
D
C
l3 , 400 M
H
z 
267 
2.87
N
O
O
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
15.91
21.83
24.93
28.91
30.86
77.16
104.90
108.41
134.86
142.94
172.35
196.94
C
D
C
l3 , 125 M
H
z 
268 
2.87
N
O
O
9
8
7
6
5
4
3
2
1
0
ppm 0.651
0.664
0.940
0.952
1.376
1.601
1.678
1.684
1.702
1.708
1.722
1.728
1.746
1.752
2.078
2.082
2.095
2.100
2.122
2.139
2.162
2.167
2.179
2.303
2.347
2.392
2.474
2.499
2.515
2.526
2.539
2.550
2.566
2.590
2.660
2.707
2.712
2.724
2.769
2.774
2.783
2.787
2.814
2.819
2.828
2.832
3.375
3.389
3.419
3.432
7.260
1.03
1.01
3.13
1.03
1.08
1.08
1.09
4.04
0.99
1.00
C
D
C
l3 , 300 M
H
z 
269 
N
O
H
O
2.86
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
10.95
22.73
25.84
27.17
30.66
31.80
41.52
45.06
60.12
77.16
178.85
207.55
C
D
C
l3 , 100 M
H
z 
270 
N
O
H
O
2.86
9
8
7
6
5
4
3
2
1
0
ppm
0.851
0.859
1.329
1.337
1.463
2.406
2.435
2.438
2.466
2.709
2.878
2.886
2.909
2.917
3.792
3.800
3.820
3.827
6.130
6.149
6.962
6.981
7.260
1.08
1.08
3.18
1.06
3.13
1.08
1.01
0.98
1.00
C
D
C
l3 , 500 M
H
z 
271 
2.85
N
O
H
O
200
180
160
140
120
100
80
60
40
20
0
ppm
10.91
23.53
27.30
32.08
32.89
41.87
58.58
77.16
131.35
148.38
177.77
197.01
C
D
C
l3 , 125 M
H
z 
272 
2.85
N
O
H
O
9
8
7
6
5
4
3
2
1
0
ppm
1.190
1.264
1.438
1.445
1.451
1.458
1.464
1.470
1.477
1.484
1.549
1.570
1.596
1.623
1.650
1.655
1.676
1.681
1.707
6.169
6.175
6.374
6.378
6.380
6.385
7.095
7.097
7.260
9.003
6.35
6.16
1.17
5.40
1.00
1.04
1.00
0.93
C
D
C
l3 , 500 M
H
z 
273 
N
O
O
NH
O
2.148
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
16.85
20.86
31.72
39.90
61.45
77.16
95.59
111.70
136.44
144.89
154.59
C
D
C
l3 , 125 M
H
z 
274 
N
O
O
NH
O
2.148
10
9
8
7
6
5
4
3
2
1
0
ppm 1.072
1.093
1.230
1.265
1.326
1.351
1.369
1.387
1.406
1.424
1.443
1.539
1.550
1.555
1.574
1.595
1.609
1.616
1.621
1.627
1.635
1.646
1.655
1.673
1.694
3.311
3.345
3.380
5.931
6.046
6.051
6.054
6.059
6.897
6.899
6.902
6.904
7.160
15.10
6.34
2.36
6.32
7.09
8.93
2.01
0.84
1.00
1.00
C
6 D
6 , 400 M
H
z 
275 
N
O
O
N
2.149
Bu3 Sn
O
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
9.33
9.40
11.00
12.59
12.67
14.03
17.24
20.55
27.65
27.94
28.22
29.49
29.59
29.69
32.02
36.72
39.39
60.36
101.45
111.25
128.06
138.77
151.12
157.20
C
6 D
6 , 100 M
H
z 
276 
N
O
O
N
2.149
Bu3 Sn
O
9
8
7
6
5
4
3
2
1
0
ppm 0.225
0.234
0.743
0.752
0.922
0.925
1.046
1.073
1.079
1.225
1.254
1.271
1.306
1.337
1.546
1.555
1.578
1.644
1.675
1.705
2.400
2.402
2.430
2.432
2.536
2.964
2.970
2.997
3.003
3.370
3.520
3.555
3.737
3.774
5.347
5.371
5.421
5.423
5.446
5.447
5.893
5.895
5.901
5.903
5.981
5.987
5.989
5.995
6.809
6.811
6.814
6.816
7.160
1.07
1.08
6.11
1.25
8.80
3.40
2.28
1.00
1.02
3.10
1.08
0.95
1.05
1.02
1.03
1.02
1.01
1.01
1.00
C
6 D
6 , 400 M
H
z 
277 
2.111
N
H
O
OH
N
O
O
N
O
−1
8
7
6
5
4
3
2
1
0
ppm 0.641
0.651
0.916
0.933
0.938
1.128
1.337
1.352
1.360
1.367
1.383
1.390
1.475
1.509
1.565
1.573
1.597
1.625
1.636
1.655
1.666
1.678
1.695
1.731
1.763
1.794
2.489
2.491
2.519
2.521
2.600
3.304
3.310
3.337
3.343
3.722
3.759
3.888
3.925
5.612
5.637
5.814
5.838
6.131
6.133
6.139
6.141
6.398
6.404
6.406
6.412
7.260
7.264
7.266
0.97
7.03
6.11
4.09
2.04
1.06
2.54
1.03
0.99
2.98
0.99
1.00
1.96
0.96
1.00
1.00
1.00
0.70
SRM
−683
−024
−d1
−
C
D
Cl3
−400Mhz
C
D
C
l3 , 400 M
H
z 
278 
2.111
N
H
O
OH
N
O
O
N
O
200
180
160
140
120
100
80
60
40
20
0
ppm
10.82
16.92
20.46
24.57
27.16
31.68
31.87
32.07
32.44
35.76
39.09
58.20
59.49
60.81
60.89
75.10
77.16
103.06
111.48
128.80
132.26
139.52
148.94
159.01
179.15
S
R
M
−683
−024
−d1
−
C
D
Cl3
−400Mhz
C
D
C
l3 , 100 M
H
z 
279 
2.111
N
H
O
OH
N
O
O
N
O
9
8
7
6
5
4
3
2
1
0
ppm 0.247
0.256
0.776
0.785
0.925
1.099
1.237
1.244
1.255
1.281
1.294
1.320
1.328
1.550
1.582
1.592
1.597
1.629
1.660
2.102
2.105
2.109
2.112
2.132
2.135
2.139
2.142
2.466
3.482
3.512
3.519
3.544
3.550
3.816
3.820
5.469
5.494
5.650
5.652
5.675
5.676
5.867
5.869
5.875
5.877
6.021
6.026
6.029
6.034
6.852
6.854
6.857
6.859
7.160
1.08
1.17
6.46
1.64
12.43
3.23
1.05
3.15
2.00
2.09
1.06
1.04
1.05
1.04
1.00
C
6 D
6 , 400 M
H
z 
280 
N
H
O
OH
N
O
O
N
O
epi-2.111
−0.5
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
ppm
0.578
0.584
0.884
0.890
0.928
1.124
1.129
1.355
1.382
1.482
1.504
1.540
1.562
1.585
1.589
1.615
1.644
1.667
1.678
1.689
1.698
1.719
2.212
2.231
2.689
3.641
3.658
3.662
3.679
3.683
3.754
3.779
3.815
3.840
5.689
5.705
5.845
5.861
6.116
6.122
6.398
6.402
6.407
7.260
1.06
1.36
6.14
6.31
4.39
3.90
3.62
1.09
3.22
1.96
1.06
1.06
1.06
1.04
1.04
1.00
1.19
S
R
M
−735
−014
−
D2
−
cdcl3
−600 MHz
C
D
C
l3 , 600 M
H
z 
281 
N
H
O
OH
N
O
O
N
O
epi-2.111
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
10.83
16.95
20.47
23.55
27.21
31.74
31.75
31.92
32.29
37.22
39.09
57.14
60.84
60.85
61.01
73.98
77.16
103.40
111.40
129.64
131.02
139.57
148.71
158.79
179.49
C
D
C
l3 , 150 M
H
z 
282 
N
H
O
OH
N
O
O
N
O
epi-2.111
ppm
8
7
6
5
4
3
2
1
0
ppm
8 7 6 5 4 3 2 1 0
ppm
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9
ppm
2.9
3.0
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9
4.0
4.1
K
ey R
O
ESY
 correlations in 2.111 (C
D
C
l3 , 500 M
H
z) 
N
O
H
5
N
H
2' H2
O
O
O
N
HO
H
2/2’
H
5
H
5
H
2/2’
283 
ppm
9
8
7
6
5
4
3
2
1
0
ppm
9 8 7 6 5 4 3 2 1 0
SRM
−683
−024
−
D2
−
R
O
ESY
Lack of key R
O
ESY
 correlations in epi-2.111 (C
D
C
l3 , 600 M
H
z) 
ppm
3.4
3.5
3.6
3.7
3.8
3.9
4.0
4.1
4.2
4.3
ppm
3.4
3.5
3.6
3.7
3.8
3.9
4.0
4.1
4.2
S
R
M
−683
−024
−
D2
−
R
O
E
S
Y
H
2/2’
H
5
H
5
H
2/2’
N
O
H
5
OH
N
H
2H
2'
O
OO
N
284 
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
−1.309
−1.263
100.000
−1.057
−2.541
K
ey 1D
-N
O
E correlations in 2.111 (C
D
C
l3 , 600 M
H
z) 
H
2 /H
2’ 	
H
5 	
N
-M
e	
H
4 	
H
4’ 	
H
5 	
N
O
M
e
H
5
N
H
2' H
2
O
O
O
N
HO
H
4'
H
4
285 
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
−1.314
−0.756
100.000
SRM
−683
−024
−D
2
−1H
N
O
M
e
H
5
HO
N
H
2H
2'
O
OO
N
H
4'
H
4
K
ey 1D
-N
O
E correlations in epi-2.111 (C
D
C
l3 , 600 M
H
z) H
2 /H
2’ 	 H
5 	
H
5 	
N
-M
e	H
4 	
286 
9
8
7
6
5
4
3
2
1
0
ppm
0.445
0.454
1.587
1.594
1.603
1.690
2.359
2.391
2.412
2.565
2.569
2.598
2.628
2.632
2.758
2.768
2.787
2.797
3.114
3.124
3.145
3.159
3.166
6.815
6.816
6.832
6.833
6.899
6.903
6.907
7.067
7.087
7.104
7.125
7.127
7.145
7.147
7.260
7.895
1.11
1.20
3.20
3.09
1.25
1.18
1.11
2.15
0.97
0.91
0.98
1.01
1.00
C
D
C
l3 , 400 M
H
z 
287 
NH
N
H
 (–)-(2.1)
200
180
160
140
120
100
80
60
40
20
ppm
16.63
24.36
25.10
27.94
34.54
40.06
65.75
69.77
77.16
108.06
110.52
113.45
118.21
123.08
128.84
133.73
135.59
C
D
C
l3 , 100 M
H
z 
288 
NH
N
H
 (–)-(2.1)
9
8
7
6
5
4
3
2
1
0
ppm
1.023
1.033
1.190
1.200
1.630
2.492
2.530
2.566
3.001
3.011
3.040
3.050
3.065
3.117
4.072
4.082
4.107
4.117
6.159
6.183
7.003
7.027
7.260
1.06
1.18
2.99
1.15
1.04
2.88
1.09
0.95
1.00
289 
N
O
H
S
(±)-2.116
C
D
C
l3 , 400 M
H
z 
200
180
160
140
120
100
80
60
40
20
0
ppm
14.05
26.51
32.25
34.40
42.08
42.99
64.32
77.16
131.44
148.13
196.59
208.07
SRM
−575
−029
−13C
290 
N
O
H
S
(±)-2.116
C
D
C
l3 , 100 M
H
z 
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 0.884
0.902
0.946
0.966
0.987
1.264
1.282
1.300
1.319
1.337
1.344
1.355
1.493
1.507
1.513
1.533
1.548
1.553
1.572
3.215
5.976
5.989
5.993
6.006
6.729
6.734
6.746
6.751
7.232
7.237
7.254
7.259
7.272
7.283
7.288
7.292
7.305
7.315
7.320
7.332
7.336
7.339
7.346
7.351
7.359
7.364
9.16
5.75
6.50
6.10
1.86
1.00
1.00
0.74
3.95
1.07
SRM
−683
−031
−1H
291 
O
N
O
SnBu3
O
2.121
C
D
C
l3 , 400 M
H
z 
200
180
160
140
120
100
80
60
40
20
0
ppm
11.05
13.90
27.61
29.21
36.39
77.16
105.67
127.70
128.39
130.16
133.82
135.60
138.87
150.41
159.42
170.39
SRM
−683
−031
−13C
292 
O
N
O
SnBu3
O
2.121
C
D
C
l3 , 100 M
H
z 
14
13
12
11
10
9
8
7
6
5
4
3
2
1
ppm 1.497
1.500
1.519
1.871
1.884
1.888
1.890
1.901
1.903
1.906
1.919
1.925
2.031
2.043
2.063
2.417
2.436
2.460
2.479
2.498
2.587
2.589
2.631
2.633
3.694
3.719
5.665
5.668
5.671
5.673
5.677
5.688
5.694
5.698
5.703
7.260
7.466
7.470
7.487
7.492
7.503
7.506
7.508
7.528
7.531
7.535
7.543
7.549
8.009
8.012
8.018
8.026
8.030
8.033
0.87
1.82
1.11
1.13
1.14
1.11
1.13
1.11
1.97
2.94
1.80
1.00
S
R
M
−683
−066
−1
293 
O HN O
2.124
C
D
C
l3 , 400 M
H
z 
200
180
160
140
120
100
80
60
40
20
0
ppm
20.67
29.72
30.85
35.43
39.19
77.16
112.77
121.58
128.01
128.74
128.94
132.43
134.51
150.19
166.51
203.61
SRM
−683
−066
−1
294 
O HN O
2.124
C
D
C
l3 , 100 M
H
z 
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
ppm
1.549
2.100
2.116
2.132
2.148
2.164
2.172
2.742
2.760
2.775
3.005
3.020
3.035
6.974
6.977
6.993
6.996
7.260
7.521
7.540
7.544
8.083
8.088
8.104
8.107
8.843
8.864
13.133
2.10
2.03
2.04
1.00
4.18
1.97
1.00
1.09
S
R
M
−683
−066
−2
295 
O HN O
2.125
C
D
C
l3 , 400 M
H
z 
200
180
160
140
120
100
80
60
40
20
0
ppm
22.93
31.19
40.96
77.16
118.55
118.86
123.35
127.71
128.93
132.05
135.19
135.50
142.53
146.34
166.36
203.93
S
R
M
−683
−066
−2
−13C
296 
O HN O
2.125
C
D
C
l3 , 125 M
H
z 
297 
N
O
O
N
Bu3 Sn
2.141
C
D
C
l3 , 300 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm 0.898
1.219
1.243
1.267
1.292
1.316
1.340
1.415
1.418
1.434
1.443
1.450
1.458
1.467
1.489
1.495
1.497
1.542
1.684
1.697
1.706
1.715
1.728
3.038
3.060
3.082
3.151
3.191
3.232
5.818
5.821
5.828
5.831
6.303
6.310
6.313
6.320
7.178
7.181
7.184
7.188
7.260
15.11
6.34
5.92
4.21
4.16
2.13
1.02
1.00
0.99
S
R
M
−656
−066
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
10.43
13.92
25.60
27.59
29.23
37.79
47.69
77.16
101.08
111.12
138.22
152.22
158.55
S
R
M
−656
−066
−13C
298 
N
O
O
N
Bu3 Sn
2.141
C
D
C
l3 , 100 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm 0.923
1.125
1.343
1.365
1.370
1.376
1.464
1.470
1.491
1.530
1.557
1.567
1.578
1.585
1.589
1.605
1.637
1.644
1.664
1.690
1.695
1.701
1.706
1.720
1.739
1.746
1.759
1.765
1.928
1.935
2.010
2.017
2.020
3.656
3.685
3.734
3.763
5.611
5.631
5.796
5.804
5.811
5.816
5.824
5.831
6.098
6.104
6.366
6.370
6.372
6.377
7.240
7.243
7.260
6.63
6.60
1.17
2.70
7.95
2.30
0.93
2.25
1.09
1.09
1.05
1.07
1.00
S
R
M
−683
−011
299 
HO
N
O
OO
N
2.150
C
D
C
l3 , 500 M
H
z 
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
16.97
19.09
20.45
25.34
31.75
31.78
33.85
39.09
60.35
60.71
60.73
70.91
77.16
103.10
111.21
130.18
130.61
139.31
149.14
158.74
SRM
−683
−011
−13C
300 
HO
N
O
OO
N
2.150
C
D
C
l3 , 100 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
1.147
1.314
1.606
1.616
1.634
1.648
1.659
1.690
1.716
1.742
1.985
2.005
2.026
2.046
2.066
2.795
2.814
2.832
2.836
2.885
2.905
2.925
5.319
6.972
6.996
7.202
7.229
7.254
7.298
7.797
7.824
6.21
6.22
6.29
2.38
2.26
2.24
1.06
1.09
0.94
1.00
301 
N
O O
N
2.151
C
D
2 C
l2 , 300 M
H
z 
302 
N
O O
N
2.151
C
D
C
l3 , 100 M
H
z 
 70 °C
 
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
17.40
21.49
22.06
24.53
27.49
31.94
39.86
60.78
113.43
118.55
119.21
120.34
125.59
128.06
130.07
132.63
134.84
152.33
SRM
−683
−023
−1H
−
C6D6
20
25
30
35
p
p
m
17.400
21.494
22.065
24.528
27.488
31.936
9
8
7
6
5
4
3
2
1
0
ppm
1.514
1.613
1.618
1.622
1.631
1.636
1.641
2.285
2.290
2.295
2.304
2.309
2.314
5.320
5.559
5.564
5.568
5.638
5.644
5.649
3.08
1.06
1.04
0.99
1.00
S
R
M
−771
−067, 500 MHz, CD2Cl2
303 
O
O
ent-1.109
F
FF
F
F
C
D
2 C
l2 , 500 M
H
z 
10
9
8
7
6
5
4
3
2
1
0
ppm
1.314
1.319
1.323
1.333
1.338
1.343
1.498
1.538
1.784
1.789
1.794
1.804
1.809
1.813
2.289
3.154
5.530
5.697
5.700
5.706
5.711
5.724
7.260
8.351
8.379
1.09
3.22
1.08
3.03
3.06
1.05
2.09
1.00
S
R
M
−771
−079, 500 MHz, cdcl3
304 
N
O
O
ent-2.87
C
D
C
l3 , 500 M
H
z 
10
9
8
7
6
5
4
3
2
1
0
ppm
0.238
0.247
0.988
1.227
1.234
1.242
1.258
1.266
1.273
1.471
1.699
1.731
1.738
3.131
4.231
5.451
5.494
5.540
5.673
7.261
7.631
7.676
6.03
9.33
1.24
3.30
1.05
3.17
2.14
1.08
1.12
1.06
1.00
SRM
−801
−007
−
c
r
,
 300 MHz, cdcl3
305 
N
O
O
TB
S
ent-2.91
C
D
C
l3 , 300 M
H
z 
−1
8
7
6
5
4
3
2
1
0
ppm 0.656
0.666
0.943
0.952
1.378
1.690
1.695
1.708
1.713
1.723
1.727
1.741
1.746
2.093
2.096
2.126
2.138
2.168
2.171
2.317
2.351
2.384
2.492
2.510
2.523
2.531
2.541
2.549
2.561
2.579
2.662
2.704
2.716
2.780
2.783
2.789
2.813
2.823
2.827
3.385
3.395
3.417
3.427
7.260
1.03
1.02
3.09
1.03
1.06
1.05
1.12
4.02
1.02
1.00
SRM
−801
−009
−
t
r
a
n
s
306 
N
O
H
Oent-2.86
C
D
C
l3 , 400 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm 0.921
0.936
1.343
1.785
1.804
1.822
1.827
1.833
1.851
1.859
1.866
2.248
2.267
2.281
2.298
2.329
2.344
2.364
2.394
2.416
2.430
2.449
2.465
2.481
2.499
2.533
2.722
2.801
2.821
2.851
2.871
3.705
3.726
3.748
7.260
1.05
1.06
3.09
1.03
4.29
3.04
1.09
1.00
SRM
−801
−009
−
cis, 300 MHz, cdcl3
307 
N
O
H
Oepi-ent-2.86
C
D
C
l3 , 300 M
H
z 
308 
N
O
H
O
ent-2.85
C
D
C
l3 , 400 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
0.857
0.867
1.336
1.346
1.471
2.352
2.386
2.407
2.421
2.442
2.445
2.480
2.717
2.882
2.891
2.921
2.930
2.938
3.794
3.804
3.830
3.839
6.137
6.161
6.966
6.990
7.260
1.02
1.18
3.38
1.26
3.09
1.10
0.99
0.91
1.00
S
R
M
−801
−020, 400A MHz, cdcl3
−1
9
8
7
6
5
4
3
2
1
0
ppm 0.229
0.470
0.744
0.751
0.920
0.926
1.050
1.077
1.234
1.254
1.270
1.305
1.518
1.531
1.544
1.551
1.570
1.640
1.665
1.689
2.373
2.392
2.416
2.530
2.956
2.961
2.983
2.987
3.299
3.521
3.551
3.729
3.758
5.349
5.368
5.415
5.434
5.884
5.889
5.977
5.981
5.983
5.987
6.804
6.806
7.160
1.12
1.08
6.33
1.25
9.17
3.44
2.44
0.92
1.07
3.24
1.10
0.90
1.09
1.08
1.10
1.12
1.08
1.06
1.00
S
R
M
−801
−024
−diast. 1, 500 MHz, C6D6
309 
ent-2.111
N
H
O
OH
N
O
O
N
O
C
6 D
6 , 500 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
0.204
0.216
0.539
0.752
0.763
0.930
1.119
1.230
1.256
1.277
1.299
1.535
1.581
2.061
2.100
2.457
3.096
3.128
3.177
3.431
3.475
3.739
5.431
5.463
5.585
5.617
5.854
5.857
5.865
5.867
6.007
6.013
6.017
6.024
6.837
6.840
6.843
6.846
7.160
1.02
1.09
6.25
1.36
12.39
3.29
1.05
3.07
0.90
0.93
1.94
1.03
1.05
1.03
0.96
1.00
S
R
M
−801
−024
−
D2
310 
epi-ent-2.111
N
H
O
OH
N
O
O
N
O
C
6 D
6 , 300 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
0.836
0.844
1.134
1.143
1.530
1.797
2.644
2.648
2.674
2.678
2.683
2.708
2.712
2.793
3.270
3.280
3.304
3.314
3.763
3.774
3.793
3.803
5.320
6.787
6.804
7.018
7.071
7.091
7.109
7.199
7.219
8.141
1.08
1.13
3.00
1.39
2.80
1.27
1.27
1.08
1.13
1.19
1.13
1.11
S
R
M
−801
−003, 400B MHz, cd2cl2
311 
NH
N
H
Oent-2.110
C
D
2 C
l2 , 400 M
H
z 
9
8
7
6
5
4
3
2
1
0
ppm
0.444
0.451
1.586
1.595
1.603
1.690
2.358
2.391
2.408
2.571
2.574
2.594
2.598
2.602
2.622
2.625
2.760
2.768
2.783
2.791
3.116
3.124
3.144
3.152
3.162
6.816
6.817
6.830
6.831
6.897
6.901
6.904
7.070
7.087
7.101
7.125
7.126
7.141
7.260
7.888
1.01
1.42
3.16
3.13
1.06
1.04
1.00
2.09
1.00
0.97
1.00
0.97
0.91
SRM
−801
−005, 500 MHz, cdcl3
312 
NH
N
H
(+)-(2.1)
C
D
C
l3 , 500 M
H
z 
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
16.64
24.37
25.10
27.94
34.54
40.06
65.74
69.77
77.16
108.06
110.52
113.45
118.21
123.08
128.84
133.72
135.59
SRM
−801
−005, 150 MHz, cdcl3
313 
NH
N
H
(+)-(2.1)
C
D
C
l3 , 150 M
H
z 
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
1.008
1.277
1.295
1.315
1.528
1.546
1.565
1.583
1.601
2.080
2.753
2.771
2.788
6.964
6.999
7.082
5.72
2.32
2.00
1.82
S
R
M
−801
−079, 400A MHz, tol
−d8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
p
p
m
1.008
1.277
1.295
1.315
1.528
1.546
1.565
1.583
1.601
2.080
2.753
2.771
2.788
5.725
2.319
2.000
1.815
314 
HN
2.173
P
hM
e-d8, 400 M
H
z 
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
ppm
20.44
26.43
28.94
39.90
46.31
58.80
125.13
127.97
128.87
137.48
SRM
−801
−079
−13C, tol
−d8, 100A MHz
315 
HN
2.173
P
hM
e-d8, 100 M
H
z 
10
9
8
7
6
5
4
3
2
1
0
ppm
1.033
1.198
1.212
1.228
1.492
1.500
1.502
1.507
1.511
1.514
1.522
1.531
1.532
1.538
1.542
1.552
2.080
6.966
6.968
6.970
7.008
7.089
12.00
3.94
1.93
S
R
M
−801
−077
−2,2,6,6
−
T
M
P
 
s
t
a
ndard, tol
−d8, 400A MHz
1.2
1.4
1.6
p
p
m
1.033
1.198
1.212
1.228
1.492
1.500
1.502
1.507
1.511
1.514
1.522
1.531
1.532
12.000
3.938
1.932
316 
HN
2.172
P
hM
e-d8, 400 M
H
z 
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
ppm
18.86
20.43
32.02
38.66
49.64
125.13
127.96
128.87
137.48
S
R
M
−801
−077
−
T
M
P
−
s
t
a
ndard, 13
−
C
,
 100A MHz, tol
−d8
317 
HN
2.172
P
hM
e-d8, 100 M
H
z 
318 
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
0.992
1.029
1.188
1.203
1.218
1.252
1.270
1.290
1.504
1.515
1.522
1.540
1.555
2.080
2.720
2.738
2.755
6.440
6.448
6.646
6.653
6.969
7.009
7.080
7.090
7.109
7.127
7.131
7.135
7.142
7.145
7.153
7.161
7.179
7.182
7.617
7.636
4.78
2.64
1.28
1.79
1.90
1.23
1.50
0.96
1.00
2.23
1.22
SRM
−801
−077
−
c
r
ude rxn, toluene
−d8, 400A MHz
1.00
p
p
m
0.992
1.029
4.778
2.642
NO
ON
NH
HN
+
HN
2.172
2.173
O2.174
+
2.171
2.169
+
150 °C, PhM
e-d8 
(1M
), 20 h
Table 2-9 Entry 1
1.03
1.0
1.03
319 
20
30
40
50
60
70
80
90
100
110
120
130
140
150
ppm
18.83
20.43
23.38
26.35
28.83
29.93
31.95
38.66
39.85
46.21
49.69
58.88
102.57
111.23
119.93
121.99
123.97
125.14
127.97
128.88
136.39
137.49
SRM
−801
−077
−
c
r
,
 13C NO
ON
NH
HN
+
HN
2.172
2.173
O2.174
+
2.171
2.169
+
150 °C, PhM
e-d8 
(1M
), 20 h
Table 2-9 Entry 1
320 
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.154
1.196
1.211
1.226
1.275
1.294
1.313
1.484
1.522
1.527
1.532
1.538
1.546
1.557
1.562
1.581
1.643
1.646
1.835
1.838
2.080
2.755
2.772
2.790
3.007
3.024
3.034
3.041
3.926
4.003
6.415
6.420
6.425
6.572
6.578
6.585
6.969
7.040
7.090
7.117
7.120
7.130
7.133
7.150
7.152
7.167
7.170
7.598
7.618
3.01
2.61
1.51
1.00
1.13
3.95
0.73
0.69
0.99
0.52
0.22
0.21
1.00
1.03
1.11
2.31
1.01
SRM
−801
−080
−
c
r
1.00
p
p
m
1.012
1.033
3.012
2.610
4.00
p
p
m
4.0030.214
1.03
1.01
NO
ON
NH
HN
+
HN
2.172
2.173
O2.174
+
2.171
2.169
+
N
2.175
+
150 °C, degassed 
PhM
e-d8 (1M
), 9 h
Table 2-9, Entry 2
H
4.00
1.03
321 
9
8
7
6
5
4
3
2
1
0
ppm
1.010
1.033
1.195
1.210
1.226
1.272
1.290
1.310
1.523
1.541
1.557
1.573
1.577
2.080
2.751
2.768
2.786
6.425
6.584
6.590
6.597
6.969
7.009
7.030
7.050
7.090
7.119
7.122
7.132
7.135
7.152
7.169
7.602
7.621
6.00
3.53
1.29
2.21
8.09
2.00
1.72
1.74
2.12
2.80
1.75
S
R
M
−801
−083
−
c
r
,
 400A MHz, tol
−d8
0.95
1.00
1.05
p
p
m
1.010
1.033
6.004
3.529
Table 2-9, Entry 3
NO
ON
NH
HN
+
HN
2.172
2.173
150 °C, PhM
e-d8 (1 M
)
H
2 O (4 eq), 21.5 h
O2.174
+
2.171
2.169
+
1.03
1.01
1.03
322 
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.035
1.155
1.174
1.198
1.213
1.228
1.279
1.297
1.317
1.530
1.538
1.547
1.556
1.566
1.585
2.080
2.761
2.779
2.796
3.928
4.005
6.418
6.564
6.571
6.578
7.036
7.117
7.120
7.130
7.133
7.150
7.598
7.617
6.23
7.03
2.75
2.43
6.86
2.00
0.08
0.08
1.89
2.07
2.02
3.87
1.99
SRM
−801
−082
−
c
r
,
 400A MHz, tol
−d8
1.00
1.02
1.04
p
p
m
1.016
1.035
6.228
7.027
NO
ON
NH
HN
+
HN
2.172
2.173
O2.174
+
2.171
2.169
+
1.04
1.02
Table 2-9, Entry 4
135-140 °C, PhM
e-d8 
(1 M
), 32.5 h
1.04
 323 
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